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/ Thesis / Abstract
Introduction 
Tapered uncemented femoral stems are popular implants in total hip arthroplasty 
(THA). They are easy to use and excellent long-term results have been reported for 
patients with primary osteoarthritis of the hip (OA). 
The disadvantages of these devices include post-operative periprosthetic bone 
loss, the clinical importance of which is still uncertain, and an increased risk 
of early periprosthetic fractures. These stems rely on initial primary stability to 
achieve biological fixation to bone. Poor bone quality, such as in patients with 
previous surgery of the hip or osteoporosis, is therefore generally considered to 
be a contraindication.
Hypotheses 
We hypothesized that (1) femoral periprosthetic bone loss occurs after implanta-
tion of these devices and is related to the stem size used as well as the pre-operative 
bone mineral density (BMD) of the hip, (2) that femoral hip revision surgery using 
these implants is a reliable procedure with predictable mid-term results despite 
compromised proximal femoral bone stock prior to revision, (3) that a bisphos-
phonate will reduce the femoral periprosthetic bone loss and finally (4) that a 
tapered, uncemented, hydroxyapatite-(HA) coated femoral stem can provide 
durable fixation and good clinical outcome in elderly patients with osteoporotic 
fractures of the femoral neck.
Materials and methods 
Two similar tapered uncemented HA-coated femoral stems were used in the 
studies. Bone mineral density (BMD) was measured using Dual-energy X-ray Ab-
sorptiometry (DXA), migration was assessed using radiostereometry (RSA) and 
Einzel-Bild-Röntgen-Analyse (EBRA). Clinical outcome was evaluated using the 
Harris hip score (HHS) and health related quality of life (EQ-5D)
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Results
study i
In a retrospective study, a single cohort of 138 patients with a unilateral THA 
was examined 3 years after surgery with DXA. It was found that periprosthetic 
proximal bone loss was related to stem size. Patients with the larger stem sizes lost 
more bone than patients with smaller stems. 
study ii 
In a retrospective analysis of 60 patients, who were examined 6 years after unce-
mented femoral stem revision surgery due to aseptic loosening, we found a 95% 
survival rate of the stem and no cases of aseptic loosening. We also noted that 
all stems were stable according to radiological parameters and that the clinical 
outcome was acceptable. 
study iii 
In a randomized, double-blind, placebo-controlled trial of 73 patients with hip 
OA, risedronate was given once weekly for 6 months following THA surgery. 
Risedronate reduced the proximal femoral bone loss by 7% up to 12 months post-
operatively. In both groups, patients with a low pre-operative BMD lost signifi-
cantly more bone than patients whose initial BMD was high. 
study iV
In a prospective single-cohort study of 50 cognitively intact elderly patients oper-
ated with a new HA-coated stem due to a displaced FNF, we found stable stems 
after 3 months. We also found a continuous decrease in BMD around the stems 
up to 2 years after surgery. Patients with osteoporosis lost more bone than patients 
with a normal BMD.
Conclusions
Periprosthetic bone loss after THA can be reduced with bisphosphonate treat-
ment. Future studies on prevention of bone loss after THA should focus on pa-
tients who have a low pre-operative BMD of the hip. 
An uncemented, tapered HA-coated stem can be used successfully for elderly 
patients with osteoporotic fractures of the femoral neck. Further studies are 
needed to ascertain whether uncemented femoral stems are superior, equivalent 
or inferior to cemented stems in the treatment of FNFs in the elderly. ◉
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AsA 
American Society of Anesthe-
siologists
Bmc
Bone mineral content
Bmd 
Bone mineral density
cdH 
Congenital dysplasia of the hip
cocrmb
Cobalt Chrome Molybdenum
dXA 
Dual-energy X-Ray Absorpti-
ometry
eQ-5d
European Quality of Life-
5 Dimensions
fnf 
Femoral neck fracture
HA 
Hydroxyapatite
HHs 
Harris hip score
oA 
Osteoarthritis
pmmA 
Polymethyl methacrylate
pnrs 
Pain Numeric Rating Scale
rct 
Randomized controlled trial
rsA 
Radiostereometric analysis
tHA 
Total hip arthroplasty
ti-6Al-4V
Titanium-6Aluminium-4Vana-
dium
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Bone cement
PMMA mixed with barium 
sulfate and (often) antibiotics, 
used as a filler to fix implants 
to bone. 
Bone ingrowtH
New bone formation (osteo-
genesis) directly into the po-
rous structure of an implant.
Bone loss 
When bone remodelling leads 
to a decrease of bone mass.
Bone remodelling
In this thesis, bone remodelling 
refers to the adaptive change 
of bone architecture leading to 
a detectable change in either 
BMD or radiological appear-
ance on x-ray.
disuse AtropHy
Bone mineral decrease due 
to offloading of bone (stress-
shielding).
eQ-5d
A 5-dimensional standardized 
instrument for use as a measure 
of health outcome.
HemiArtHroplAsty
A surgical procedure for repair 
of an injured or diseased hip 
joint (in this thesis) involving 
replacement of the head of the 
femur with a prosthesis and 
leaving the acetabulum intact.
HydroXyApAtite
A basic calcium phosphate 
mineral that is the principal 
inorganic constituent of bone 
and teeth.
loosening
When implants are debonded 
from the substrate fixing them 
to bone, be it bone cement or 
osseous ingrowth.
osseointegrAtion
The direct structural and func-
tional connection between liv-
ing bone and the surface of a 
load-bearing artificial implant, 
typically made of titanium or 
titanium alloy.
osteoconductiVe
Refers to any structure that fa-
cilitates the formation of bone 
structure, often used to de-
scribe the properties of various 
types of bone grafts and bone 
graft substitutes.
osteolysis
Localized areas of bone de-
struction and resorption 
caused by wear particles from 
the joint, can cause loosening 
of an implant.
pedestAl sign
Radiographically visible endos-
teal bone formation at the tip of 
the stem.
polymetHyl metHAcrylAte
A transparent plastic used in 
bone cement. 
porous coAting
Coating on an implant applied 
to contain void regions with the 
intent of enhancing the fixation 
of the implant.
reVision
In this thesis, revision surgery 
refers to a reoperation with 
replacement of one or several 
implant-parts.
spot weld 
Radiographically visible end-
osteal bone formation bridging 
from the cortical bone to the 
implant surface.
stress-sHielding
Off-loading of (in this thesis) 
bone.
ti-6Al-4V
An alloy of titanium, 6% alumi-
num and 4% vanadium, used 
extensively as an alloy for unce-
mented implants.
titAnium 
A shiny, white metallic element 
that is lightweight, strong, and 
highly resistant to corrosion.
uncemented
Implants designed for fixation 
by bone ingrowth.
2 DEFINITIONS
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Degenerative joint disease and sequele after 
trauma have plagued man through history.115 
Evidence of joint pathologies have been found in 
excavations of medieval homo sapiens as well as 
pre-historic homo neanderthalensis.278 
During the 18th century, excision arthroplasty 
of a damaged joint was becoming increasingly 
popular. One of the early advocates of this proce-
dure was Henry Parker (1744-1831). He worked 
at the Royal Infirmary in Liverpool and reacted 
to the appalling frequency with which amputa-
tion was used for injuries to the extremities. Liv-
erpool was a port city with many sailors arriving 
from long voyages, sometimes with traumatic 
injuries that were months old. He practiced this 
procedure on the knee and elbow joints. In a let-
ter to his mentor he describes his principles for 
treatment:229
“The resource I mean is the total extirpation 
of the articulation, or the entire removal of 
the extremities of all the bones which form 
the joints, with the whole, or as much as 
possible of the Capsular Ligament; thereby 
obtaining a cure by means of Callus.”
Anthony White (1782-1849) of the West-
minster Hospital in London is credited with 
performing the first excision arthroplasty of the 
hip joint in 1821, although he never published a 
paper on the subject. The surgery was described 
in his obituary as follows:305
“He who first excised the head, neck and tro-
chanters of the femur, the patient surviving 
the operation twelve years, and then dying 
consumptive* . . . . Mr. White had been un-
able, from his extensive practice, to contrib-
ute any literary work to the advancement of 
medical science . . .”
Incidentally, he was also the first to describe 
phlegmatic alba dolens in an extremity, the condi-
tion which is now known as deep vein thrombosis. 
It is a common medical complication after THA.
However, this was before the dentist William 
Morthon’s discovery of sulphuric ether as an an-
aestetic agent. The most important skill a surgeon 
possessed at this time, besides precision, was the 
ability to perform an amputation quickly. As am-
putation could be performed more quickly than 
excision arthroplasty, this prevented the surgery 
from gaining popularity. In addition, it was not 
until Joseph Lister’s (1827-1912) contribution of 
asepsis in the surgical field that the mortality rate 
for hip joint surgery dropped to below 50%. This 
was considered to be high, even by the surgical 
standards of the time. 
The Berliner Professor Themistocles Glück 
(1853-1942) is attributed with performing the 
first total joint replacement operation.96 On 20 
3 INTRODUCTION
3.1 HISTORY OF HIP ARTHROPLASTY
Total hip arthroplasty (THA) is an extraordinarily successful surgical procedure that has 
rightly been proclaimed “The Operation of the Century”.171 Since the introduction of the 
modern low-friction arthroplasty by Sir John Charnley,54 millions of patients with degene-
rative and traumatic joint disease have been restored to good function and an improved 
quality of life after surgery. 
figure 1. The Glück ivory total knee arthroplasty, with exploded view 
of knee prosthesis showing slots for horizontal fixation pegs. Reprinted 
from Eynon-Lewis et al.96 with permission. *Relates to that the patient was affected with tuberculosis of the lungs. Septic 
tuberculosis of the joints was a common reason for surgery during this period.
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May 1890 he performed a total knee replacement 
on a 17-year old woman whose knee had been 
destroyed by tuberculosis (Figure 1). One year 
later he implanted the first total hip arthroplasty 
consisting of an ivory ball and socket joint that 
he fixed to bone with nickel-plated screws.114 He 
subsequently experimented with a mixture of 
plaster of Paris and powdered pumice with resin 
to provide fixation. 
Although his results, for his time, were spec-
tacularly successful in the short term, they all ul-
timately failed due to chronic infection and pros-
thetic loosening. He was later forced to publish a 
declaration of repentance in which he took full 
responsibility for these failures. His idea of a total 
joint replacement was, nevertheless a very good 
idea, although the operations were performed on 
the wrong patients, at the wrong time. 
Glück was far ahead of his time, discussing 
and experimenting on topics such as uncemented 
or cemented fixation of implants, stress-shielding 
and issues of biocompatibility.
Several more attempts at joint replacement were 
carried out with horrendous results during the 
later part of the 19th century. The first partially 
successful operation was not done until after the 
end of the First World War. Pierre Delbet, (1861-
1925) a French surgeon, used a rubber femoral 
prosthesis in 1919 to replace one-half of the hip 
joint. 
In 1923, the Norwegian-born American sur-
geon Marius Smith-Petersen (1886-1953) from 
Boston, Massachusetts performed a synthetic 
interpositional arthroplasty with a glass mold 
prosthesis. This arthroplasty was intended to 
facilitate bone-implant movement both on the 
femoral and the acetabular side of the implant. 
He also described the anterior surgical ap-
proach to the hip which was used in this proce-
dure. This approach is still commonly used in hip 
arthroplasty.273 It was not until 1937 however, 
when his dentist suggested that he try Vitallium® 
(an alloy of 60% cobalt, 20% chromium, 5% 
molybdenum and other substances) that predict-
able, and for the time, spectacular results, in pain 
relief for patients with degenerative joint disor-
ders were achieved.272 Smith-Petersen implanted 
more than 500 of these devices (Figure 2). 
The Judet brothers, Robert (1901-80) and Jean 
(1905-95) from Paris, France, received a lot of 
attention for their early prosthesis. They used 
an acrylic prosthesis in 1948 (Figure 3).144 The 
Judet prosthesis showed itself to be exceptionally 
susceptible to wear, and failed even before the 
general acclaim had died down. However, there 
are still reports of Judet prostheses serving the 
patients well 50 years after implantation. 
figure 3. Newspaper advertisement for “the next big thing”, an 
artificial hip joint by the Judet brothers. This is a later version of the 
prosthesis in which the implant stem has been strengthened by stain-
less steel.
figure 2. A Vitallium® Smith-Petersen interpostion arthroplasty. 
Courtesy of Dr Ahl, photo by Carin Wesström.
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The radical solution of excision arthroplasty, was 
popularized by Gathorne Robert Girdlestone 
(1881-1950) in Oxford, United Kingdom111 and 
is still occasionally used today as last resort in 
failed THA, a procedure that is simply called 
“conversion to a Girdlestone.” 
The Judet brothers’ concept was refined by 
Frederick Röeck Thompson, (1907-83) who de-
veloped a Vitallium® prosthesis in 1950 which 
featured a distinctive flared collar below the head 
and a vertical intramedullary stem (Figure 4),291 
by Harold R. Böhlman (1893-1979) from Ne-
braska, and Austin Moore (1899-1963). 
The stem was placed inside the femoral canal 
for stability and was connected in one piece (so 
called monoblock) with the artificial metal head 
(Figure 5). Dr. Moore inserted the first such met-
al prosthesis at John Hopkins Hospital in 1940 
in a patient with a recurrent giant cell tumor.211 
Böhlman and Moore refined their implant and 
in 1952 described a model that featured a fenes-
trated stem which allowed bone ingrowth. These 
were the first hip arthroplasty products that were 
to become widely used. Eventually they became 
legendary and are still used today for replace-
ment of the femoral head and neck, especially 
following femoral neck fractures (FNFs) in the 
elderly. In Sweden, 23 such hemiarthroplasties 
were implanted in 2008.109 
McKee and Watson-Farrar (1905-1991) of Nor-
wich, England, developed prostheses in the late 
1940s and experimented with dental acrylic ce-
ment [polymethyl methacrylate (PMMA)] for 
fixation. In the early 1950s, they started using the 
Thompson prosthesis on the femoral side that ar-
ticulated with a three-claw type cup on a metal-
on-metal articulation that was screwed into the 
acetabulum.204 
Their high incidence of failure resulted from 
loosening of the components and there were 
unpredictable long-term results. However, there 
are several long term follow-ups showing a 84% 
survival of the implants at 20 years.44 
The concept of metal-on-metal articulation 
was “rediscovered” by McMinn205 and today an-
other wave of metal-on-metal bearings is on the 
rise. The next contribution to the evolution of hip 
arthroplasty was made by Sir John Charnley and 
his so called low-friction arthroplasty of the hip, 
the modern THA.54
figure 4. Thompson monoblock hemiarthroplasty  
Photo by Carin Wesström
figure 5. Austin Moore monoblock hemiarthroplasty 
Photo by Carin Wesström
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Sir John Charnley and the low-friction arthroplasty
The remarkable achievements of Sir John Charnley (1911-1982) in the development of 
orthopaedic surgery in general and the modern THA in particular, cannot be overesti-
mated. His work focused on joint friction and lubrication, recognizing the importance of 
achieving a low friction in THA. 
He initially used McKee-Farrar’s idea of using 
PMMA55 to fixate an Austin-Moore stem in the 
femoral canal and used Teflon® – polytetrafluo-
rethylene (PTFE) as the acetabular component. 
The initial results were good, but the PTFE wore 
out very rapidly, causing massive granulomatous 
tissue reactions, osteolysis and loosening of the 
components. Over the years, he altered the de-
sign of the stem to a slender stainless steel com-
ponent with a fixed 22.2 mm head articulating on 
a high molecular weight polyethylene (HMWPE) 
acetabular component, both being cemented in 
place with PMMA, (Figure 6). 
The first operation of this low-friction ar-
throplasty was performed in November 1962 
and heralded a new era in THA surgery: that 
of predictable long-term results. Charnley also 
worked persistently on developing the surgical 
technique, improving all aspects of the procedure 
and also made enhancements to the surgical ap-
proach to the hip joint and the development of 
the instruments used as well as surgical steril-
ity. He initially limited the use of his prosthesis 
to surgeons whom he had personally trained 
and the prosthesis was not readily available to 
any surgeon who wished to use it until the early 
1970s. 
In Sweden, the first Charnley prosthesis was 
implanted into a patient at Södersjukhuset on 
17th of February, 1968. The prosthesis is still 
the gold standard for a THA and the 20-25 year 
survivorship of the original prosthesis, with revi-
sion for any reason as end point, is approximately 
80%18 for Charnley’s own series and is similar for 
other independent surgical centers.315 
In the Swedish Hip Arthroplasty Register, 
where results are presented on a nation-wide ba-
sis, the 29-year survival of the original Charnley 
prosthesis is 72%, with revision for any reason as 
end point (Figure 7).109 The cemented Charnley 
cup [although updated to ultra-high molecular 
weight polyethylene (UHMWPE)] is still one 
of the most widely used acetabular components 
in Sweden, but the stem is used more rarely. In 
1977, Charnley was knighted by the Queen of 
England for his contributions to humanity. 
figure 6. A 20 year old Charnley prosthesis on the patients’ right side.  On the left a 10 year old uncemented THA with the Bi-Metric stem.
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The post-Charnley era and cemented implants
As in all aspects of medicine, the development of the THA has continued. Most implants 
have undergone several modifications over time. Simultaneously, advancements in steri-
lity, surgical technique and instrumentation have also been made. 
Mechanisms causing failure of early total hip 
replacement include fracture of the implant,53 
aseptic loosening as a result of mechanical failure 
of the fixation interface, infection,78 polyethylene 
wear,314 and dislocation.311 The importance of 
the surgical technique and that surgeons perform 
sufficient numbers of operations to achieve and 
retain proficiency are also paramount for good 
long term results in THA. In specialized centers, 
the 10-year revision rate for the Charnley pros-
thesis is typically around 3-7%,259 whereas the 
failure rate for the average surgeon can be signifi-
cantly higher.97
During the first decades of THA, infection was 
the most common reason for revision with infec-
tion rates of 5-10%. With improved surgical tech-
nique, laminar airflow in the operating room, 
improved clean air suits for surgeons and staff 
and the addition of antibiotics intravenously and 
to bone cement, the infection rate has dropped 
significantly and is now around 1%.109
The next problem, particularly in younger 
patients, was aseptic loosening of the stem and 
cup, caused by osteolysis – localized areas of 
bone destruction and resorption.75 Since PMMA 
debris could be seen in histological samples of 
failed THAs with osteolysis,128 this was originally 
attributed to a entity called “cement disease”.143 
This lead several investigators, particularly in 
the U.S.A, to direct their efforts towards the de-
velopment of prostheses that could be implanted 
without use of cement. Later, osteolysis was 
found to be caused by wear from the polyethyl-
ene used79,125 and not by the cement itself. 
Although the chemical composition of bone 
cement has essentially remained the same 
over the years, the cementation technique has 
changed radically. Bone cement is a grout not a 
glue and fixation is achieved by mechanical inter-
lock rather than adhesion. Therefore, increased 
pressurization and cleaning of the endosteal 
bone with pulsed lavage significantly augmented 
cement intrusion into bone and enhanced the 
interface shear strength.188 
By using this so called third-generation ce-
menting technique which also includes proximal 
and distal centralisers, reproducible creation of 
a complete, uniform, cement mantle is possible. 
The benefits of this technique have been shown in 
the Swedish Hip Arthroplasty Register, and very 
good mid-to-long-term results have been pub-
lished.216 In this register and by using the third-
generation cementing technique, the 10-year 
survival rate of the Charnley THA is currently 
93% (Figure 7).109 Improvements in cemented 
femoral stems and acetabular components have 
also been made during the last decades and cur-
rently the 10-year survivorship of the 3 best per-
forming THAs on a national level is, in Sweden, 
between 95% to 97%.109 
The details of this intricate and exhausting 
development of cemented THA lie, however, 
outside the scope of this thesis. ◉
figure 7. Implant survival of the original Charnley prosthesis. 
Reprinted with permission from the Swedish National Hip Arthroplasty 
Register.109
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The problems associated with loosening of 
cemented implants and the suspected “cement-
disease” thus led to the development of unce-
mented implants, aimed at biological fixation. 
Furthermore, high failure rates were, and are 
still, reported for cemented and uncemented im-
plants in younger patients (Figure 8 and Figure 
9).51,75,109 
Today we know that particle-induced osteoly-
sis caused by excessive wear from articulation is 
responsible for the majority of loosening. Never-
theless, implant manufacturers and researchers 
have been focusing on how to get reliable bony 
fixation of the implants. Implants had to be made 
with either a porous coating or a roughened sur-
face that would allow intimate bony apposition 
to anchor the implant – bone ingrowth. Once the 
implant was biologically attached to bone, the 
component would allow normal transmission of 
biomechanical forces across the joint.
Acetabular cups
The early uncemented acetabular cups were 
threaded, had smooth surfaces and consistently 
showed poor results with continuous migration 
and alarmingly high revision rates.9,87,283 
This led to the development of modern un-
cemented press-fit hemispherical porous-coated 
acetabular components with revision rates as low 
as modern cemented acetabular components.109 
Despite this, the problem of late pelvic peri-
prosthetic osteolysis is the main factor in reducing 
the longevity of these devices and is the focus of 
heated debate and extensive research.8,90,107,126,174 
Pre-clinical and clinical research efforts in tribol-
ogy has provided alternative articulations com-
prised e.g. of new polyethylene materials, with 
improved wear characteristics, so called highly 
cross-linked polyethylene (XLPE).72 
However, it is yet uncertain whether this new 
polyethylene will reduce the osteolytic potential. 
The current research on acetabular components 
also falls outside the scope of this thesis. 
figure 9. Implant survival of uncemented implants in patients 
younger than 50 years on a national level. Reprinted with permission 
from the Swedish National Hip Arthroplasty Register.
3.2 UNCEMENTED HIP ARTHROPLASTY
figure 8. Implant survival of cemented implants in patients younger 
than 50 years on a national level. Reprinted with permission from the 
Swedish National Hip Arthroplasty Register.
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Design of stems
The first designs of uncemented femoral implants were cylindrical, with extensive porous-
coating on the whole length of the implant.85-86 One example is the anatomic medullary 
locking (AML) stem (Depuy, Warsaw, Indiana) which initially, even though achieving 
fixation of the stem, caused a high rate of cortical atrophy, proximal stress-shielding and 
bone loss. 
This remodelling of bone results from the mis-
match between the stiffness of the flexible femur 
and the implant and is discussed in detail in 
Study I of this thesis. 
The clinical manifestations of this mismatch 
are thigh pain,36,168 late presenting avulsion 
fractures of the greater trochanter137 and pre-
sumably an increased susceptibility for peripros-
thetic femoral fractures and aseptic loosening. 
The AML stem, like many others, was therefore 
modified. First the proximal two-thirds, and later 
only the proximal one-third had porous coating. 
The philosophy thus was, and still is, to achieve 
metaphyseal fixation, thereby mimicking the 
natural loading of the femur. The AML stem is 
a straight cylindrical stem design and the coveted 
metaphyseal fixation is also used as a rationale for 
the anatomic, tapered and press-fit stem designs. 
An extreme variant of the press-fit design, still 
clinically unproven in the long-term perspec-
tive, is the so called ultra-short stem where the 
diafyseal portion of the stem has been removed, 
thereby fully relying on metaphyseal fixation 
(Figure 10).4,260 The straight-stem design is still 
used widely among orthopaedic surgeons in its 
country of origin, U.S.A.
The anatomic stem design, as the name implies, 
incorporates an anterioposterior curve to match 
the natural bow of the patient’s femur and is thus 
manufactured with a left and right-sided ver-
sion. It was hoped that this curved stem would 
seat favorably in the metaphysis but instead they 
initially had problems with thigh pain and mi-
gration.48,147 The more modern design variations 
of the anatomic stem [e.g. ABG (Stryker, New-
bury, UK)] (Figure 11) have largely overcome the 
problems of their predecessors and are widely 
used.154 
The tapered femoral stem use proximal can-
cellous bony ingrowth and three-point stem 
fixation to obtain immediate stability. They can 
be provided with or without a collar to prevent 
excessive subsidence during ingrowth. The stems 
are often straight and wedged in a tight mechani-
cal fit in the lower metaphyseal region. Clinical 
results of tapered stems with at least a 10-year 
follow-up have been good, with stem survivor-
ship reported between 92% and 100%.37,233 Both 
stems used in this thesis are tapered femoral 
stems and are described in detail in chapter 6.
The press-fit femoral stem rely on the initial 
mechanichal joining of the implant and the bone 
by high contact pressure.299 Modern press-fit 
femoral stems, just like the tapered stems, consis-
tently have good results in arthroplasty registers 
with stems survivorship in arthroplasty registers 
of approximately 97% after 15 years with revision 
for all reasons as end point.109,120
The geometrical classification of uncemented 
implants is problematic however, since there are 
numerous implants that cannot easily be classi-
fied into one of these categories and which uses 
a combination of implant philosophies to obtain 
rigid fixation in the femur. 
It is also important to note that uncemented fem-
oral stems, since they all rely on firm mechanical 
initial fixation of the implant to the bone, were 
originally intended for use in patients with a 
good bone stock e.g. younger patients with os-
teoarthritis (OA). When using these implants in 
patients with osteoporosis and a FNF the results 
are probably not as good as when using a cement-
ed femoral stem*.  There are however potential 
benefits of uncemented fixation in these patients 
and this is discussed in detail in Study IV where 
the use of a new uncemented, tapered, femoral 
stem in patients with a FNF is evaluated.
* In the Swedish and Australian hip arthroplasty registers, the revision risk for 
press-fit stems and other uncemented stems is higher in patients with a FNF 
than in contemporary cemented femoral stems.
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coBAlt-cHrome molyBdenum Alloy
In the early 1970s, porous241 or sintered fiber 
metal106 cobalt-chrome molybdenum alloy 
(CoCrMb) implants, which allowed ingrowth 
of living bone into the surface, were introduced. 
Because of the concept of straight cylindrical 
femoral stems, the (initially) extensive porous 
coating and the relatively high stiffness of 
CoCrMb in relation to human femur, the stem 
was prone to cause disuse atrophy. Titanium al-
loys therefore became more popular with unce-
mented implants. CoCrMb is still a widely used 
alloy for femoral heads, for cemented femoral 
stems and together with hydroxyapatite coating 
for acetabular cups in resurfacing arthroplasties. 
titAnium Alloy
Pure titanium has a lower modulus of elasticity—
closer to that of bone—and is more biocompati-
ble than CoCrMb and was therefore the substrate 
of choice for uncemented implants.132 Titanium 
was proven by Brånemark to osseointegrate with 
living bone,40 creating a direct structural and 
functional connection between the bone and the 
surface of the implant.6 
The strength of the bond between bone and 
titanium implants is of the same magnitude as 
bone itself.29,121 Pure titanium has a strength 
that is somewhat less than CoCrMb. If titanium 
is alloyed with 6% aluminum and 4% vanadium 
(Ti-6Al-4V) it was found to have superior me-
chanical properties while still having a favorable 
modus of elasticity compared to CoCrMb. 
At present, Ti-6Al-4V is the alloy of choice for 
most uncemented femoral stems. Using it as a 
bearing surface however has proven disastrous as 
metallic wear debris from the heads caused rapid, 
massive, osteolysis and loosening.182 Modular 
heads made of CoCrMb or ceramic materials are 
therefore used in combination with these stems. 
For cemented femoral stems, there are reports 
of favorable long-term results with Ti-6Al-4V1,38 
but most researchers currently agree that the al-
loy is inferior to stainless steel or CoCrMb due to 
high revision rates.158,200,308
figure 10. A ultra-short stem (Proxima®) 
A new type of stem design to achieve metaphyseal fixation.
figure 11. The anatomic ABG II stem 
Courtesy of Dr Brangstrup, photo Carin Wesström
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composite stems
To further mimic the natural flexibility of the hu-
man femur, and thereby in theory prevent bone 
resorption due to stress-shielding, the concept 
of isoelasticity — stems with the same modulus 
of elasticity as the femur — led to several differ-
ent designs during the late l970s.46,221 In theory, 
and on numerous in vitro experiments in ca-
daver femora, this seemed to be a good idea since 
forces in the hip were transformed in a more 
physiological manner using a flexible rather than 
a rigid stem.176 The short term results were ac-
ceptable but all these concepts eventually failed 
with high revision rates due to aseptic loosening 
(Figure 12).141,294 
Computer simulated models later showed that 
flexible stems create high proximal stem/bone 
interface stresses, causing interface debonding 
and relative motions, possibly affecting implant 
loosening.138 Therefore, the concept of isoelastic-
ity should achieve a compromise between the 
optimal stem flexibility, which reduces interface 
stresses and, at the same time, only moderate 
stress shielding.294
A later attempt was made using the Epoch 
stem (Zimmer, Warsaw, Indiana, U.S.A.),113 a 
composite stem made of a thin, forged, CoCrMb 
core surrounded by polyaryletherketone, a ther-
moplastic polymeric adhesive that is molded 
between the core and a outer casting of titanium 
fiber metal (Figure 13). 
The result is a stem that enables immedi-
ate stability and bone ingrowth along its entire 
length and yet is less rigid than the correspond-
ing CoCrMb or Ti-6Al-4V stems of similar 
size. In mechanical testing, the design has been 
shown to have a proximal stiffness equivalent to, 
and distally even less stiffness than, the human 
femur. In the short and medium term, this stem 
is clinically successful with low revision rates 
and favorable migration pattern measured with 
radiostereometry (RSA).164,286
Bone remodelling in relation to the size and 
stiffness of a femoral implant is one of the main 
aspects of this thesis and is discussed in Study I. 
figure 12. Radiograph of an isoelastic stem showing inital 
close contact between the implant and bone (left) and mas-
sive osetolysis and loosening after 9.7 years (right). Reprinted 
from Trebse et al.294 with permission.
figure 13. The isoelastic Epoch® stem 
Courtesy of Zimmer, Sweden.
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porous coAtings
To enable stable fixation of the implants after the 
initial period of mechanical interlock acquired 
at surgery, bone ingrowth into porous surfaces 
of the implants was advocated.279 This porous 
surface can be manufactured with beaded micro-
spheres106, by plasma spraying the implant206 or 
by using novel methods that mimic the micro-
architecture of trabecular bone.27 
As has been previously discussed, osseointegra-
tion will occur with Ti-6Al-4V implants and this 
process can also be enhanced by grit-blasting 
the surface.66 In fact, many manufacturers use a 
combination of proximal porous coating and dis-
tal grit-blasting on their stems, one such example 
of this is the Bi-Metric stem used in Study I-III 
of this thesis. 
Regardless of whether the bone ingrowth occurs 
on an uncemented implant into a porous surface 
or directly against the prosthesis surface (osseo-
integration), load (stress) must be transferred 
with minimal micromotion at the implant/bone 
interface. 
The bone ingrowth after surgery occurs 
through a series of events that are similar to frac-
ture healing; inflammation, repair and bone re-
modelling.106 During the first days after surgery, 
coagulated blood fills voids between the implant 
and bone. Thereafter, up to a few weeks after sur-
gery, the hematoma is invaded by mesenchymal 
cells which promote osteoblast formation. 
These initial osteoblasts form woven fiber bone 
and after approximately 4 weeks remodelling be-
gins with the formation of parallel, lamellar, fiber 
bone with intramembranous ossification.213 
Micromotion between the implant and host 
bone, pore size and the size of the gap between 
the bone and the implant all influence bone in-
growth. Excessive motion of approximately 150 
 
µm or more between the implant and host bone 
leads to fibrous tissue forming rather than bone 
ingrowth.5,242 The optimum pore size is in the 
range of 100-400 µm, corresponding to the pore 
size of trabecular bone (300 µm).26-27
Early designs of proximal coatings on femoral 
stems were applied in patches around the stem. 
This led to later failures as polyethylene particles 
gained access to the distal femur through chan-
nels between the areas of porous coating.263 This 
problem was rectified by applying the porous 
coating circumferential in the proximal part of 
the stem and thus reliable mid- and long-term 
results could be achieved (Figure 14).32,94,153 
figure 14. Magnification of the circumferential proximal porous 
coating of a Bi-Metric stem that was revised for other reason than 
loosening. Note the large patches of bone ingrowth and the scratch 
marks from the revision surgery illustrating the inherent difficulty in 
removing a well fixated uncemented stem. Courtesy of Dr Eisler, photo 
Carin Wesström.
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HydroXyApAtite coAting
Up to two-thirds of the dry weight of bone 
is inorganic mineral hydroxyapatite (HA), 
(Ca10(PO4)6(OH)2), also known as bone min-
eral.93 Using plasma spraying or chemical de-
position, it is possible to coat implants with HA 
(Figure 15). 
In experimental and in vivo settings this has 
been shown to have an osteoconductive effect. 
Thus, HA-coating can significantly increase the 
attachment strength of implants and facilitate a 
more rapid development of osseointegration.290 
It also makes the surgical technique more 
forgiving by bridging gaps of up to 2 mm and 
mitigating the adverse effect of initial micromo-
tion.274,277 
The HA resorbs in vivo, micromotion ac-
celerates resorption and resorbed HA is partly 
replaced by newly formed bone, thus further 
enhancing the implant fixation.275 
HA and other ceramic coatings like tricalcium 
phosphate (TCP) have been added to uncement-
ed stems and acetabular components to enhance 
the reliability of biological fixation.274,277 Like all 
well-fixed femoral components, osseointegration 
will result in adaptive femoral remodelling over 
time. Intuitively this should result in a somewhat 
larger bone mineral content (BMC) but this has 
only been studied twice in vivo in sufficiently 
sized trials.47,281,284
These trials confirm earlier results from non-
randomized studies;76,255 that it is possible to 
influence the bone remodelling and thereby the 
migration of a stem with HA-coating. However, 
proximally porous coated femoral stems, with 
and without HA, have similar long-term results 
in arthroplasty registers,234 so the relevance of 
this small difference in migration can be of negli-
gible clinical relevance.
HA-coating  has also been questioned because 
of the concern regarding particle release from 
wear and abrasion possibly affecting the long 
term results.23 Lazarinis et al., in a recent report 
from the Swedish Hip Arthroplasty Register,170 
questioned the routine use of HA-coated cups in 
primary total hip arthroplasty. They found that 
HA-coating was a risk factor for cup revision due 
to aseptic loosening (adjusted RR 1.7; 95% CI: 
1.3-2).
Most commonly used porous coated femoral 
stems are available with and without HA and 
the surgeon’s preference dictate which implant is 
used. In this thesis all operations was performed 
with HA-coated implants. 
Thus, modern uncemented THA appears to 
have come to terms with the problem of fixation 
whereas stress-shielding (one of the subjects of 
this thesis), wear and osteolysis still remain areas 
of attention. ◉
figure 15. Hydroxyapatite
Scanning electron microscope of raw hydroxyapatite particles ranging 
from 100-300 nm in size.
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The history of THA is, like many aspects of medical development, paved with both 
triumphant successes and spectacular failures. Traditionally, new implants are evaluated 
by their inventors in single-surgeon series before they are made available to the general 
orthopaedic surgeons and ultimately patients. 
In most, but not all cases, this is preceded by 
pre-clinical laboratory and animal models trials. 
However, pre-clinical testing has a poor predic-
tive ability to foresee clinical situations and the 
complex biology of man. 
This has lead to unforeseen consequences 
where new, theoretically ingenious concepts, or 
small “improvements” to already existing suc-
cessful designs, have lead to catastrophic failures. 
The previously mentioned early generations of 
short and isoelastic femoral stems141,294 and in-
troduction of the matte surface Exeter stem207 
are two, of many, examples. 
When introducing new drugs there is an exten-
sive safety and regulatory program that com-
panies have to adhere to. For new orthopaedic 
implants however, this is only rudimentary in 
Sweden and in most other countries. One excep-
tion is the USA Food and Drug Administration 
(FDA) who approves (new designs) or clears 
(altered designs) implants after thorough docu-
mentation from the manufacturers. 
However, this is still not a guarantee for clini-
cal success. In august 2010, the FDA-approved 
ASR hip resurfacing prosthesis was recalled by 
the manufacturer due to a 5-year revision rate of 
13% in upcoming reports from the National Joint 
Registry of England and Wales (Figure 16).69
A stepwise clinical introduction of new implants 
and methods has therefore been advocated.189-190 
This involves pre-clinical testing, small prospec-
tive trials using high precision methods like 
RSA264 to assess implant fixation and wear, larger 
multicenter trials and finally population-based 
register studies. 
In Study IV, two methods, validated for fixation 
of implants and bone remodelling, RSA and DXA 
are used to evaluate a new femoral implant. ◉
3.3 INTRODUCTION OF NEw IMPLANTS
figure 16. A advertisement in 2007 for “the next big thing”, an ASR 
hip resurfacing THA. The implant was recalled by the manufacturer in 
August 2010.
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Remodelling of bone is the process by which the adult skeleton is continually being resorbed 
(osteoclasts) and formed (osteoblasts) in small cavities on the surfaces of cancellous bone 
and tunnels (Haversion systems) in cortical bone. 
In a state of equilibrium, as in healthy young adults 
with stable bone mass, the bone remodelling rate 
is low and the amount of bone formed is about the 
same as is being resorbed. The entire skeleton is 
remodeled every ten years and any given site in 
trabecular bone is remodeled every 1-2 years.194
The structure of bone requires close coopera-
tion between osteoblasts and osteoclasts. It relies 
on a complex system of signaling pathways to 
achieve normal rates of growth and differentiation. 
Osteoblasts (basically modified fibroblasts) are 
mononuclear cells responsible for bone formation 
and are derived from osteoprogenitor cells located 
in the periosteum and the cancellous bone.64 
Growth factors, in particular bone morpho-
genetic proteins (BMPs), platelet derived growth 
factor and transforming growth factor beta induce 
these precursors to mature into osteoblasts.3 Os-
teoblasts then begin to express a wide range of 
genetic markers and surface proteins which even-
tually lead to the generation of new bone.
Osteoclasts are multinuclear cells responsible 
for bone resorption and are derived from mono-
cytic cells in the synovium and cancellous bone. 
The principal regulator of osteoclast proliferation 
is the RANKLi /RANK/osteoprotegerin (OPG) 
pathway.175
RANKL is a necessary and commonly occur-
ring surface molecule that is highly expressed 
by stromal cells and osteoblasts, thus requiring 
direct contact between these cells and osteoclast 
precursors. Osteoclast formation also requires 
macrophage colony stimulating factor (M-CSF) 
acting on precursors.
RANKLs receptor, RANK, is widely expressed 
in cortical and cancellous bone located on the 
cell membrane of osteoclasts and pre-osteoclasts. 
RANKL–RANK binding stimulates the forma-
tion, activity, and survival of osteoclasts, result-
ing in osteoclast activation and increased bone 
resorption.61 
The system is balanced by OPG, a naturally oc-
curring soluble non-signaling “decoy receptor” for 
RANKL. By binding to RANKL and preventing its 
interaction with RANK, OPG inhibits osteoclast 
formation, activity, and survival, thereby reduc-
ing bone resorption.267 An increase of RANKL 
in proportion to OPG is associated with the de-
velopment of postmenopausal osteoporosis and 
other skeletal disorders,194 but has never been 
investigated in adjunction to disuse atrophy of the 
proximal femur after THA.
3.4 BONE REMODELLINg 
figure 17. Proximal femoral disuse atrophy due to stress-shielding in a 63 year old male 3 years after THA with an uncement-
ed Bi-Metric stem. Note the proximal decrease of cancellous bone in the greater trochanter compared to the unoperated side.
i Receptor Activator for Nuclear Factor κB Ligand (RANKL) belongs to the 
super family of Tumor Necrosis Factors (TNFs).
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Adaptive bone remodelling
It has long been recognized that placement of a rigid metallic device into bone alters the 
stress pattern and thereby deprives the bone of the physiological stress levels and cause 
bone resorption, named disuse atrophy.28,86,265 
This “stress-shielding” has been noted after plate 
fixation of fractures and has led to the develop-
ment of more flexible plates.240 The primary fac-
tor for bone atrophy is the mismatch between the 
stiffness of the bone and the implant. When two 
materials are joined, the stiffer of the materials 
bears the majority of the load, this is especially 
true when the loading is axial; the stiffer material 
prevents the more flexible material from deform-
ing and with less deformation there is less load 
(stress). 
In THA, this stress-shielding, with subse-
quent bone resorption, is a different entity than 
the wear-induced bone resorption known as 
osteolysis.124,126 The loss of bone induced by 
stress-shielding is typically seen on radiographs 
as cortical thinning or a more diffuse decrease in 
periprosthetic bone density (Figure 17). Osteoly-
sis on the other hand, appears as localized lesions 
with well-defined borders (Figure 18). 
The mismatch in stiffness between a femoral 
stem and the surrounding femur can be calcu-
lated by taking the elastic modulus of the implant 
(E) and a geometric factor known as the second 
moment of inertia (I) that is based on cross-sec-
tional shape and size. The stiffness of the implant 
is thus E*I.25 The moment of inertia varies with 
the fourth power of the cross-sectional dimen-
sion, thus, a small change in implant size causes a 
large change in the stiffness of the implant. 
Thus, increasing stem size and thereby stiff-
ness of femoral implants should lead to higher 
stress-shielding and thereby larger bone resorp-
tion. This has been shown in animal studies,25 in 
cadaver studies,86 in computer models103,138 and 
in clinical series using plain radiographs.85 
However, there are few studies that specifically 
study the relationship between stem size and 
bone loss in vivo and who also utilizes the most 
precise way of measuring bone mineral content, 
DXA.220,237 Therefore, in Study I, the extent of 
periprosthetic bone loss and its relationship to 
femoral stem size 3 years after surgery with the 
uncemented Bi-Metric stem is investigated in a 
large cohort of patients.
figure 18. Wear induced pelvic osteolysis (arrows).The same patient examined with both x-ray and computed tomography 
(CT). Note the asymmetry of the femoral head in relation to the cup, indicating severe polyethylene wear.
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In osteoporotic patients, these changes are associ-
ated with significant reductions in vertebral and 
nonvertebral fracture risk.22,123,203,208 Bisphospho-
nates are also used in Paget’s disease of bone208 
and in malignancies.256
Bisphosphonates have been available for more 
than two decades and currently 7 bisphospho-
nates — alendronate, clodronate, etidronate, iban-
dronate, pamidronate, risedronate (Figure 19) and 
zolendronic acid — are approved in Sweden.184 
The biological characteristics of bisphosphonates 
were first described more than 40 years ago.101-102 
They were originally used in industry, where 
inorganic pyrophosphate had been used for many 
years to inhibit the accumulation of calcium 
carbonate in water pipes and in the oil industry. 
Pyrophosphate was found to inhibit calcification 
in vivo but failed to act when given orally due to 
rapid hydrolysis. It is still used in scintigraphy and 
as an anti tartar agent in toothpaste.100
By modifying pyrophosphate, a number of 
bisphosphonates, each with its own characteristic 
profile, have been synthesized and investigated. 
They vary in their potency to inhibit bone resorp-
tion in vitro and in vivo. Bisphosphonates have a 
strong affinity to bone mineral – HA – and when 
osteoclasts try to engulf the bisphosphonate-con-
taining bone they undergo apoptosis (Figure 20). 
Once osteoclasts become apoptotic, they are 
quickly ingested by bone marrow phagocytes.252 
Interestingly, the actual effect of bisphosphonates 
on their target cells remains enigmatic, since in 
patients benefiting from therapy, little change, 
has been observed in the actual number of osteo-
clasts.303
BispHospHonAtes And ortHopAedic implAnts
The possibility to reduce periprosthetic bone 
resorption with bisphosphonates after THA has 
been addressed by several researchers and ef-
fects on periprosthetic BMD and migration have 
been noted in the short and mid-term perspec-
tive.11-12,133,219,304,306-307,317-318,320
In animal models, bisphosphonates can cause 
augmentation of osseointegration and bone in-
growth of orthopaedic implants,236,285 increase 
pull-out strength of screws268 and even reduce 
wear-induced osteolysis.266,310 
Bisphosphonates have also been shown to 
reduce the migration of uncemented acetabular 
components in THA and cemented tibial com-
ponents in total knee arthroplasty (TKA).104,134 
These are important findings since the continu-
ous migration of implants is associated with an 
increased risk for future revision.160,165 
Hilding et al. used RSA to show that intrave-
nous administration of clodronate in humans 
reduced the migration of the cemented tibial 
component in TKA.134 The same research group 
later demonstrated a similar effect of a local elu-
tion of ibandronate applied to the freshly cut bone 
surfaces, but failed to show any effect on migration 
in uncemented components with the use of oral 
alendronate.122
In Study III of this thesis, the effect of risedro-
nate on periprosthetic BMD, stem migration and 
clinical outcome after THA is studied. ◉
figure 19. Chemical structure of the bis-
phosphonate risedronate used in Study III: 
[1-Hydroxy-2-(3-pyridinyl)-ethylidene]
bis-phosphonate.
figure 20. Present hypothesis for mechanism of action of bispho-
sphonates. The osteoclast is inhibited directly after having taken up 
bisphosphonate from bone. Illustration by Max Gordon.
Bisphosphonates
Bisphosphonates are powerful inhibitors of bone resorption that exert their effect on 
already matured osteoclasts.22 Treatment with bisphosphonates decreases biochemical 
markers of bone turnover16 and increases bone mineral density (BMD). 
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The most frequent reasons for revision surgery after THA are, in order of frequency, aseptic 
loosening of the components, dislocation, deep infections, and fractures.109,129 In addition, 
the results with regard to revision rate and clinical outcome are less favorable after secon-
dary surgery than after primary surgery.79,312 
Cemented stem revision
Early reports of cemented revision for prosthetic 
loosening after cemented THA have shown an 
unacceptably high failure rate with a 15–20% re-
revision rate at 10 years of follow-up.73,80,131 
One cause of the high incidence of mechanical 
failure after cemented revision may be the lack 
of endosteal cancellous bone in the femur. How-
ever, when applying meticulous techniques with 
cement extraction, femoral canal preparation 
and third-generation cementing techniques, it is 
possible to achieve good outcome after cemented 
revisions using tapered polished stems.136
Hip revision with cement and impacted mor-
selized allograft bone has shown acceptable long-
term results in specialized centres.225,248,297 This 
technique has obvious advantages in bone stock 
restitution (Figure 21). However, impaction bone 
grafting surgery is technically demanding and 
time consuming. There are well known compli-
cations associated with this technique, such as 
major subsidence and per- and post-operative 
fractures. 224 
3.5 STEM REvISION AFTER FAILED HIP ARTHROPLASTY
figure 21. Femoral stem revision with impaction bone grafting using 
morselized allograft and a cemented collarless, polished, tapered stem. 
Note restitution of bone defect at 6 years compared to immediate 
postop radiograph (white arrows).
Postop 6 years
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Uncemented stem revision
Uncemented stem revision after aseptic loosen-
ing has shown itself to be promising in the short 
to medium term34,212,296 and also in the long 
term.228,247,249,298 
The aim of using these components is to 
achieve biological fixation, i.e. ingrowth of end-
osteal bone by new bone formation within the 
porous surface structure of the implant.86 In a 
revision situation, proximal bone stock in the 
femur is often compromised and to achieve early 
post-operative stability, most uncemented stems 
are designed to bypass the proximally damaged 
zone and to achieve initial stability from press-fit 
distally. 
Most stems used in these studies are long-
stemmed, extensively porous or HA-coated, or 
distally anchored (Figure 22). A disadvantage 
with these stems is the transfer of excessive load 
distally, leading to diminished proximal bone 
stock and in some cases to a high incidence of 
thigh pain. Despite this, there are good long-term 
results reported with the use of distally anchored 
stems. 34
Extensively coated uncemented stems in femoral 
revision surgery get fixated both proximally and 
distally and are used with good results.62,169,228 
However, these devices are prone to stress-
shielding and therefore stems with only proximal 
coating, such as the Bi-Metric stem, have also 
been used (Figure 23). 
The aim of using any of these implants is to 
enhance the proximal fixation in order to prevent 
further bone loss proximally and to minimize the 
load transfer distally. Earlier studies with stems 
aimed at proximal fixation have not shown en-
tirely promising results,19 later reports show bet-
ter outcome with survival rate in the mid- and 
long term of 95-100%.83,149   
In Study II, clinical and radiographic results after 
stem revision surgery with a tapered, proximally 
porous and HA-coated stem are presented. ◉
figure 22. Femoral stem 
revision using a uncemented 
distally anchored stem.
figure 23. Stem revision using the Bi-metric stem.
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In an international perspective, osteoporotic fractures represent a significant public health 
burden, which is likely to increase in the future. The lifetime risk is high; up to 50% in 
women and 22% in men. Since life expectancy, and thereby osteoporosis, is increasing, 
these demographic changes alone can be expected to increase the number of hip fractures 
occurring worldwide from 1.7 million in 1990 to 6.3 million in 2050.68  
Hip fractures are classified as femoral neck frac-
tures (FNFs) (51%), trochanteric fractures (41%) 
and subtrochanteric fractures (8%).81 FNFs are 
usually (65-75%) displaced (Garden III and 
IV108), (Figure 24), and these differ from the oth-
er hip fractures with regards to its high incidence 
of healing complications.292 
The majority of displaced FNFs in elderly 
patients were, until recently, treated with inter-
nal fixation (IF) in Sweden. However, there is 
now solid evidence to support recommending 
a primary hip arthroplasty instead of IF for a 
displaced FNF in elderly patients who are inde-
pendent walkers and have no severe cognitive 
impairment.14,112,218,253,293 This leads to a higher 
quality of life, hip function and a significant re-
duction of reoperations compared to IF without 
increasing mortality. 
In most Swedish hospitals, the standard of 
care has thus changed to primary arthroplasty 
instead of IF for this patient group (Figure 25).254
Cemented or uncemented stems
Earlier studies have supported the use of cement-
ed stems in hip fracture patients, mainly due to 
decreased post-operative pain during rehabilita-
tion.151,181,230 However, the concept of inserting 
an uncemented stem, even in elderly patients, is 
attractive to many surgeons148 as bone cement 
has several major, albeit uncommon, negative 
side-effects. These are mainly cardiac arrhyth-
mias and cardio-respiratory collapse which can 
occur during the cementing process.232 
The mechanisms involved are not fully under-
stood but the side-effects are most likely caused 
by pulmonary embolization of bone marrow 
and PMMA particles.57,243 The mortality rate in 
this frail patient group may therefore be higher 
after cemented rather than uncemented arthro-
plasty.173,231 The potential advantages of an unce-
mented femoral stem are also related to the shorter 
duration of surgery (thereby possibly minimizing 
intra-operative bleeding and decreasing the risk 
of infection).230 The disadvantages include an in-
creased risk for periprosthetic fractures with sub-
sequent increased revi-
sion rates,109 thigh pain 
and stress-shielding of 
the proximal femur. 
A new uncemented 
femoral stem, based on 
the Bi-Metric stem,32,206 
with full HA-coating to 
enable fast ingrowth in 
osteoporotic bone,281 
and a collar to avoid 
excessive subsidence, 
has been developed spe-
cifically for FNFs and is 
evaluated in Study IV of 
this thesis. ◉
3.6 HIP ARTHROPLASTY AND FEMORAL NECK FRACTURES
figure 24. Displaced femoral 
neck fracture in a 82-year old 
woman from Study IV.
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Arthroplasty 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
0
1000
2000
3000
4000
5000
6000
7000
8000
figure 25. Yearly number of procedures used for femoral neck 
fractures over time in Sweden. Reprinted from Rogmark et al.254 with 
permission.
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Up until July 2009, 1.718 stems in 1.420 patients 
have been implanted as primary THA, and data 
on these has been collected in a clinical audit 
database. In the first 8 cases, the stem was proxi-
mally porous coated and Ti-6Al-4V heads were 
used. After these initial cases, stems with plasma-
sprayed HA-coating on the porous coating and a 
CoCrMb head were used. 
On the acetabular side, an uncemented cup 
with inferior results was initially used in most 
cases.270 Nowadays, we use an uncemented 
press-fit shell with a XLPE liner or a cemented 
XLPE cup.
Patients
The selection criteria for uncemented fixation in 
the femur were initially patients below 60 years of 
age, a good general health and good bone qual-
ity equivalent to a type A or B femur.74 Over the 
years, the indication has broadened and since 
2007 the uncemented stem is our standard im-
plant for elective THA (Figure 26). 
No formal age limit now exists, but most 
surgeons use a cemented stem for patients over 
75 years of age, for patients with a C-type femur 
(regardless of age), and in patients with FNFs.
3.7 UNCEMENTED HIP ARTHROPLASTY  
       AT DANDERYD HOSPITAL
figure 26. Scatter plot of all 1.718 primary THA using the Bi-Metric stem 1989-2009 at Danderyd Hospital as a function of 
age at surgery. Hips revised and reasons for revision are marked as well as the yearly mean age at surgery (solid line).
tABle 1. Anthropometrical data on patients operated 
with the uncemented Bi-Metric and the cemented 
CPT stem at Danderyd Hospital 
Bi-metric cpt
Sexa
Male 695 (41) 582 (31)
Female 1023 (59) 1309 (69)
Ageb 61 (20-92) 76 (35-98)
Diagnosisa
OA 1405 (82) 1575 (83)
FNF 120 (7) 223 (12)
RA 77 (4) 19 (1)
Other 116 (7) 74 (4)
a n (%), b mean (range
Primary THA with uncemented femoral stems has been performed at the Orthopaedic 
Department, Danderyd Hospital, Stockholm since 1985. From 1989, the same stem,  
Bi-Metric (Biomet, Warsaw, Indiana, U.S.A.) has been routinely used in THA surgery. 
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Stem survival
Until September 2010, with a follow-up time of 
mean 7 (1-21) years, 14 stem revisions have been 
performed [due to fracture (n=11), infection 
(n=1) and dislocation (n=2)] indicating a sur-
vival rate of 99.2% (95%CI 98.7%-99.6%) with all 
reasons for revision as end point.32,270 We have 
no cases of aseptic loosening. Median time to 
revision was 28 (7-476) days and the majority of 
fractures were calcar-split fractures with little or 
no preceding trauma.
When comparing these revisions with a co-
hort of all primary THAs performed at Danderyd 
Hospital with a tapered, polished, cemented stem 
during 1999-2009 [CPT (Zimmer, Warsaw, Indi-
ana, U.S.A.)], there is a significant difference in 
revision rate. The revision rate, with all reasons 
for revision as end point, and with a follow-up 
time of mean 6 (1-12) years for the cemented 
stem is 96.3% (95%CI 95.2%-97.4%), (Figure 27). 
The 53 revisions were performed due to fracture 
(n=25), dislocation (n=14), infection (n=9) and 
aseptic loosening (n=5). The majority of the frac-
tures in the CPT-group were periprosthetic frac-
tures after low energy trauma (time to fracture 
median (range) 22 (1-90) months)
The demographics of the patients differ, with 
more males, younger patients and a lower rate 
of THAs performed as a result of a FNF in the 
uncemented group (Table 1). When adjusting for 
these inequalities with a Cox regression (Table 2), 
a diagnosis of FNF [odds ratio (OR) 1.9 (1.0-3.7)] 
and a cemented stem [OR 2.8 (1.2-1.9)] were 
found to be independent risk factors for revision, 
whereas age or sex were not. For revisions due 
to fracture, a diagnosis of FNF [OR 2.9 (1.3-
6.5)] was found to be an independent risk factor, 
whereas sex, age or stem type were not.
figure 27. Survival curves with 
all reasons for stem revision as 
end point
tABle 2. Multivariate Cox regression to evaluate factors as-
sociated with risk of stem revision
Explanatory n
revisions 
(n)
revision 
rate (%)
OR (95% CI) p-value
Sex
Male 1277 18 1.4 1
Female 2332 49 2.1 1.3 (0.8–2.3) 0.2
Age
≤65 1384 13 0.9 1
>65 2225 54 2.4 1.6 (0.8–3.3) 0.2
Indication
OA 2980 52 1.7 1
FNF 343 11 3.2 1.9 (1.0–3.7) 0.05
RA 96 0 0.0 0 (0.0-0.0) 1.0
Other 190 4 2.1 1.7 (0.6-4.7) 0.3
Stem type
Uncemented 1718 14 0.8 1
Cemented 1891 53 2.8 2.4 (1.2-4.9) 0.02
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Conclusion
These excellent mid- to long term results of an uncemented Ti-6Al-4V, tapered, proximally 
porous and HA-coated femoral stem demonstrate two things. Firstly, when using these im-
plants there is an increased risk for early fractures, most of them occurring during surgery, 
though they are not always detected. Secondly, once a modern stem osseointegrates it is 
seldom revised. 
However, we have, particularly in patients with 
a pre-operatively poor bone stock, seen radio-
graphic signs of severe stress-shielding (Figure 
28) and in some cases this has lead to peripros-
thetic fractures after minimal trauma (Figure 29). 
 
We have not seen an impact on revision rates, but 
our main concerns are that this bone remodel-
ling, in the long term, may lead to an increased 
rate of periprosthetic fractures. Many of our pa-
tients are young and can be expected to have a 
life expectancy of over 30 years. 
Our research group at the Joint Replacement 
Unit at Danderyd Hospital has, prior to this 
thesis, published several papers and one thesis 
on outcome and bone remodelling after unce-
mented THA.2,29-30,32-33,269-270
The general aims of this thesis are to further de-
scribe this phenomenon in primary and second-
ary surgery and to attempt to treat this peripros-
thetic bone atrophy using a drug. Based on our 
results in degenerative joint disease, we were also 
looking to extend the indication for uncemented 
femoral stems to patients with FNFs. ◉
figure 28. Severe stress-shielding 
10 years after revision surgery. Note 
thin cortex proximally. Distally ped-
estal sign and cortical hypertrophy as 
a sign of distal fixation.
figure 29. Disuse atrophy due to stress-shielding.  
Postoperatively (A). At 4 years (B) there are clear signs of stress-shielding (atrophy in Gruen 
zone 1, 2, 6 and 7). After 5 years the patient sustained a periprosthetic fracture after 
minimal trauma (C). The patient was successfully treated with open reduction and internal 
fixation. The stem was not revised.
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I To study the relationship between periprosthetic bone loss and femoral stem 
size after THA for degenerative joint disease when using a tapered uncement-
ed proximally porous- and HA- coated femoral stem.
II To study the clinical outcome and radiological results of hip revision surgery 
for aseptic stem loosening when using a tapered uncemented proximally po-
rous- and HA- coated femoral stem.
III To study the effect of oral risedronate on femoral periprosthetic bone resorp-
tion after total hip arthroplasty in patients with OA of the hip when using a 
tapered uncemented proximally porous- and HA- coated femoral stem.
IV To evaluate the fixation of, bone remodelling around, and clinical outcome 
after surgery of a new, uncemented, fully HA-coated, collared and tapered 
femoral stem, designed specifically for elderly patients with a FNF.  ◉
I Periprosthetic bone loss is related to stem size; larger stems will increase the 
bone loss after THA.
II Femoral hip revision surgery using an uncemented technique with a proxi-
mally coated stem is a reliable procedure with predictable mid-term results if 
bone defects prior to surgery are moderate.
III Risedronate, 35 mg given post-operatively once weekly for 6 months, will, up 
to 2 years, reduce the periprosthetic bone resorption around an uncemented 
stem.
IV An uncemented, fully hydroxyapatite-coated femoral stem can be used to treat 
FNFs. ◉
4 AIMS
5 HYPOTHESES
The general aims of the studies were to investigate the bone remodelling around and migra-
tion of uncemented femoral stems after primary and secondary THA. The specific aims of these 
investigations were:
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6 END POINTS
I The primary end point was periprosthetic bone loss in the Gruen118 zones 
1 - 7 and its relationship to femoral stem size. Secondary end points in-
cluded hip function assessed using the Harris hip score127 (HHS) and the 
number of complications after surgery. 
II The end points were clinical outcome and radiographic signs of bone 
remodelling. This was measured by gathering data on complications and 
revision surgery, hip function (HHS) and by assessing pre- and post-oper-
ative radiographs with regards to the Stability/Fixation score.
III The primary end point was change in BMD in the Gruen118 zones 1 and 
7 around the femoral stem in subjects receiving risedronate compared to 
these receiving placebo during a 2-year period with measurements at 2 
days, 3, 6, 12 and 24 months. Secondary end points included change in 
BMD in the other Gruen zones, vertical migration of the stem, radiological 
results, clinical outcome and the occurrence of adverse events.
IV The primary end point was migration of the stem measured with RSA dur-
ing a 2-year period with measurements at 2 days, 6 weeks, 3, 6, 12 and 
24 months. Secondary end points included change in BMD in the Gruen 
zones118 around the stem and clinical outcome. ◉
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7 PATIENTS
From these, between 2003-2008, a study popu-
lation of 617 hips (615 patients) was eligible for 
inclusion in one of the studies. After inclusion, 
Studies I-IV contained a sample of 314 hips in 
312 patients (Table 3).
All 1.757 uncemented THA operations done between 1989-2008 as either a primary 
(n=1.608) or secondary (n=149) intervention at the Orthopaedic Department at Dande-
ryd Hospital constituted the study base for Studies I-III. For Study IV, the study base was 
recruited from 750 patients with hip fractures admitted to Danderyd Hospital between 
2005-2008 (Figure 30).
tABle 3. Anthropometrical data on patients in study I-IV
study study i study iia study iii study iV
risedronate (n=36) placebo (n=37)
Male/femalec 66/72 37/23 14/22 16/21 36/14
Ageb 58 (37-91) 65 (35-84) 61 (41-69) 60 (41-69) 81 (70-92)
Heightb 171 (146-198) 174 (159-191) 171 (160-187) 174 (156-192) 168 (9)
Weightb 81 (47-120) 81 (51-28) 79 (59-104) 86 (55-130) 66(14)
Diagnosisc OA 123
CDH 5
Other 10
OA 44
CDH 4
Other 14
OA 36 OA 37 FNF 50
a for the original 60 patients (62 hips), b mean (range), c n, at primary surgery
Study II
53 hips
Study III
73 hips
Study IV
50 hips
179 primary 
unilateral THA 
1997-2001
62 revision THA 
due to aseptic 
loosening 
1989-2002
147 hips with 
OA 
2006-2008
229 hips with
FNF 
2005-2008 
Study I
138 hips
1.757 uncemented THA 1989-2008
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fractures 
2005-2008
figure 30. Sample selection for study I-IV
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Study I
We identified a consecutive series of 179 primary 
unilateral THAs performed with the uncemented 
Bi-Metric femoral implant at Danderyd Hospital 
from 1997 to 2001. A total of 31 patients were ex-
cluded from the study [rheumatoid arthritis (15), 
per-operative or post-operative fractures of the 
femur (7), corticosteroid treatment as a result of 
systemic illness (6), congenital hip dysplasia with 
abnormal anatomy of the proximal femur (2), 
and per-operative damage to the sciatic nerve 
(1)]. Ten other patients were lost to follow-up 
(4 died, 2 refused to participate and 4 could not 
be contacted). A total of 138 patients were thus 
included in the study and followed up at a mean 
of 3 (2-7) years after surgery. 
Study II
In study II, all patients who had undergone revi-
sion of THA at Danderyd Hospital with the Bi- 
Metric stem between 1989 — 2002 due to aseptic 
loosening were eligible for inclusion in the study. 
62 hips in 60 patients were identified. At follow-
up, 9 of the 60 patients had died. 1 of these had 
been re-revised 3 months after the uncemented 
stem revision due to a fracture adjacent to a per-
operative fenestration. The other 8 patients still 
had their stem in place. Thus, 51 patients (53 
hips) were followed up at a mean of 6 (2–13) 
years.
Study III
All 147 patients planned for primary THA dur-
ing 2006-2008 were screened for participation 
in the study. Patients aged 40-70 years, with 
primary OA of the hip, and a type A or B femur 
according to Dorr et al.74 were eligible for inclu-
sion in the study. 
Patients were excluded if they had a condition 
that could affect BMD. Patients with a hypersen-
sitivity to risedronate, who had hypocalcaemia, 
or who, for any reason, were unsuitable to take 
part of a randomized controlled trial, or patients 
who sustained a periprosthetic fracture during 
surgery, were also excluded.
We enrolled 73 patients, 36 in the risedronate 
group and 37 in the placebo group (Figure 31). 
All patients received at least 1 dose of study med-
ication and completed the 24 month follow-up. 
Study IV
All 229 patients who were admitted to our emer-
gency department with an acute (<24h before 
admission) FNF during the inclusion period be-
tween October 2005 and April 2008 were screened 
for participation in the study. The inclusion crite-
ria were a displaced fracture (Garden III or IV)108, 
an age of at least 70 years, intact cognitive function 
[at least 8 correct answers on a 10-item (SPMSQ) 
mental test],238 the ability to walk independently 
with or without the help of walking aids and a 
willingness to participate in the study. 
Patients with a previous fracture in the same 
hip, a pathological fracture, those deemed not 
suitable for THA by the anaesthesiologist or 
those who for any other reason were considered 
unsuitable to participate in the study, were ex-
cluded. A research nurse gave the patients oral 
and written information about the study, and 50 
patients who agreed to take part in the study gave 
their written informed consent.
Ethics
All studies were conducted in conformity with 
the principles of the Helsinki declaration and 
were approved by The Ethics Committee of the 
Karolinska Institute and the Committee for Pro-
tection Against Radiation at Danderyd hospital. 
Approval for Study III was also granted from The 
Swedish Medical Products Agency. 
The studies were initiated, designed and per-
formed as academic investigations. In Study III, 
the pharmaceutical company Sanofi-Aventis/
Warner Chilcott Pharmaceuticals Inc. funded in 
part the risedronate and placebo used. In Study 
IV, Biomet (Biomet Orthopaedics AB, Sjöbo, 
Sweden) marked the implants. Beyond this, nei-
ther company had any further input or participa-
tion in the studies. ◉
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figure 31. consort diagram study iii
Flow of patients in accordance with CONSORT (Consolidated Standards of Reporting Trials). Three subjects in the risedronate 
group were excluded from the BMD and radiological analysis of end points [stem revision 6 days postoperatively due to disloca-
tion (n=1), unwillingness to complete protocol due to nausea (n=2)].  All patients completed the end points for clinical outcome.  
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The Bi-Metric stem
In Study I-III, all patients received the uncement-
ed, tapered, collarless Bi-Metric stem (Biomet 
Inc., Warsaw, Indiana, U.S.A.) (Figure 32). It is 
made of Ti-6Al-4V, where the proximal one-
quarter has a circumferential, plasma-sprayed, 
Ti-6Al-4V porous coating with a mean pore size 
of 300 μm. 
The distal part has a grit-blasted surface with 
a roughness of 6.9 μm. The porous part has a 
plasma-sprayed HA layer of 40–70 μm thickness, 
crystallinity of 50–70%, and a purity of >95%. 
The stem has a straight 3º proximal-to-distal 
taper in 2 planes and a taper from the lateral 
shoulder to the medial calcar area. 
The stem is available in 13 proportional sizes 
from 7 to 19 mm, with corresponding lengths of 
115 to 175 mm and has both standard and later-
alized offset options. 
In Study I-II, there was initially (1989-1999) 
only a standard offset stem available. For ar-
ticulation, a 28-mm modular CoCrMb head of 
varying lengths of neck extension was used in all 
cases in Study I and III. In Study II the diameter 
of the head varied between 22 and 32 mm.
8 MATERIALS
figure 32. Bi-Metric stem. 
photo by Carin Wesström.
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The BFX stem
In Study IV, all patients received the Biomet 
Fracture Stem, BFX® (Figure 33), (Biomet UK 
Ltd, Bridgend, U.K.). It is a tapered, collared, 
stem intended for uncemented fixation in the 
femur. It is made of Ti-6Al-4V with a grit-blasted 
surface roughness of 7.5-10 µm. 
The geometry of the stem, except for the collar, 
is identical to the Bi-Metric® stem, but it has no 
proximal porous coating. The stem has plasma-
sprayed HA on the entire surface (thickness 
65-95 µm, crystallinity 50-70%, purity >95%) to 
enable fast ingrowth in osteoporotic bone.59 
The stem is available in 6 sizes (7-17 mm, un-
even sizes only), and has a standard offset with a 
neck/shaft angle of 140°. For articulation, a 32-
mm modular CoCrMb head of varying lengths 
of neck extension was used in all cases.
Acetabular Components
In Study I-III, both uncemented and cemented 
cups were used according to the surgeons’ prefer-
ence and in Study IV only cemented cups were 
used (Table 4). 
In Study I-II, standard polyethylene, and in 
Study III-IV, XLPE (Longevity®) was used.
In Study I and II, two types of uncemented 
acetabular components were used. The first 
(Romanus®, Biomet UK Ltd, Bridgend, U.K.), 
used 1989-1999, is a partially threaded acetabu-
lar Ti-6Al-4V shell with plasma-sprayed Ti-6Al-
4V porous coating covered with HA, combined 
with a polyethylene liner. The second (Trilogy®, 
Zimmer, Warsaw, Indiana, U.S.A), is a Ti-6Al-4V 
hemispherical press-fit shell with sintered Ti-
6Al-4V porous coating covered with HA, com-
bined with a polyethylene liner. Both acetabular 
components have a ring locking mechanism to 
secure the liner to the shell. ◉
figure 33. Biomet Fracture Stem (BFX®). 
The implant has been modified for RSA with tantalum marker beads 
at the shoulder, collar and tip of the prosthesis. Photo by Carin 
Wesström.
tABle 4. Acetabular components used in Study I-IV
type study i study ii study iii study iii
risedronate placebo
Uncemented 74 18 9 11 0
Cemented 64 35 27 26 50
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Study protocol and follow-up
Study I and II were both retrospective, cross-
sectional studies with patients attending a single 
follow-up visit. In both these studies, prospec-
tively collected data from hospital charts and 
radiographs were available for analysis in all 
patients. Study III and IV were both prospective 
studies with data collected at regular follow-up 
visits up to 2 years after inclusion. The study pro-
tocol and follow-up visits are shown in Figure 34.
9 METHODS
Orthopaedic researchers use a number of objective and subjective instruments to measure the 
outcome after THA. Radiological outcome includes evaluation of the fixation and stability 
of the implant from plain radiographs,91 RSA of implant migration264 and DXA to access the 
amount of bone remodelling. Clinical outcome involves patient satisfaction, measured by hip 
specific127 and generic outcome scores,245 as well as complication rates after surgery. 
On a national level, hip arthroplasty registers provide not only valuable epidemiological 
information but also patient, hospital and implant related risk factors for revison.109,117,129
figure 34. Study protocol and follow-up visits
RadRSA=Calibrated stereo radiographs for RSA, DXG=DXA scan 
of Gruen zones, DXF=DXA scan of the contralateral (Study 
IV) or diseased (Study III) proximal femur (WHO), DXV=DXA 
scan of vertebrae L1-L4, Rad
AP= anterioposterior and lateral 
radiographs, Clin=clinical outcome. a=mean follow-up time. 
n=number of patients evaluated at each follow-up visit. 
 ◉
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Surgical technique
Pre-operative planning was performed with 
templates on plain radiographs in Study I-II and 
with a digital templating software (mDesk®, RSA 
Biomedical, Umeå, Sweden) in Study III-IV. 
In Study IV, all operations were done within the 
first 48 hours after admission and in Study I-III 
all were performed as planned procedures. The 
surgical technique and instrumentation used 
were identical for both stems. 
A standard posterolateral approach,210 with re-
pair of the posterior capsule and external rotator 
muscles,163 was used. In Study II, the repair was 
not routinely done in the first years of the study. 
Once the femoral head has been dislocated from 
the acetabulum, the resection of the femoral neck 
was done using a template (Figure 35). The femoral 
canal was then reamed with increasing sizes until 
cortical bone contact was obtained (Figure 36). 
 
Thereafter, the proximal femur was prepared 
with broaches of increasing size until rotational 
stability was achieved (Figure 37). With the final 
broach in place, the calcar femoris was planed 
flush using a planing tool and the final implant 
was inserted (Figure 38). 
In Study IV, the prosthetic collar thus rests on the 
calcar femoris when the prosthesis is fully seated 
and rotationally stable (collar-calcar contact). 
For some hips, the fracture line was more distal 
than the ideal collar resection line; in these hips, 
the collar of the stem did not rest on bone when 
the stem was rotationally stable (no prosthetic 
collar-calcar contact). 
Before the final implant was inserted, 5 to 9 
tantalum marker beads (1.0 mm in diameter) 
were inserted in the cancellous bone of the proxi-
mal femur. 
In Study II bone grafting around the neck of the 
stem was carried out in 33 of the 62 original cases.
figure 35. Head resection figure 36. Reaming
9.1 SURgERY
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figure 37. Broaching figure 38. Final implant
Per- and post-operative care
After 2001, in Study I and II and for all patients 
in Study III and IV, intravenous tranexamic acid 
(Cyclokapron®, Pfizer, Sweden) was administered 
before the start of surgery to reduce bleeding. 
Prophylactic antibiotics (Cloxacillin®, Meda, 
Sweden) were given to all patients 30 minutes 
prior to the start of surgery and in the first 24 
hours post-operatively. 
To reduce the risk for thromboses, intrave-
nous dextran (Macrodex® Meda, Solna, Sweden) 
was given during the first 3 days in Study I-II. In 
Study III-IV, daltaparin (Fragmin®, AstraZeneca, 
Sweden) was given 10 days post-operatively to 
prevent thromboses. 
The patients were mobilized using a standard 
physiotherapy program. In Study I-II, no protocol 
regarding weight bearing or use of crutches was 
used. In Study III-IV, patients were encouraged 
to weight bear fully using crutches for support. 
Risedronate
In Study III, the patients were randomized on the 
second post-operative day to take either a tablet 
of 35 mg risedronate or placebo once weekly for 
6 months. 
Patients were instructed to take the tablet on an 
empty stomach 30 minutes before breakfast and 
to remain in an upright position for 1 hour after 
ingestion of the tablet. 
All patients received oral supplements of 
calcium carbonate (1000 mg) and vitamin-D 
(400 IU) daily for 6 months. The computerized 
randomization and blinding procedure was car-
ried out by the central pharmacy (Apoteket AB, 
Stockholm, Sweden), which produced the study 
drug and the placebo tablets in physically indis-
tinguishable and coded containers. 
Patients were block-randomized in groups of 
10 using sealed envelopes and the randomization 
was stratified to ensure that the gender distribu-
tion would be the same in both groups. All pa-
tients, staff and investigators were blinded as to 
the treatment assignment during the study. 
Two patients in the risedronate group were 
unblinded due to adverse events. 
Compliance (≥80% of study drug taken) was 
controlled at the 6 week, 3 and 6 monthly follow-
up visits. The compliance was 93% in the risedro-
nate and 97% in the placebo group. ◉
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Fixation/Stability score 
In 1990, Engh and co-workers presented a semi-
quantitative radiological assessment of the bio-
logical fixation of porous-coated femoral com-
ponents.91 They developed a scoring system that 
is divided into signs of fixation (in the original 
article synonymous with osseointegration) and 
stability. The score is used in Study I-III.
Signs of fixation are absence/appearance of 
endosteal bone bridges (spot welds) (Figure 39) 
and absence/appearance of reactive lines in the 
coated region of the stem. 
Signs of stability include absence/appearance 
of reactive lines in the uncoated region, pedestal 
formation (Figure 40), calcar modeling (Figure 
39), interface deterioration (widening radiolu-
cent lines), migration of the implant and visible 
shedding of particles from the porous coating. 
Migration was considered definite if the 
change was more than 4 mm.191
Distal cortical hypertrophy is not part of the 
original score but is a sign of firm distal fixation 
(Figure 40). In Study IV, in addition to assessing 
the Stability/Fixation score, the presence of oste-
olysis and distal cortical hypertrophy were noted. 
By assigning points for each sign when present, 
absent or if undetermined, a scoring system was 
developed (Table 5) and validated against clinical 
parameters such as hip pain and walking ability.91 
A score of ≥0 indicates a fixated and stable stem, 
a score <0 clinically uncertain and <5 a definitely 
unstable (loose) stem.
This scoring system is still widely used to de-
scribe the radiological outcome after THA with 
uncemented stems despite the fact that DXA and 
RSA have emerged as more precise methods of 
measuring fixation and bone remodelling.
9.2 RADIOLOgICAL METHODS
tABle 5. Fixation/Stability score91
sign present no undeter-mined yes
fiXAtion scAle
spot welds? -2.5 0 +5.0
reactive lines in ≥50% of porous 
coating
+5.0 0 -2.5
stABility scAle
reactive lines in ≥50% of distal stem +5.0 0 -3.5
pedestal formation and reactive lines +2.5 0 -3.5
calcar atrophy -3.5 0 +4.0
interface deterioration +2.5 0 -2.5
migration +3.0 0 -5.0
particle shedding +1.0 0 -5.0
figure 39.  The 2-year radiograph of a 41-year old man in the 
placebo group in Study III. Note calcar atrophy (A), spot welds (B) and 
proximal cancellous bone atrophy (C).
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Other radiological parameters
In all studies, anterioposterior and lateral radiographs were reviewed at follow-up visits. In 
Study I-II, plain, and in Study III-IV, digital radiographs were used.
rAdiolucent lines
In Study I-III, radiolucent lines between bone and 
cement (for cemented cups) or bone and porous 
coating (for uncemented cups) in DeLee and 
Charnley67 zones around the cups were recorded. 
Heterotopic ossificAtion
In Study II-IV, the presence of heterotopic ossifi-
cation was evaluated according to Brooker et al.42 
position of implAnt
In Study IV, varus/valgus angle and fill153 of the 
stem in the femoral canal were measured on ra-
diographs with the digital templating software. 
The proximal fill was measured at the upper 
border of the lesser trochanter and the distal fill 
3 cm proximally of the tip of the prosthesis. Fill 
was defined as good when there was an 80% fill 
on the anterioposterior radiograph and 70% fill 
on the lateral radiograph.153
dorr clAssificAtion
A simple classification for pre-operative bone 
quality before primary THA, aimed at estimating 
the suitability of a uncemented stem, and based 
on the radiographic appearance of the femur, is 
the Dorr classification.74 
Dorr suggested that there are three types of 
proximal femur, A is the normal taper and thick 
cortex, C is a clear loss of taper and thin cortex 
(also called stove pipe femur), and B is in be-
tween. In Study III, A and B femur were used as 
an inclusion criterion in the trial.
figure 40. Example of distal cortical hypertrophy (A) 
and pedestal formation (B).
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Classification of bone defects
All failed THA’s have bone defects and often this bone loss is more advanced than the 
radiographs indicate.79 Nevertheless, for the surgeon it is necessary to assess this pre-ope-
ratively so as to be able to best plan for the revision surgery.196 
In Study II, we used the Bi-Metric stem in cases 
where the pre-operative bone defects were mod-
erate (type I-III) according to the following two 
classification systems (Figure 41): 
gustilo-pAsternAK clAssificAtion119
According to this classification a type I defect is 
denoted by minimal endosteal or inner cortical 
bone loss. A type II defect involves proximal ca-
nal enlargement with cortical thinning of 50% or 
more and sometimes a lateral wall defect with an 
intact circumferential wall is presented. 
A posteromedial wall defect involving the 
lesser trochanter is classed as type III. A type IV 
defect exhibits total proximal circumferential 
bone loss of varying distances below the lesser 
trochanter.
endo-KlinK clAssificAtion84
A type I defect means there are radiolucent lines 
limited to the proximal half of the cement mantle 
in combination with clinical signs of loosening. 
A complete radiolucent line surrounding the 
cement mantle with endosteal erosion around 
the proximal section of the cement mantle result-
ing in widening of the medullary canal indicates 
a type II defect. 
In a type III there is a widening of the medul-
lary cavity around the loose implant due to end-
osteal erosion and expansion of the femur. 
A type IV defect displays large destruction of 
the proximal third of the femur with involvement 
of the middle third femur.
figure 41.  Aseptic loosening with bone defects type I, II and III according to both classification systems.
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The method requires the insertion of tantalum 
markers (0.8 – 1.0 mm) into the skeleton (Fig-
ure 42) as well as corresponding marking of the 
implant (or other skeletal structure) to create two 
rigid bodies called segments. Post-operatively, 
and at regular follow-up intervals, simultaneous 
calibrated stereo radiographs are taken. 
The migration of the center of gravity of the 
implant segment in relation to the skeleton seg-
ment for translation and rotation around the x-, 
y- and z-axes (the six degrees of freedom) is then 
calculated using readily available computer soft-
ware (Figure 43).146,282,301 
By doing measurements over time, implant 
migration can be quantified and loosening pre-
dicted with high sensitivity.165,257 The precision 
of RSA is, in laboratory conditions, close to per-
fect302 and in clinical trials typically around 0.2 
mm in translations and 0.5° in rotations.13,35,39,49
In RSA studies, the amount of migration that 
increases the risk for revision varies between 
implants and the method of fixation. For the 
cemented Lubinus SP I stem, a subsidence ex-
ceeding 1.2 mm during the first post-operative 
year indicates a 50% risk for revision within 5-7 
years.165 In uncemented stems, there is evidence 
that subsidence should be lower than 1-1.5 mm 
and retroversion less than 3° during the first year 
to avoid revision surgery.166 
rsA in study iV
The RSA method in Study IV follows the pub-
lished guidelines for RSA.301 We took digital 
calibrated radiographs (Bucky Diagnostic®, Phil-
ips, Eindhoven, Netherlands) using a fixed and a 
mobile x-ray source (120 kV, 4-6 mAs), and an 
uniplanar calibration cage (Uniplanar digital 43, 
RSA Biomedical AB, Umeå, Sweden), (Figure 
44). All data were analysed using the UmRSA® 
computer software (RSA Biomedical AB, Umeå, 
Sweden). 
The markers in the proximal femoral bone 
form one segment. The centre of the prosthetic 
head, in combination with the tantalum marker 
beads in the femoral stem, forms another seg-
ment. The 3-D translations and rotations of the 
Radiostereometry
Radiostereometry (synonyms; radiostereometric analysis and roentgen stereophotogram-
metric analysis) is a high-precision method to measure three-dimensional (3-D) micro-
motions from calibrated stereo radiographs.264 Since its introduction in the 1970s, it has 
been widely used to measure 3-D motion between skeletal structures,199 between implants 
and host bone165 and for wear analysis.71 
figure 42. Tantalum markers in proximal femur (white ar-
rows) and implant (black arrows).
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calculated centre of gravity of the femoral stem 
segment in relation to the femoral bone segment 
were calculated at each follow-up visit with the 
immediate post-operative examination as base-
line. 
We also measured the maximum total point 
motion (MTPM). This is the 3-D translation 
vector of the femoral stem marker that has the 
largest movement and is seen as an indicator of 
the overall magnitude of migration. 
At 12 months, we performed double examina-
tions 15 minutes apart on 25 patients with com-
plete repositioning of the x-ray tubes and the 
calibration cage. We calculated the precision as 
the 99% confidence limits (SD 2.7) of the differ-
ence between these examinations. For transla-
tion along the x (transverse), y (vertical) and z 
(anterioposterior) axes, it was 0.27, 0.19 and 0.52 
mm, respectively. For rotation about the x-axis 
(flexion/extension), y-axis (ante-/retroversion) 
and z-axis (varus/valgus) the values were 0.52, 
0.76 and 0.27°, respectively and for MTPM it was 
0.74 mm. The precision for our RSA-setting is 
similar to that of previously reported trials.122,281
The mean error of rigid body fitting282 is used 
to evaluate the stability of marker position over 
time. We excluded examinations where this value 
was >0.3 mm, indicating migration of markers. 
Condition number282 is used to evaluate 
marker distribution and a high value precludes 
accurate measurements of z-translation as well as 
segment rotation and MTPM. Therefore, in ex-
aminations where the condition number exceeds 
100, only transverse (x) and vertical (y) transla-
tions were calculated.
figure 43. RSA evaluation of calibrated stereo radiographs in semi-automated software.
figure 44. RSA setting in Study IV showing the fixed and the mobile 
x-ray tubes.
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Einzel-Bild-Röntgen-Analyse
Einzel-Bild-Röntgen-Analyse159 (EBRA) can also be used to measure migration of im-
plants. Compared to RSA, it has both advantages and limitations. 
The greatest advantages are that it can be used 
retrospectively on plain radiographs, that the 
precision is significantly better than manual 
methods and that no implant or host-bone mark-
ing is necessary.239 
Initially, it could only be used to assess migra-
tion of acetabular components159 but the method 
was later expanded to include assessment of mi-
gration in femoral components (EBRA-FCA) as 
well.21 
The biggest disadvantages are its lower preci-
sion compared to RSA, that it can only be used 
to evaluate THA and that more patients are re-
quired for a trial. 
EBRA has been used in several studies to 
analyze clinically relevant migration of a femoral 
stem after THA157,160 and has, as in Study III, 
been used to study the effect of bisphosphonates 
on cup and stem migration after THA.104,306
eBrA-fcA in study iii
As in RSA, a semi-automated software is used for 
the analysis, and points are placed in predefined 
areas around the contours of the implant (Figure 
45).201 At least 4 plain radiographs are required 
for each patient at different follow-ups. 
The software excludes radiographs that are not 
comparable. Thereafter, it calculates the vertical 
migration of the stem shoulder in relation to the 
greater trochanter, as well as, the angle between 
the bone and stem. The diameter of the femoral 
head is used to correct for magnification. 
The software uses algorithms to calculate 
corrected migration based on comparable radio-
graphs (Figure 46). 
Using these landmarks, the method has an ac-
curacy of 1.5 mm and it can detect a migration 
larger than 1.0 mm with a specificity of 100% and 
a sensitivity of 78%.21
figure 46. EBRA-FCA graph of migration based on compa-
rable radiographs.
figure 45. EBRA-FCA measurement.
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Dual-energy X-ray Absorptiometry
Radiographs are insensitive when used for quantifying bone density change, requiring 
losses of up to 30% before being reliably detectable.88 DXA is a more sensitive tool for 
measuring bone remodelling around femoral stems and was first used to measure BMD of 
the spine150 and the femoral neck.227 
For scanning, the patient is placed in the supine 
position on the patient table. A narrow x-ray 
beam (small angle fan-beam), filtered through 
a metal filter (cerium) producing two x-ray en-
ergies, is scanned across the patient. The x-rays 
transmitted through the body are collected by a 
digital detector which produces a signal. 
The detector can separate the signal into two 
different energy regions corresponding to the 
energies produced from the x-ray source. The 
greater the BMD, the greater the difference in the 
detected signal between the two energy regions 
will be. The difference in attenuation coefficient 
for muscle as opposed to bone is used in an equa-
tion to calculate the BMD.
Quantitative computed tomography is the only 
technique that can directly measure bone density 
and volume and can distinguish trabecular from 
cortical bone. However, DXA scanning is less 
expensive, exposes the patient to less radiation145 
and is more sensitive and accurate at measuring 
subtle changes in bone density over time30,33 or 
changes that occur in response to drug thera-
py12,63,304 as in Study III of this thesis. 
DXA measures bone mineral content (BMC) 
in grams in the frontal plane only and by dividing 
it with the scanned surface area the BMD in g/
cm2 can be calculated. 
In the early 1990s, new software developments 
made it possible to measure BMD adjacent to 
metal implants152 which spawned a plethora of 
published reports in the field of bone remodel-
ling after THA.17,60,161,258 
The standard method is to measure BMD 
around the stem in the 7 frontal Gruen zones118 
(Figure 47), but it can also be used around ac-
etabular cups,70,98 in modified zones for ultra-
short stems4 or for resurfacing implants.130,177
dXA in study i, iii And iV
In Study I, III and IV, a DXA scanner was used 
(DPX-L™, Lunar Co., Madison, Wisconsin, 
U.S.A.) to measure BMD of the periprosthetic fe-
mur in the 7 Gruen118 zones in the frontal plane. 
During scanning, the patient was placed in the 
supine position with knee and foot supports and 
the femur was positioned in neutral rotation. The 
software then detects the interface between the 
bony part and the prosthesis stem on the basis 
of density changes and simulated the stem in the 
form of a prosthesis mask corresponding to the 
Gruen zones.
figure 47. The 7 Gruen zones in the frontal plane. Illustration by 
Max Gordon.
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AccurAcy of dXA
Accuracy is defined as the closeness of a true 
value and the most probable value, which has 
been derived from a series of measurements. 
Accuracy includes both random and systematic 
errors. 
The accuracy of DXA in determining the 
true BMD of bone is controlled in several ways. 
Firstly, a HA phantom with known BMC of the 
lumbar spine and hip is used to calibrate the 
scanner after manufacture. Secondly, the physi-
cist performed weekly scans with an aluminium 
vertebrae phantom (Figure 48). In addition, daily 
scans of another phantom were performed to 
calibrate hardware and software parameters and 
radiation dose. 
The accuracy error using this control method 
is typically 0.5-1%. 
precision of dXA
Precision, also called reproducibility, is the de-
gree to which repeated measurements under 
unchanged conditions show the same results and 
refers to random errors. The precision of BMD 
measurements around an implant is, in a HA 
phantom 0.6% and in cadavers 2-3%.60
To estimate the precision error of the DXA meth-
od, we had previously made double measure-
ments in 10 patients with complete repositioning 
of the patients and the scanner and calculated the 
error of the difference between these two mea-
surements. 
The precision error was found to be 2.3% in 
Gruen zone 1, 1.0% in zone 2, 2.0% in zone 3, 
3.5% in zone 4, 4.2% in zone 5, 1.3% in zone 6, 
and 3.7% in zone 7.30 This precision compares 
well with that reported in other studies.152,220
cAlculAting Bmd cHAnge
In Study I, the healthy hip was scanned at the 
corresponding level and the prosthesis mask was 
superimposed on the healthy side and used as 
control to calculate percentage BMD change. 
In Study III-IV, the change in periprosthetic 
BMD ratio in all individual zones, as well as 
the entire periprosthetic region (zone 1-7), was 
calculated by dividing the BMD value at each 
follow-up visit by the post-operative BMD and 
converting it to a percentage change.
In Study III-IV, as well as periprosthetic BMD, we 
also assessed the patients general BMD. In Study 
III, this was done pre-operatively (at inclusion) 
by scanning the proximal femur of the diseased 
hip (WHO total hip) and vertebrae L1-L4 (WHO 
lumbar spine). In Study IV this was done imme-
diately post-operatively by scanning the proximal 
femur in 36 patients with a healthy contralateral 
hip at inclusion. This was then used as a proxy for 
the pre-operative BMD of the injured side. 
In Study III-IV we also scanned the lumbar spine 
of all patients. In both studies the BMD of the 
L1-L4 vertebrae were also measured at 24 months 
post-operatively. ◉
figure 48. Aluminum phantom used for weekly accuracy calibration.  
Photo by Hans-Jerker Lundberg
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Charnley classification
In his original article on low-friction arthro-
plasty,54 Charnley suggested a simple classifica-
tion system for assessing the walking ability of 
patients who are candidates for hip arthroplasty 
surgery. (A) denotes a patient with unilateral hip 
disease or unilateral THA. (B) is a patient with 
bilateral hip disease (or with a THA in one hip 
and disease in the other). (C) is a patient with 
a co-morbidity contributing to loss of walking 
ability, such as rheumatoid arthritis, knee OA, 
cardiovascular or respiratory disability. 
This commonly used classification system al-
lows a comparison between groups and is used as 
a co-morbidity factor in the Swedish Hip Arthro-
plasty Register.109
Charnley’s classification has also been criticized 
because of its simplicity as those graded as class 
B consists of two very different patient groups: 
those with a THA in one hip and a diseased joint 
in the other, and those who have bilateral THAs. 
An extension of the traditional Charnley clas-
sification has therefore been proposed, taking 
into account the two different patient groups in 
Charnley class B. The new fourth Charnley class 
consists of patients with bilateral THA and is la-
beled BB in order to express the presence of two 
artificial hip joints.251 
In this thesis however, the original A, B and C 
classification has been used.
Harris hip score
The most widely used hip-specific outcome score 
after THA is the Harris hip score (HHS).127 
Originally developed for outcome measurements 
of mold arthroplasty after traumatic arthritis, it 
has been found to be a valid and reliable score for 
hip function after THA.276 HHS was originally 
surgeon-assessed but since then has been vali-
dated for self-reporting,186 and also for outcome 
after FNFs.105
The HHS gives a maximum of 100 points (full 
function of the hip) and a minimum of 0 (no 
function in the hip). It has 4 domains: pain, func-
tion, deformity, and range of motion. Pain and 
function are the two domains with the heaviest 
weighting (44 and 47 points, respectively). Func-
tion is further subdivided into activities of daily 
living (14 points) and gait (33 points). Range of 
motion, deformity and limb length discrepancy 
receives 9 points. The somewhat elaborate calcu-
lations for the last three categories can be simpli-
fied with on-line tools.56
In this thesis, the assessment of the HHS was 
done as it was originally intended; by the surgeon 
at the follow-up visit.127 
EQ-5D
EQ-5D95 is a standardized, self-reported, non-
disease-specific instrument for measurement of 
health-related quality of life that was developed 
by the EuroQoL group.43,245 It is now widely used 
in many countries around the world and has 
been translated into most major languages.43,45
EQ-5D describes health status in 5 dimensions: 
mobility, self-care, usual activity, pain/discom-
fort and anxiety/depression. Each dimension is 
divided into 3 levels: 1 - no problems, 2 - some 
problems and 3 - extreme problems. This gener-
ates 243 different “health states” and the EQ-5D 
index score assigns each “health state”  a value, 
ranging from -0.59, indicating the worst possible 
health state, to a value of 1, indicating full health. 
EQ-5D has been used in clinical trials in many 
different fields of medicine and is frequently used 
to access quality of life after both hip fracture 
surgery24,293 and THA.187,209
9.3 CLINICAL OUTCOME MEASUREMENTS
50 olof sköldenberg
UNCEMENTED FEMORAL STEMS 
/ Thesis / Methods
Pain Numeric Rating Scale
The Pain Numeric Rating Scale (PNRS)77 is an 
11-point (0-10) numerical rating scale that is 
easy to administer, and has been validated as a 
measure of pain intensity in populations with 
known pain.142 A score of 0 denotes no pain and 
10 indicates the worst possible pain. In Study III 
and IV, patients were asked to evaluate the level 
of pain they experienced in the operated hip dur-
ing the previous week (Figure 49).
Complications
In all studies information regarding the occur-
rence of complications and reoperations was 
collected on all patients. This was done retro-
spectively by checking hospital records in Study 
I- II and prospectively at regular follow-up visits 
in Study III-IV.
HHS was used to evaluate hip function in all 
studies and the Charnley classification was used 
in Study II-IV. EQ-5D and PNRS was used at 
follow-up visits in Study III-IV. In Study I-II the 
presence of thigh pain was graded by the patient 
as either mild, moderate or severe. ◉
In Study I-II, the statistical package JMP 6.0 was 
used for all analyses. In Study III-IV, the statisti-
cal software PASW Statistics 18.0 for Windows 
was used. Sample size calculations were per-
formed using the software SamplePower 2.0. 
Sample size calculation
study i
A power analysis was performed in advance 
(one-sided, p=0.05) and indicated a 90% power 
to detect a 15% difference in BMD (SD 10%) 
between the non-operated and operated side in 
Gruen zones 1 and 7 using 21 patients.
study ii
No power analysis was performed in advance.
study iii
A power analysis (two-sided, p=0.05) based 
upon Study I was performed in advance on 
the primary end point. A total of 30 patients in 
each group indicated a power of 90% to detect 
a clinically relevant difference of 10% (SD 11%) 
in BMD in the periprosthetic zones 1 and 7 
between the 2 treatment groups. We estimated 
that we would have a loss of data of up to 20% 
and therefore planned to recruit 37 patients in 
each group.
study iV
A power analysis performed in advance indicated 
that the study, with 20 patients, would have a 
power (two-sided, p=0.01) of more than 99% and 
93% to detect a continuous migration in MTPM 
and y-translation, respectively. 
These estimates were based upon a previous 
RSA study with the HA-coated version of the 
Bi-Metric stem281 where MTPM was mean (SD) 
1.9 (1.3) mm and y-translation was 0.2 (0.2) mm. 
We recruited 50 patients to accommodate for 
an expected loss to follow-up and to allow for 
subgroup analyses in subjects with high and low 
BMD.
9.4 STATISTICAL METHODS
figure 49. Pain Numeric Rating Scale.
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Statistical analysis
Due to varying journal policies, the methods re-
garding parametric or nonparametric tests differ 
somewhat in the studies. We used the chi-square 
test to test for differences between distributions. 
P-values ≤0.05 were considered significant.
study i
Student’s t-test was used to analyze the difference 
in BMD between the operated and non-operated 
hip and also the difference between stem sizes in 
the different Gruen zones. To investigate factors 
that may influence bone remodelling, we used 
the Pearson’s product moment correlation coef-
ficient to analyze the relationship between BMD 
and sex, age, weight, height, body mass index, 
implant time, initial BMD—expressed as BMD 
on the healthy femur—and Harris hip score. 
study ii
The Mann-Whitney U-test was used to test the 
association between HHS and Charnley’s clas-
sification system. 
study iii
Analyses of efficacy were based on the intention-
to-treat principle and all patients, who received at 
least 1 dose of either risedronate or placebo, were 
included in the final analyses. Subjects with miss-
ing BMD data at any of the follow-ups (5 follow-
ups in the risedronate group and 4 in the placebo 
group) were analyzed with the last observation 
carried forward. The analyses were repeated with 
the use of only the available data, and the same 
results were produced (data not shown).
We used a one-way repeated measures analysis of 
variance (ANOVA) to detect an overall effect of 
treatment throughout the study period. 
Factors known to influence periprosthetic 
bone loss, for example sex,7 age, BMI, stem 
size271 and pre-operative BMD of the hip246, were 
included as covariates in the analyses. Stem size 
was categorized into sizes 8-10/11-13/14-15 (size 
8-10 as reference). 
Median pre-operative hip BMD (1.014 g/
cm2) was used to dichotomize the subjects into 
2 groups; patients with either high or low BMD 
(mean 1.173±0.130 g/cm2 and 0.896±0.096 g/
cm2, respectively). The reference category was 
patients with a high BMD. The effect of general 
bone mass (WHO total hip and WHO lumbar 
spine) on periprosthetic bone loss was also ana-
lyzed using the Pearson’s correlation coefficient at 
24 months. 
The unpaired Student’s t-test was used for 
group comparisons and the paired Student’s t-test 
for comparing longitudinal changes. Between-
group comparisons of clinical outcome scores at 
follow-up visits were analyzed with the Mann-
Whitney U-test and within-group comparisons 
between baseline and follow-up were analyzed 
with the Wilcoxon signed-rank test. 
study iV
We used analysis of covariance (ANCOVA) to 
study covariates affecting implant migration and 
bone loss. Firstly; to evaluate the effect of peri-
prosthetic BMD on implant migration and bone 
loss, we used MTPM and a BMD change in zone 
1-7 as dependent variables and sex, age, BMI, 
stem size and immediate post-operative BMD in 
zone 1-7 as covariates. 
Median BMD was used to dichotomize the 
subjects into 2 groups, patients with either high 
or low BMD (high vs. low: mean BMD 1.77 ± 
0.33 g/cm2 and 1.35 ±0.11 g/cm2, respectively). 
In the second analysis, we evaluated the effect 
of pre-operative BMD on bone loss in a subgroup 
of 36 patients. These patients had a healthy con-
tralateral femur at inclusion and post-operative 
DXA scans of the unaffected hip and vertebrae 
L1-L4 (WHO total hip and lumbar spine) were 
used as a proxy for pre-operative BMD and cat-
egorized as normal (T-score >-1 SD), osteopenia 
(-1 SD≥ T-score >-2.5 SD) and osteoporosis (T-
score ≤-2.5 SD). In the analyses, BMD change in 
zone 1-7 then was used as the dependent variable 
and sex, age, BMI, stem size and T-score category 
of the hip or lumbar spine as covariates. 
Between-group comparisons of continuous 
variables at follow-up were analyzed with the 
Mann-Whitney U test and within-group com-
parisons between baseline and follow-up values 
were analyzed with the Wilcoxon signed-rank 
test. ◉
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Study I
clinicAl outcome
Within 6 weeks of surgery, 16 non-fatal com-
plications (7 superficial wound infections that 
required antibiotics, 4 deep venous thromboses, 
3 pulmonary emboli, and 2 myocardial infarc-
tions) were diagnosed. 
All stems were stable according to the Fixa-
tion/Stability score and no stem revision was 
required. The mean HHS was 97 (63–100) points 
with 6 patients having mild thigh pain. 
stem size And Bone loss
The distribution of stem sizes in females and males 
differed somewhat (Figure 50), the most common 
size for females being 11 and for males 13. 
The periprosthetic bone loss was most pro-
nounced in zones 1 and 7 with a -19% difference 
compared to the unoperated side (Table 6 and 
Figure 51). In the proximal zones 1, 2, 6 and 7 we 
found a decreasing BMD correlated to the stem 
size used (r2=0.16, 0.09, 0.16 and 0.14, respec-
tively), (Figure 52 and Figure 53). The multiple 
regression analysis with stem size as control vari-
able showed no correlation between bone loss 
in any zone of the operated femur and sex, age, 
weight, height, body mass index, implant time, 
initial BMD—expressed as BMD on the healthy 
femur—or HHS. 
In addition, no difference was found in BMD 
loss in any zone between the patients who re-
ceived an uncemented HA-coated cup and those 
who received a cemented polyethylene cup.
10 RESULTS
tABle 6. BMD in the 7 Gruen zones for all stem sizes. Mean 
(SD) values.
gruen zone operated  side (g/cm2)
unoperated  
side (g/cm2) change (%)
1 0.85 (0.16) 1.05 (0.17) –19 (11)
2 1.81 (0.28) 1.85 (0.26) –2 (10)
3 2.00 (0.25) 1.92 (0.25) +5 (8)
4 1.91 (0.29) 1.95 (0.26) –2 (9)
5 2.09 (0.23) 1.99 (0.23) +5 (7)
6 1.78 (0.28) 1.87 (0.23) –5 (10)
7 1.09 (0.29) 1.35 (0.24) –19 (15)
figure 50. The distribution of femoral stem diameters.
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figure 52. Scatter plot of correlation between stem size and BMD 
ratio (percentage of the contralateral value) in Gruen zone 1. 
figure 51. Bar graph illustrating the mean 
percentage changes in Gruen zones 1-7 as a 
function of the 11 different stem sizes. 
* indicates a statistically significant (p≤0.05) 
side-related difference for this size in that zone.
figure 53. Scatter plot of correlation between stem size and BMD 
ratio (percentage of the contralateral value) in Gruen zone 7.
stem sizestem size
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Study II
clinicAl outcome
Between the femoral revision operation and 
the follow-up, 6 of the original 60 patients (62 
hips), had undergone a cup revision/liner ex-
change and 3 stems required re-revision (Table 
7). The 6-year prosthetic survival rate was 95% 
(95% CI: 0.83–0.98). The dislocation rate was 
15 % (9/62). 
At follow-up, the mean HHS score was 75 
(30–100) points. We noted a lower HHS for pa-
tients classified as Charnley class C compared 
to patients classified as class A (p < 0.001) and 
B (p < 0.005), (Figure 54). 
rAdiogrApHic results
Bone defects were predominately type II in 
both classifications, and no type IV defect was 
observed (Table 8). 
At follow-up, all stems showed several signs 
of rigid fixation (Table 9).
The most commonly used stem sizes in 
Study II were 15 and 17. There were no differ-
ences in HHS or bone remodelling parameters 
between large and small diameter stems (data not 
shown). However, only 4 patients received a stem 
smaller than 15 mm and the smallest stem used 
in the study was 11 mm. 
tABle 8. Femoral bone defects at revision (53 hips)
type gustilo and pasternak endo-Klinik
I 17 4
II 35 38
III 1 11
IV 0 0
tABle 9. Bone remodelling at follow-up (53 hips)
no.
STEM STABIlITy PARAMETERS
Fixated stems 53
Subsidence (maximum 8 mm) 19
Change in varus-valgus alignment 0
Spot welds 30
STRESS-SHIElDINg PARAMETERS
Calcar resorption 16
Calcar ”round-off” 7
Distal cortical hypertrophy (1-4 mm) 14
BONE REMODEllINg PARAMETERS
Osteolysis at revision 48
Regression of osteolysis
total 7
partial 37
Newly formed osteolysis 2
UNSPECIFIED PARAMETERS
Pedestal formation 36
Reactive lines 16
Heterotopic ossification
grade 1 13
grade 2 6
grade 3 5
grade 4 0
tABle 7. Complications and revision surgery of the original 
62 hips
Complications n
Stem re-
revision
Cup revision/
liner exchange
Dislocationa 9 1
Cup loosening 5 5
Periprosthetic fracture
Peroperativeb 4 1
Postoperative 4 2c
Deep infection 1
Superficial infection 2
DVT 1
Sensory sciatic nerve injury 1
a  Two had recurrent dislocations, 1 underwent liner exchange 
converting it to a larger articulation.
b  Two of these were treated with cerclage wiring peropera-
tively. The revised patient, who sustained a fissure in the 
lesser trochanter peroperatively, suffered from pain and 
subluxations. The stem had subsided and he was re-revised 
using impacted morselized bone allograft and a cemented 
stem.
c  One immediate re-revision and another 2 years postopera-
tively .
figure 54. Box plot of Harris hip score (53 hips) in the dif-
ferent Charnley classes.
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Study III
clinicAl outcome
The frequency of adverse events was comparable 
in both groups (risedronate vs. placebo; 20 of 
36 versus 24 of 37, p=0.416). In the risedronate 
group, a significantly larger number of patients 
discontinued the study drug because of adverse 
events [2 due to urticaria and 2 due to nausea 
(p=0.037 versus placebo)]. 
Two patients in the placebo group suffered a 
non-traumatic dislocation of the hip; one patient 
had to undergo a stem revision 6 days post-oper-
atively and another required a closed reduction 8 
weeks post-operatively. Both hips have remained 
stable since then. 
One patient suffered a pulmonary embolism 
and another a deep vein thrombosis, both in the 
placebo group. The patients’ HHS, EQ-5D and 
PNRS had all improved compared to the pre-
operative value and no differences were found 
between the groups at any time. The HHS was 
median 100 (81-100) and 98 (46-100) in the 
risedronate and placebo groups at 24 months, 
respectively.
efficAcy for primAry end point
In the placebo group, a continuous bone loss 
was seen with a BMD decrease of 18% in zones 1 
and 7 after 24 months. In the risedronate group, 
bone resorption was effectively reduced during 
the first 6 months with an efficacy (difference 
between the 2 groups) of 9.2% and 8.0% at 6 
months in zone 1 and 7 respectively (p<0.001 
and p=0.003). In zone 1, the difference between 
the groups was still statistically significant at 12 
months (risedronate vs. placebo; -7.4% versus 
-14.5%, p=0.006) with a trend towards a dif-
ference at 24 months (risedronate vs. placebo; 
-13.6% versus -17.7%, p=0.066). In zone 7, there 
was no statistically significant difference between 
the risedronate and placebo groups at either 12 
or 24 months (Table 10). 
The protective effect of risedronate on bone 
resorption during the entire study period was 
statistically significant when controlling for sex, 
age, BMI, stem size and pre-operative BMD of 
the operated hip (zone 1, p=0.005 and zone 7, 
p=0.006, ANOVA), (Figure 55). 
In addition, the larger stem sizes (size 11-13 
and 14-15) were associated with increased bone 
loss in zone 1 (p=0.045). 
Low pre-operative BMD of the hip correlated 
with an increased bone resorption after surgery 
in zones 1 and 7 (p=0.05 and p<0.001, respective-
ly), (Figure 56). Sex, age or BMI did not affect the 
primary end point at any time (data not shown).
tABle 10. The effect of risedronate on BMD
Outcome risedronate placebo difference (95% CI) p value
CHANgE IN BMD zONE 1 (%)a
3 months 1.2±7.6 -5.9±9.0 7.2 (3.2 – 11.1) <0.001
6 months -0.5±10.8 -9.7±9.9 9.2 (4.2 – 14.1) <0.001
12 months -7.4±14.7 -14.5±11.2 7.2 (1.0 – 13.3) 0.006
24 months -13.6±12.3 -17.7±13.1 4.1 (-2.0 – 10.2) 0.066
CHANgE IN BMD zONE 7 (%)a
3 months -3.6±10.2 -10.3±10.9 6.7 (1.6 – 11.7) 0.007
6 months -5.1±10.6 -13.1±11.7 8.0 (2.7 – 13.4) 0.003
12 months -11.9±12.3 -16.1±12.0 4.3 (-1.5 – 10.1) 0.318
24 months -17.2±13.2 -18.1±14.9 0.9 (-5.9 – 7.7) 0.699
a  mean ±SD, p-value Student’s t-test.
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figure 55. The mean (95% CI) percentage change in BMD around the stem in patients receiving risedronate (solid line) or placebo 
(dashed line). *p≤0.05.
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efficAcy for secondAry end points 
In the combined periprosthetic regions (zones 
1-7), the patients in the risedronate group had a 
significantly lower bone resorption at all follow-
up visits compared to patients in the placebo 
group (Figure 55). Bone resorption was also re-
duced in the risedronate group in zones 2, 3 and 
6 with the same tendency as for zones 1 and 7; 
reduced resorption during the first 6 and 12 
months and then increased resorption up till 24 
months. 
The vertical migration of the stem did not dif-
fer between the groups and was mean -1.7 mm 
in both groups at 24 months. At 24 months, we 
found no difference in vertebral BMD or the rate 
of heterotopic ossification between the groups. 
All stems were stable according to the fixa-
tion/stability score,91 but the score was higher in 
the placebo group (risedronate vs. placebo; 15.5 
versus 18.0, p=0.004, Mann-Whitney U-test). 
This was due to a higher number of spot welds 
in the placebo group (risedronate vs. placebo; 9 
of 33 versus 21 of 37, p=0.013). There was no dif-
ference between the groups with regard to other 
fixation/stability parameters (data not shown). 
On the acetabular side, we found radiolucent 
lines between bone and cement in DeLee and 
Charnley67 zone 1 in 2 hips in the risedronate 
group and 1 in the placebo group. There was no 
radiolucent line around the uncemented cups. 
figure 56. The mean (95% CI) percentage change in BMD in patients with high (bold line) or low (thin line) preoperative BMD of the 
hip in the risedronate (solid line) and placebo (dashed line) groups.
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Study IV
clinicAl outcome
One stem was revised 3 weeks after the primary 
operation due to a deep wound infection; the 
infection later healed uneventfully. We noted 1 
intra-operative fracture of the greater trochanter 
and, in the same patient, an undisplaced femoral 
fracture at the distal tip of the prosthesis. 
At 18 months post-operatively, this patient 
presented with a deep infection in the operated 
hip and was treated with an open synovectomy 
and antibiotics. A total of 7 hips (14%) dislo-
cated, 3 of these suffered recurrent dislocations 
and in 1 of these the cup was converted to a 
double-mobility cup. Two patients were treated 
with antibiotics for a superficial wound infection.
There was a slight deterioration in function 
and increased pain in the operated hip during the 
study period (HHS and PNRS prefracture vs. 24 
months; mean 88 ±11 and 0.4 ±1.3 versus 82 ±13 
and 1.0 ±1.9, p=0.006 and 0.033, respectively). 
The outcome was less favourable for patients in 
Charnley class C where degenerative disease in 
other joints and/or associated medical comor-
bidities affected the outcome. The median HHS 
was 88 (100-52), 90 (91-80) and 76 (88-51) in 
class A, B and C, respectively. Health-related 
quality of life also declined during the study but 
did not reach statistical significance (EQ-5D pre-
fracture vs. 24 months; mean 0.71 ±0.23 versus 
0.63 ±0.37, p=0.112). 
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DdWD ĚĞƚĞĐƚŝŽŶůŝŵŝƚ figure 57. The mean (95%CI) migration of the stem in translation and rotation. X-
translation and z-rotation are not shown due 
to insignificant migration. Total migration 
(MTPM) is shown with mean (95% CI) (solid 
strong line) and individual (dashed line) 
values.  The length of the arrow corresponds 
to the detection limit of true (at 99% level) 
migration. 
*indicates a significant (p≤0.05) mean migra-
tion compared to the previous examination.
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figure 58. Periprosthetic bone remodelling. The mean (95% CI) percentage change in BMD around the stem. * indicates a signifi-
cant (p≤0.05) change in BMD compared to the preceding value.
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migrAtion
Thirty-four stems migrated above the detection 
limit up to 6 weeks post-operatively and 4 stems 
continued to migrate up until the 3 month fol-
low-up. After 3 months, all stems had stabilized. 
The mean (SD) initial translation in the x, y 
and z-axes was -0.03 ±0.27, -0.16 ±0.48 and -0.26 
±0.56 mm with the corresponding rotation -0.16 
±0.53, -1.16 ±1.88 and 0.01 ±0.62 degrees at 6 
weeks. MTPM was 1.83 ±1.30 mm at 6 weeks. 
After this, the mean migration stopped ex-
cept for rotation in flexion/extension (x), which 
indicated a small, but statistically significant, 
continuous migration between 12 and 24 months 
(Figure 57). Migration of the stem was more 
pronounced in patients with a low periprosthetic 
BMD. 
Bone remodelling
We found a continuous decrease of periprosthet-
ic BMD, with the highest rate of bone loss occur-
ring during the first 12 months, in all zones but 
zone 4, and a reduction in the total periprosthetic 
BMD of mean 16% at 24 months (Figure 58). 
The bone loss was greatest in zones 1 and 7, 
with a decrease of 30% and 26%, respectively, at 
24 months. Bone loss was significantly related to 
the patient’s general bone mass (Figure 59). The 
24-month BMD of vertebrae L1-L4 did not differ 
from the immediate post-operative value. 
otHer rAdiologicAl pArAmeters
The fill of the implant in the femoral canal was 
classified as good in 17 hips (34%) and we suc-
ceeded in achieving a collar-calcar contact in 33 
hips (66%). The fill or collar-calcar contact did 
not affect either migration or bone loss (data not 
shown). 
At 24 months, 25 hips had no heterotopic 
ossification, 13 had class I-II and 7 class III-IV 
ossification.42 ◉
figure 59. The relation between preoperative BMD and 
bone loss. Change in BMD in zones 1-7 in for 36 patients, 
with complete follow-up data at 24 months, who were 
included in a substudy of what effect the BMD of total hip 
(the non-operated contralateral hip) and lumbar spine had on 
bone loss after 24 months. Osteopenia and osteoporosis in the 
hip and lumbar spine were significantly related to peripros-
thetic bone loss after controlling for sex, age, BMI and stem 
size (total hip p=0.015, p<0.001 and vertebrae L1-L4 p=0.021, 
p=0.027, ANCOVA).
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The Bi-Metric stem
The clinical outcome in Study I-III is similar to other studies with the Bi-Metric stem and 
other uncemented porous-coated THAs from a midterm point of view (Table 11).32,65,206,244,250 
The Bi-Metric stem was developed as a straight 
taper alternative to the Taperloc stem and is com-
monly used in Scandinavia. In published papers, 
the revision rate for aseptic loosening is 0-1% 
after 10 years. There are however, as is described 
in chapter 3.7, more revisions performed due to 
fractures and dislocations. 
In several studies, particularly these from 
the Finnish Arthroplasty Register,226  the re-
sults for the stem is less favorable as a result of 
frequent cup revisions due to osteolysis caused 
by poorly performing uncemented acetabular 
components.94,217,244 Register studies have the 
drawback of being dependent on the quality of 
the data registered. The Bi-Metric stem has, over 
the years, been marketed in a number of varying 
configurations in different countries; cemented, 
uncemented, with/without HA-coating, as a long 
revision stem and even as a grit-blasted fracture 
stem similar to the BFX stem in Study IV.
The HA-coating increases the amount of 
ingrowth and attachment to bone59 thereby re-
ducing the migration of the stem.281 The only 
study specifically examining the influence of HA-
coating on the Bi-Metric stem on a nationwide 
basis is a study from the Danish Hip Arthroplasty 
Register.234 
With a follow-up of median 2.7 years in a 
cohort of patients under 70 years of age who 
received a Bi-Metric stem with (n=3158) and 
without (n=4749) HA-coating , the survival rate 
concerning stem revision due to aseptic loosen-
ing was 100% (CI: 99–100%) for stems both with 
and without coating. The survival rate concern-
ing stem revision for any reason was 96% (CI: 
94–97) and 96% (CI: 95–96%) for stems with or 
without HA-coating, respectively. 
 It appears that the stems with and without HA-
coating are, at least in the short time perspective, 
equivalent with regard to revision rate. Whether 
the HA-coating on the Bi-Metric stem affects the 
bone remodelling has not yet been studied.
11 DISCUSSION
11.1 DISCUSSION ON MATERIAL
tABle 11. Studies on the uncemented Bi-Metric stem with and without HA-coating.  Only studies with a minimal follow-
up of 5 years of 50 hips are shown. In the bottom is, for comparison, the unpublished data from Danderyds Hospital 
(chapter 3.7).
Authors year n age fu (yr) HA aseptic loosening all revisions
Puolakka et al.244 1999 384 n.r. 7.5 no 0.8% 2.7%
Jacobsen et al.140 2003 97 50 8.0 no 0% 1%
yamamoto et al.319 2003 70 55 6.8 no 0% 0%
lybäck et al.183 2004 77 28 9.6 no 0% 2.1%
Meding et al.206 2004 105 56 11 no 0% 0%
Bodén et al.32 2006 115 52 12.2 yes 0% 0%
Eskelinen et al.94 2006 1982 <55 6.6 no 1.9% 3.7%
Isaac et al.139 2007 58 57 7.6 no 0% 0%
Sköldenberg et al.270 2009 332 52 12.9 yes 0% 0%
Davies et al.65 2010 64 54 15.2 no 0% 0%
Mäkelä et al.217 2010 5379 >55 6.8 no 1.0% 2.5%
Danderyd Hospital 2010 1718 61 7.3 yes 0% 0.8%
n: number of hips
age: mean age at surgery
fu: mean follow-up time in years
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The BFX stem
The BFX stem was designed to be easy to use by traumatologists or general orthopaedic 
surgeons and is marketed with a unipolar or bipolar hemi-articulation. 
In clinical practice, operation with a hemiarthro-
plasty is still the most common procedure for a 
displaced FNF in elderly patients despite recent 
evidence that a THA provides better hip func-
tion than a hemiarthroplasty.24 In Study IV, we 
wanted to exclude the possibility of acetabular 
erosion and the pain associated with this ero-
sion, and therefore all patients who participated 
received a THA.
The BFX stem has been modified compared 
to the original Bi-Metric design. It is available in 
uneven sizes only, has a single offset option and 
has a collar. The first 2 factors are unnecessary 
limitations of the stem; particularly in males, two 
offset options is lacking and the high dislocation 
rate seen in this study can, in part, be attributed 
to this fact.
We cannot prove that the collar affects migra-
tion.  Still, we believe that it makes insertion of 
the implant safer with regard to the risk of ac-
cidentally causing calcar split fractures at final 
impaction of the stem. 
The full HA-coating is probably also advanta-
geous in this patient group since the coating has 
strong osteoconductive properties. Despite the 
fact that we only attained a tight fill in the femo-
ral canal in about one third of the hips, all stems 
were fixated after 3 months. ◉
UNCEMENTED FEMORAL STEMS 
Discussion / Thesis / 
63olof sköldenberg
Risedronate
When Study III was planned, the first publica-
tions on prevention of bone loss after THA had 
just been published with alendronate304 and 
pamidronate.307 Risedronate was, at that time, 
the only bisphosphonate available with once-
weekly administration and had not previously 
been studied in conjunction with orthopaedic 
implants in humans. 
In addition, in other bisphosphonates, the amino 
group is open and is thought to be responsible for 
the increased risk for upper GI effects seen with 
these drugs. This shielding of the amino group 
in risedronate may account for the decreased 
incidence of GI effects in published trials.123,203 
This, together with its strong antiresorptive po-
tential,100 led us to using it for Study III.
Previously, when trying to decrease the effect 
of stress-shielding using bisphosphonates, a 6 
month treatment regime had been advocated as 
the greatest bone loss occurs during the initial 
post-operative period.14,336 Arabmotlagh et al.12 
studied the duration of antiresorptive treatment 
and suggested that the minimum time needed 
for treatment is 6 months, at least when using 
alendronate. 
Thus, when the trial was designed, our hypoth-
esis was an efficacy up to 2 years with 6 months 
of treatment and the study was designed accord-
ingly. During the course of Study III, results from 
several new trials involving bisphosphonates and 
outcome after THA have been published. 
Stability/Fixation score
The Stability/Fixation score used in Study I-III 
is the most commonly used radiological instru-
ment for evaluation of uncemented stems.91  As 
in Study II, the method is often modified to assess 
other parameters such as osteolysis and distal 
cortical hypertrophy. 
Developed in the 1980s, before DXA evolved 
as a quantitative way to measure bone remodel-
ling and RSA became the standard for evaluating 
migration. The system has a definite “ceiling ef-
fect” when it comes to assessing the fixation and 
stability of a modern Ti-6Al-4V stem with proxi-
mal porous coating. Since all stems described in 
this thesis, according to this score, were fixated/
stable (a score of ≥0), the BMD measurements 
should not have been influenced by instability. 
This is essential for accurate BMD measurements 
since unstable/loose stems leads to a BMD de-
crease as has been shown by Bodén et al.31 
It has proved difficult to draw any definite con-
clusions from some of these Stability/Fixation-
signs. In Study III, we found a higher number 
of endosteal bone bridges (spot welds) in the 
placebo group resulting in a lower score for the 
risedronate group. Despite this, all stems were 
firmly fixed and the amount of migration (mea-
sured with EBRA-FCA) did not differ between 
the two groups. 
One possible explanation for this finding 
could be the higher regional bone resorption 
identified in the placebo group in which the low-
er attenuation makes these bone bridges easier 
to observe on plain x-ray film. Typically, spot 
welds are found in the proximal regions where 
the stress-shielding effect is most pronounced 
and the bone bridges contrast distinctly from 
the surrounding bone. In the risedronate group, 
where the stems were also well fixated according 
to other parameters, the spot welds are blurred by 
the high attenuation. 
Another explanation for this finding is pos-
sibly that normally, foci of traumatized and devi-
talized cancellous bone trabeculae are remodeled 
post-operatively by osteoclasts followed by an 
tABle 12. Calcar remodelling and its relation to 
mean (SD) BMD change in zone 7 at 24 months in 
Study III. Despite the wide SDs, the difference be-
tween the groups is statistically significant (ANOVA).
calcar remodeling % Bmd zone 7
No -6.8 ±9.4
Calcar round-off -11.1±14.7
Calcar atrophy -22.9±12.2
11.2 DISCUSSION ON METHODS
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osteoblast phase. Since risedronate effectively 
stops the osteoclast response at the interface, we 
hypothesize that bone repair is slower and prob-
ably more homogenous which would explain the 
absence of spot welds in the risedronate group.
In Study III, the presence of pedestal formation 
or distal cortical hypertrophy did not correlate to 
BMD gain in the distal zones (3-5), while visible 
calcar remodelling did correlate to BMD loss in 
zone 7 (Table 12).
Radiostereometry
RSA, used in Study IV, is technically demanding 
and requires that all aspects of the method are 
followed meticulously. Few studies have been 
conducted in which a cohort of elderly patients 
with hip fractures has been examined using 
RSA.167,198-199 This frail patient group is often dif-
ficult to study. In our study 11% of the RSA data 
was lost due to patients being unable to come to 
follow-up visits. Some of the data loss can also 
be explained by technical errors e.g. inability to 
locate the tantalum markers on both RSA x-rays. 
This is an acceptable rate when compared to 
other RSA studies.164,300,321
Dual-energy X-ray Absorptiometry
DXA is the most widely used tool to assess gen-
eral bone mass and bone resorption due to stress-
shielding. The method is highly accurate and, if 
patients are correctly positioned in the scanner, 
it is also precise enough to allow for continuous 
measurements of BMD around implants.
positioning of tHe pAtients
The positioning of the patients in the scanner is 
crucial to achieve a good precision. Leg rotation 
must be strictly controlled since there is a large 
variation with different rotations, particularly 
in Gruen zone 7.60 In Study I, III and IV, a leg 
holder was used to insure that the femur was in 
neutral alignment and rotation.
timing of meAsurements
Retrospective studies using contralateral compar-
isons such as Study I have shown a 40% decrease 
in proximal femoral BMD after 7–14 years.202 
The retrospective approach is convenient for 
the researcher but requires that measurements 
are performed when the bone remodelling has 
reached a steady state. 
In Study I we found no correlation between 
duration of implantation and BMD changes in 
any zone and we concluded that a longer im-
plant time would not have affected the results. 
However, in a later study, we have found that, at 
least in zone 7, the bone loss occurs more rapidly 
than the normal ageing of the contralateral side 
in the long-term perspective.33
Other important aspects of retrospective 
BMD studies are that the contralateral hip is 
healthy and that the software is capable of su-
perimposing the exact Gruen zones scanned in 
the operated hip on the healthy hip. The effect 
of per-operative bone loss, due to reaming and 
broaching, can also affect the BMD in retrospec-
tive studies.162,195 
In Study III-IV, we performed longitudinal 
measurements, as recommended,295 and thereby 
circumvented the problems described above. ◉
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11.3 DISCUSSION ON RESULTS
Study I
In a single cohort of 138 patients examined with DXA 3 years after THA we found femoral 
periprosthetic proximal bone loss which was related to the stem size used. Despite this, 
most patients had an excellent clinical outcome, with only 6 patients (4%) complaining of 
slight thigh pain, and no loosening of any stem occurred. 
stem size And Bone loss
In the original work examining the relation-
ship between stem stiffness and bone loss, Engh 
and Bobyn assessed bone resorption at 2 years’ 
minimum follow-up using the plain radiographs 
of 411 patients who received the AML stem.85 
With regard to stem size, they found a five-fold 
increase in bone resorption in subjects with the 
larger stem sizes (stem size ≥ 13.5 mm). They 
also noted that the extent of the porous coat-
ing affects the amount of bone loss. Extensively 
coated stems transfer more load distally and 
result in loss of bone over a greater area of the 
bone-implant interface. Therefore, many stem 
designs with porous coating are now confined to 
the metaphyseal region of the stem. 
The Bi-Metric stem is one example of a stem 
which is intended to load proximally (Figure 60). 
Despite this the bone loss after 3 years in zones 
1 and 7 was approximately 20%.30 This is prob-
ably due to the fact that the greatest mismatch 
between femur stiffness and implant stiffness 
is in these zones. Here, almost all uncemented 
implants flare to facilitate an immediate rigid 
fixation during insertion of the implant. This 
leads to an exponential increase in stiffness (ac-
cording to the fourth power size relationship).29 
Even for smaller stems, this stiffness exceeds the 
natural stiffness of the femur by a factor of 10-20, 
depending on the stem size and the stiffness of 
the alloy used.
In addition to several studies using semi-
quantitative methods on plain radiographs or 
cadaver femora280 only three studies utilizing 
DXA to assess the relationship between stem 
size and bone loss have been published.220,237,316 
The study by Nishii et al. involved an exten-
sively porous coated CoCrMb stem used in 32 
patients who were followed-up for 12 months. 
They found a clear correlation between stem 
size and proximal periprosthetic bone loss.220 In 
contrast, both Petersen et al.,237 using a Taperloc 
Ti-6Al-4V stem in 22 patients, and Yamaguchi et 
al.,316 using two different CoCrMb stems in 44 
patients, failed in finding such a correlation. Due 
to the low number of patients in these studies, it 
is doubtful whether any of them really had suf-
ficient power to verify or dispute whether size is 
associated with bone loss. 
figure 60. The coveted proximal fixation 
In A the load on the normal femur. B after in-
sertion of a stem with proximal fixation and C 
the usual result; distal fixation and off-loading 
of the proximal femur.
 
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fActors Affecting periprostHetic Bone loss
It is evident that there are many other factors in-
fluencing the extent of bone loss after THA. Our 
correlation coefficient squared (r2) ranged be-
tween 0.14 and 0.16, indicating that only 14-16% 
of the bone loss can be explained by stem size. 
Factors, besides stem size, that influence peri-
prosthetic bone remodelling after THA include 
sex,7,41 age,41 weight,155 BMD,7,193,220,246 activity 
level, diagnosis, disease state, medications, dura-
tion of implantation,33 stem design,246 extent of 
porous coating,85,316 surgical approach235 and 
ceramic (HA/TCP) coating.47,284 
Researchers have found conflicting results 
regarding the effect of these co-variables on 
bone remodelling (Table 13). Brodner et al.,41 
found a correlation between sex and BMD in 
most Gruen zones, and between age and BMD in 
Gruen zones 1 and 7. Kärrholm et al.164 evaluated 
possible confounding factors (sex, age, weight, 
diagnosis, BMD and stem size) immediately af-
ter the operation, and found that periprosthetic 
BMD was influenced only by stem design (the 
low stiffness composite Epoch stem). However, 
a follow-up study after 7 years using the same 
cohort of patients has shown that the difference 
in BMD tended to disappear over time and was 
only significant in zone 7.286
The most important predictor for bone loss, 
verified in Study III and IV, is the pre-operative 
BMD of the hip.7,193,220,246 In a recently published 
study, female patients with low systemic BMD 
had greater bone loss in Gruen zone 7 after unce-
mented THA than patients with normal BMD,7 
confirming the interaction between anthropo-
metrical factors and the host bone reaction to the 
stem.
We found no correlation between anthropo-
metrical factors and BMD loss in Study I. This 
is possibly due to the retrospective design of the 
study. 
tABle 13. Factors influencing bone loss after uncemented THA. Only in vivo studies with DXA are shown.
Authors year n fu (y) factor finding
Kiratli et al.157 1996 32 2 weight low weight was a predictor for bone loss
Nishii et al.220 1997 32 2 stem size, BMD low BMD and larger stem size loose more bone
yamaguchi et al.316 2000 44 2.5 porous coating porous coated stems loose more bone in zones 3, 6
Tanzer et al.284 2001 39 2 ceramic coating (TCP) smaller bone loss in zone 1, 2 and 7 in TCP group
Kärrholm et al.164 2002 68 2 stem stiffness
lower bone loss in zone 1, 2, 6 and 7 in 
low stiffness group
Brodner et al.41 2004 100 5 sex, age older females lost more bone in zone 1 and 2
Rahmy et al.264 2004 60 3 stem design, BMD
anatomic stem (zone 4 and 7) and low BMD loose 
more bone (zone 1-7)
Perka et al.235 2005 82 6 surgical approach
transgluteal, compared to  abductor split approach, 
induces more bone loss in zone 1, 2, 6 and 7
Bodén et al.33 2006 28 10-14 time
bone loss rate in zone 7 is faster than 
the normal ageing
Sköldenberg et al.271 2006 138 3 stem size larger stems loose more bone in zone 1, 2, 6 and 7
Alm et al.8 2009 39 2 sex, BMD females with low BMD lost more bone in zone 7
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Study II
In this retrospective analysis of femoral revision surgery in patients with aseptic loosening, 
who had moderate pre-revision bone defects, we found a 95% survival rate of the Bi-Metric 
stem after 6 years and no aseptic loosening of the stem. We also noted that all stems were 
stable according to the Stability/Fixation score and that the clinical outcome was acceptable. 
clinicAl outcome
Dislocation was the most common complication 
in our series (9 of 62 hips). We believe that this 
was caused by our use of 22- to 29-mm head sizes 
(except in 3 cases in which the head diameter was 
32 mm), and the fact that only one femoral offset 
option was available at the time. We had 4 per-
operative fractures during stem insertion and 4 
patients suffered post-operative fractures. This 
serious complication was responsible for all the 
re-revisions although the rate is lower than in 
previous reports.192,215 
The great proportion of patients were classi-
fied as Charnley’s functional class C, which con-
tributed to a lower HHS than would have been 
the case if it were only the operated hip that inter-
fered with their functional capacity (Figure 54). 
The HHS of 75 points compares favorably with 
other studies of uncemented femoral revision 
using stems intended for proximal fixation.149,215 
peripprostHetic Bone remodelling
Our radiographic data revealed that the Bi-
Metric stem osseointegrates both proximally and 
distally. We saw several signs of stress-shielding 
and distal fixation — such as calcar resorption, 
proximal cortical thinning, proximal osteopenia, 
and distal cortical hypertrophy —of varying de-
grees (Figure 61). 
Patients who require femoral revision have a 
lower quality femoral bone stock than patients 
in need of a primary hip arthroplasty. Because of 
this, the surgeon also has to use larger diameter 
stems than in primary surgery to achieve initial 
stability. 
Both these factors will contribute to a more 
pronounced stress shielding after femoral revi-
sion than after a primary arthroplasty and we 
have extreme examples of this in our study (Fig-
ure 28). However, perhaps because of the distal 
fixation, the longevity of the artificial joint is as-
sured, as is the case with stems designed for distal 
fixation.34,298
It is also important to mention that both the 
sensitivity and the specificity of evaluating bone 
loss on plain radiographs are low. Bone loss is not 
detectable on plain radiographs until one third of 
the bone is lost and the loss is not reproducibly 
recognized by several observers until two-thirds 
of the bone is resorbed.88 Thus, it is sometimes 
difficult to determine whether bone remodelling 
seen in the femur is due to osteopenia or to os-
teolysis. 
We have recently published a DXA study of 22 
hips from the cohort in Study II where we found 
a marked reduction in BMD in the operated fe-
mur in all Gruen zones compared to the healthy, 
unoperated, side. The largest bone reduction was 
in zones 1-2 and 6-7 where it was lowered by 36-
45%.2
figure 61. Signs of stress shielding and distal fixation: calcar atrophy, 
distal cortical hypertrophy.
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Study III
In patients with OA, 35 mg of oral risedronate taken once weekly for 6 months is effec-
tive in reducing femoral periprosthetic bone resorption up to 12 months after THA with a 
trend towards an effect up to 24 months. 
clinicAl outcome
The clinical outcome in this study was excellent 
with both groups improving significantly in HHS 
and EQ-5D. The overall incidence of adverse 
events during the study period did not differ 
between the groups. However, 4 subjects in the 
treatment group experienced either nausea or ur-
ticaria which lead to them having to discontinue 
the risedronate treatment. 
This reflects the clinical setting and if patients 
not taking their medication are excluded from 
the study, this will boost the effect of the studied 
drug, something for which most previous studies 
on prevention of bone loss after THA can be criti-
cized for (Table 14).
preVention of Bone loss
The primary outcome variable, prevention of 
bone resorption after THA, is, as with migration 
of implants, a proxy variable for clinical success. 
Thillemann et al.  recently published a nation-
wide population-based study examining post-
operative use of bisphosphonates and the risk 
for revision after primary THA in osteoporotic 
patients.289 
A total of 632 patients, who were revised after 
primary THA were compared to 1262 non-
revised controls. No overall difference in risk for 
revision due to aseptic loosening was detected 
between these taking bisphosphonates and these 
who were not. However, a subgroup analysis of 
patients with bisphosphonate treatment for more 
than 240 days, showed a a decreased risk for revi-
sion. 
In Study III, we found that patients with a lower 
pre-operative BMD lost significantly more bone 
after THA (Figure 56). We found that patients in 
the placebo group with low pre-operative bone 
mass had lost 23% and 27% in zones 1 and 7 of 
the operated hip after 2 years whereas patients 
with high systemic BMD lost only 14% and 11%, 
respectively. This is consistent with results from 
earlier studies showing a correlation between low 
pre-operative bone mass and increased bone loss 
around uncemented stems (Table 13).10,246 
Our results, together with these of Thillemann 
et al.289 indicate that prolonged treatment with 
bisphosphonates after THA in osteoporotic pa-
tients is warranted. Since bone loss around THA 
is suspected to be continuous and occurs more 
rapidly than normal ageing, at least in zone 7,33 
the length of treatment must be long enough 
duration so as to be able to reach normal steady-
state in bone metabolism. This may even require 
life-long treatment.
tABle 14. Studies on bisphosphonates and THA in humans, Study III in the bottom for comparison.
Authors year bisphosphonate n diagnosis stem method fu (m) blinding intention
Venesmaa et al.304 2001 alendronate 13 OA UPP DXA 6 no n.r.
Wilkinson et al.307 2001 pamidronate 47 M CT DXA/EBRA 6 yes no
Hennigs et al.133 2002 alendronate 66 M UPP/gB DXA 12 no n.r.
Nehme et al.219 2003 alendronate 38 N/A CT DXA 24 yes n.r.
yamaguchi et al.338 2003 ethidronate 53 CDH UFP/UPP DXA 12 no no
yamaguchi et al.317 2004 ethidronate 45 CDH UFP/UPP DXA 30 no no
Wilkinson et al.306 2005 pamidronate 47 M CT DXA/EBRA 24 yes no
Arabmotlagh et al.12 2006 alendronate 51 OA UPP/gB DXA 12 yes n.r.
yamasaki et al.320 2007 risedronate 40 CDH UFP/UPP DXA 6 no no
Arabmotlagh et al.11 2009 alendronate 49 M UPP/gB DXA 72 no n.r.
Friedl et al.104 2009 zoledronic acid 49 ON gB EBRA 36 yes n.r.
Study III 2010 risedronate 73 OA UPPH DXA/EBRA 24 yes yes
n = sample size diagnosis: = OA=osteoarthritis, M=mixed diagnoses, CDH=congenital dysplasia of the hip, ON=osteonecrosis of the femoral head stem = 
gB=uncemented grit-blasted, CT=cemented tapered, UFP=uncemented fully porous-coated, UPP=uncemented proximally porous-coated, UPPH=uncemented 
proximally porous-coated with hydroxyapatite intention = study conducted according to intention-to-treat n.r. = not reported
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Study IV
In a cognitively intact cohort of elderly patients with a displaced FNF and who received a 
new HA-coated stem, we found a favourable migration pattern and stable stems after 3 
months post surgery. We also found a continuous decrease in BMD around the stems up 
to 2 years after surgery.
clinicAl outcome
During the study one intra-operative femoral 
fracture occurred (treated conservatively) as well 
as two implant revisions (1 stem due to infection 
and 1 cup due to dislocation) were required. The 
HHS was lower than in Study I and III and the 
EQ-5D lower than in Study III, but this is to be 
expected in this patient group and is consistent 
with other studies done on THA after a FNF.24,293 
Despite using the posterior repair technique163 
and 32 mm heads in all surgeries the dislocation 
rate was 14%. A high dislocation rate for the pos-
terolateral approach after THA in patients with 
a FNF has previously been reported.92 After the 
completion of the current trial our Orthopaedic 
Department has subsequently reduced the dis-
location rate by changing to  the anterolateral 
approach for hip arthroplasty in patients with a 
FNF.269 
migrAtion And Bone remodelling
Despite having individual stems with a large 
initial migration, all stems had stabilized within 
3 months. The migration (Figure 57) was less 
than,49 or equivalent to,281 results reported from 
previous RSA studies of clinically successful 
uncemented stems. There was however a ten-
dency for a continuous migration (z-rotation and 
MTPM) at 24 months. This could be attributed to 
the bone loss that had occurred around the stem. 
The best predictor for migration was the BMD 
around the stem; stems with low surrounding 
BMD had a significantly higher mean migra-
tion than stems with high BMD. The patients 
who were osteopenic or osteoporotic before the 
fracture, as confirmed by the BMD of the contra-
lateral femur, had also lost more bone around the 
stem at 2 years. 
This is potentially problematic as this bone loss 
could lead to loosening of the stem or predispose 
to a periprosthetic fracture. As this has not been 
studied before, we cannot know whether there 
would be any difference in bone remodelling if 
we had used a cemented stem. 
The migration of, and bone remodelling 
around, this stem can serve as a reference for 
other implants in this patient group.
compArison to otHer studies
The majority of data available on modern un-
cemented stems (i.e. excluding Thompson or 
Austin-Moore types) in patients with a FNF is 
from single cohort studies.15,20,52,156-157,322 They 
are equivalent to Study IV with regards to the age 
group studied and functional outcome. The rate of 
calcar split/periprosthetic fractures range between 
0-17% and is typically around 4% (Table 15).
There are only 2 trials where HA-coated 
stems are compared to other stem types99,180 and 
Figved et al. has performed the only randomized 
study comparing a modern cemented implant 
(Spectron) and a HA-coated press-fit implant 
(Corail).99 Their study showed equivalence be-
tween the groups in HHS after 1 year (their main 
outcome variable). 
The patient selection was similar to that in our 
study, with a mean age of 83 years, and predomi-
nantly female patients. HHS and EQ-5D was 
similar to our results. They had more intra- and 
post-operative periprosthetic fractures in the 
uncemented group, compared to the cemented 
group; 6% versus 2% after 1 year. They also ex-
cluded 4 patients during surgery because they 
could not achieve primary stability with unce-
mented fixation of the stem. Despite this, they 
concluded that both femoral implants could be 
used with good results in displaced FNFs.  
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wHy use uncemented femorAl stems in  
treAtment of femorAl necK frActures?
The rationale for using these devices for displaced 
FNFs in osteoporotic elderly patients, often with 
a stove-pipe femur, is mainly theoretical. Dur-
ing pressurization, cement and fat embolism are 
known to occur57,243 and can have an impact on 
mortality.173,231 Nevertheless, we acknowledge 
that there are several potential problems which 
may occur when using an uncemented stem 
in this patient group. The most obvious is the 
increased risk for periprosthetic fractures, oc-
curring either intra-operative as in our series of 
Bi-Metric stems (chapter 3.7), or, perhaps due to 
the above described periprosthetic bone loss, late 
presenting after minor trauma. 
In a coming report from the Swedish Hip Ar-
throplasty Register, modern HA-coated unce-
mented stems used for hemiarthroplasty in this 
elderly population are, compared to modern ce-
mented stems, associated with an increased risk 
for revision due to femoral fractures (odds ratio 
3.8, 95%CI 2.0-7.1).110 Similar results can be 
seen from the Australian National Arthroplasty 
Register where uncemented stems in fracture pa-
tients have a significantly higher risk for revision 
compared to cemented stems.117 
 
 
In our trial, we had only one fracture; a femoral 
crack distal to the tip of the prosthesis. We had 
no femoral split fractures or calcar fractures. 
However, all the surgeons who performed the 
operations in this trial were experienced hip sur-
geons, and therefore it is uncertain as to whether 
these results can be reproducible in a standard 
clinical setting. 
The risk for femoral split fractures is perhaps 
also implant-specific; the most commonly used 
uncemented stem for FNFs in Sweden is a press-
fit type (Corail®), where the technique is to use 
increasing sizes of broaches and to impact as 
much cancellous bone as possible. ◉
tABle 15. Studies on modern uncemented stems in FNFs with the current study for comparison.
Authors stem year coating type trial fu (y) n age fx (%) rev HHS appr disl (%)
livesley180 JRI/Austin-Moore 1993 HA BHA RCT 1 48 81 17/0 2/1 n.r. n.r. 4
Bezwada20 Taperloc 2004 PP BHA PSC 3.5 168 77 0 2 82 n.r. n.r.
Klestil157 zweimüller 2006 gB UHA PSC 2 46 76 0 0 n.r. Al 0
Klein156 Taperloc, Accolade 2006 PP THA RSC 3.8 85 78 4 0 82 Al 4
Chandran52 Furlong 2006 HA BHA RSC 4 112 78 2 5 n.r. Al n.r.
Öztürkmen322 F40, Helios 2008 FP BHA RSC 4.2 48 88 n.r. 1 84 Pl 2
Barnett15 Corail 2009 HA THA PSC 1 46 72 7 0 n.r. Al 0
Figved99 Corail/Spectron 2009 HA BHA RCT 1 200 83 6/3 2/1 79/80 Pl 5
Study IV BFX 2010 HA THA PSC 2 50 81 2 1 82 Pl 14
coating:  HA=hydroxyapatite-coated, FP=fully porous-coated, PP=proximally porous-coated, gB=grit-blasted
type:  THA=total hip arthroplasty, UHA=unipolar hemiarthroplasty, BHA=bipolar hemiarthroplasty
trial:  PSC=prospective single cohort, RSC=retrospective single cohort, RCT=randomized controlled trial
fu: follow-up
fx:  intra- and post-operative periprosthetic fractures (%)
rev: stem revisions (n)
HHS: Harris hip score (mean)
appr: surgical approach, Al=anterolateral, Pl=posterolateral
disl: dislocation rate (%)
n.r.: not reported
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Study I
Though the majority of patients who participated 
in the study underwent surgery for OA (89%), 
several other diagnoses were also included in the 
study, for example, congenital dysplasia of the 
hip (CDH) and post-traumatic arthritis. This is 
a potential source of error as patients with CDH 
may have a different pre-operative BMD of the 
hip compared to patients with OA.223 We have, 
also, analyzed the data using only subjects with 
OA and the results were the same as those for the 
overall study (data not shown).
Study I is a cross-sectional study in which peri-
prosthetic BMD is compared to the value of the 
unaffected side. This could be a possible source 
for error as there may exist a side-related differ-
ence in bone mass pre-operatively. Some studies 
have shown findings that indicate a lower BMD 
in the Gruen zones 1-7 on the affected side before 
operation.155,195 In addition, the initially BMD 
can be high due to the impaction of cancellous 
bone. 
Thus, the BMD difference found in cross-
sectional studies may be either under- or overes-
timated. In the longitudinal Study III, we found 
very similar BMD changes in the placebo group 
when compared to the findings in Study I. This 
may indicate that these possible sources of error 
may not be as important.
We did not assess the patients general bone 
mass by scanning the lumbar spine or total hip, 
as was done in Study III-IV, and could therefore 
not verify, or disprove, the impact of this on the 
periprosthetic BMD.
 
We used both uncemented and cemented acetab-
ular cups in Study I-III but we could not find any 
correlation between mode of fixation and BMD 
change or bone remodelling parameters. From a 
previous study however, it is known that different 
bearing materials, in the short-term perspective, 
do not affect BMD of the proximal femur.222
As in Study II, it was not possible to assess the 
HHS prior to surgery due to the retrospective 
design. However, the majority of patients had 
an excellent HHS at follow-up and no relation to 
BMD change was found. 
The main strength of our study is the large 
sample size that, despite its limitations has en-
abled us to verify the relationship between stem 
size and bone loss in vivo which has previously 
been hypothesized.85 
Study II
The same limitations regarding the retrospective 
designs mentioned above also apply for Study II. 
In addition to these, differences in cup fixation, 
the lack of pre-operative HHS data and the meth-
od of assessing radiographic bone remodelling 
parameters can also be regarded as limitations. 
As previously mentioned (chapter 11.2) the 
Stability/Fixation score used in Study I-III has 
limitations regarding its ability to accurately 
identify subtle changes in bone loss or stem mi-
gration over time. The method cannot, as with 
RSA, be used as a predictor of revision.  However, 
because of its easy availability, and the possibility 
of using it in retrospective studies, it is still widely 
used in orthopaedic research. 
The semi-quantitative method of describ-
ing radiographically visible bone remodelling 
changes also has the advantage of the intuitive 
understanding of the biological response of the 
proximal femur to the stem. 
The strengths of the study lie in the fact that 
we were able to examine all patients and the rela-
tively large sample size for a revision arthroplasty 
study.
11.4 STRENgTHS AND LIMITATIONS
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Study III
Unfortunately, the intention-to-treat analysis 
was not perfect; we had to exclude 3 patients 
who suffered an undisplaced calcar split fracture 
during surgery. All were treated with protected 
weight bearing for 6 weeks and their later clini-
cal outcome was excellent. They were excluded 
because the fracture healing would interfere with 
the BMD analysis. 
Another limitation of the study is the 2 
different concepts used in the fixation of the 
acetabular component. The method used to as-
sess the migration of our implants, EBRA, has 
a lower resolution than RSA, and, even though 
one study, using EBRA, has shown less migra-
tion of uncemented acetabular components after 
bisphosphonate treatment,104 another study, has 
failed to do so.306 For TKA, the mean effect of 
bisphosphonate treatment is in the magnitude of 
0.1 mm122,134 which is too small to be detected 
by EBRA. 
The strengths of our study include a high 
follow-up rate and a large sample size. To our 
knowledge, this is the largest randomized clini-
cal trial studying the effect of bisphosphonates 
after an arthroplasty. In addition, the study was 
double-blinded and analysis of efficacy was done 
according to the intention-to-treat principle, an 
approach that has not been used, or reported, in 
most previously published studies.304,307,317-318,320 
As a result of the prospective design, we were 
also able to obtain consistent and reliable BMD 
data with which to calculate the effect of treat-
ment.
Study IV
To assess the influence of the injury on clinical 
outcome scores (HHS, EQ-5D and PNRS), the 
patients were asked to report their prefracture 
status when they were included in the study. The 
patients’ ability to correctly evaluate this while 
waiting for acute surgery may be questioned. It 
is however impossible to collect this data in a 
prospective manner and the method is generally 
used in studies on trauma patients e.g. hip frac-
ture patients.14,253,293
As this was a pilot study of a new medical de-
vice, only patients with intact cognitive function 
were included. This had consequences for the 
sample as we had to screen 229 patients in order 
to include the 50 patients studied. It also meant 
that our cohort is relatively healthy, and our mor-
tality rate of 4% and the loss of follow up rate of 
10% is low compared to other hip fracture stud-
ies.82,135,185,197 However, we were able to include 
patients with a mean age and general bone mass 
that is representative for patients with a displaced 
FNF since the majority of patients were either 
osteopenic or osteoporotic.
The strengths of the study are, for an RSA 
study, the large sample size and the quality of 
data acquired in using both RSA and DXA to 
evaluate migration and bone remodelling. ◉
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In earlier studies of extensively porous-coated 
stems, not only was the revision rate high, pre-
sumably due to massive bone resorption, but the 
acetabular components were also plagued with 
high wear rates and inferior fixation. 
This made it almost impossible to identify 
which implants required revision due to disuse 
atrophy and which were revised as a result of 
wear and/or osteolysis. 
As yet, no studies have shown a correlation 
between periprosthetic BMD decrease and revi-
sion rate or clinical outcome. Such a study would 
require a large number of patients and a follow-
up of at least 10 years. If performing longitudinal 
DXA scans, it would also be difficult to distin-
guish BMD decrease from osteolytic lesions. 
There is however, a intuitive sense that bone 
loss over time cannot have a positive effect on the 
longevity of the implant. There is also the debate 
as to whether this makes patients susceptible to 
wear induced osteolysis or that it increases the 
risk for periprosthetic fracture, the incidence of 
which may be increasing.178-179
It is evident from the literature that as of yet there 
is no definitive explanation for the large individ-
ual variation of periprosthetic BMD change after 
surgery. In this thesis, the BMD in the proximal 
zones varies between +11% and -37% 2 years 
after surgery for individual patients (Figure 62). 
Even though anthropometrical,41,155 surgi-
cal,235 and implant related factors246,271  affect 
bone loss, it is still impossible to predict the 
individual patient’s outcome with regards to 
this bone remodelling. A patients’ susceptibility 
to osteolysis has recently been shown to be as-
sociated with individual differences in response 
to immune stimuli.116 Perhaps this susceptibility 
could also apply for adaptive bone remodelling 
due to stress shielding.  Orthopaedic researchers 
clearly need to focus more on the actual biologi-
cal response of the host bone after THA. 
The most important predictor for bone loss, 
a initial low BMD, clearly shown in Study III 
and IV, incorporates several factors. The lower 
strength of the bone creates a mismatch in stiff-
ness between the implant and bone, thereby 
increasing the stress-shielding. Secondly, osteo-
porosis in itself disrupts the bone micro-archi-
tecture and makes patients even more susceptible 
to bone loss. 
In addition, osteoporosis is a disease caused 
by the effects of a sex steroid deficiency, aging 
osteoblasts, impairment of the growth hormone/
insulin-like growth factor axis and a long list of 
secondary causes.58,262 Whether these biological 
factors also influence periprosthetic bone loss 
after THA has not yet been studied. 
Study I shows that Ti-6Al-4V stems induce bone 
loss that is related to the size (and thereby stiff-
ness) of the implant. In terms of patient outcome, 
it has been suggested that larger diameter stems 
cause an increased frequency of thigh pain.313 
Though, in a recent report from a study done on 
a large number of patients, no correlation was 
found between stem size and revision, loosening, 
pain, or patient satisfaction for the extensively 
porous-coated coated AML stem.89  
The authors concluded that patients with 
large-diameter, extensively porous-coated femo-
ral components were no more likely to require 
revision or have thigh or activity-limiting pain 
than patients with smaller stems. This compares 
favorably with our results from Study I- IV, 
where the patients with larger stems have the 
11.5 gENERAL DISCUSSION
Clinical relevance of bone remodelling
It is apparent that there is a BMD decrease in the proximal femur after uncemented THA. 
What is more uncertain is the interpretation of this phenomenon. Is it a benign, natural 
response to off-loading in accordance with Wolff ’s law309 that is necessary for the longe-
vity of these devices? Or is it a potential catastrophy that, several decades from now, will 
result in increased numbers of periprosthetic fractures and high revision rates? 
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same clinical outcome and HHS as these with 
smaller stems. 
The choice of stem size per-operatively is 
ultimately not decided by the surgeon, it is the 
anatomical characteristics of the femur which 
dictates the size to be used to achieve initial sta-
bility and subsequently bony ingrowth. In Study 
II this is evident, where large diameter stems 
were frequently used due to the presence of large 
bone defects at revision caused by the loosen-
ing process. Since the initial stability is crucial, 
downsizing implants is not an option. 
Design variations such as ultra-short stems,4 
only proximally porous coated stems,33 custom 
made stems,214 isoelastic stems164 etc. have all 
shown a moderate effect on bone loss. The only 
clinically successful stem with an elasticity close 
to that of the femur (Epoch) has a bone loss af-
ter 7 years which is equivalent to that of the Bi-
Metric stem.286 A more aggressive post-operative 
weight bearing regime also seems to be of limited 
benefit.30,287
Our concern regarding this bone loss is that 
it, alone, or in combination with wear particles 
from the polyethylene liner, may facilitate the 
development of osteolysis, with a periprosthetic 
fracture as the ultimate consequence. We have, 
as has been previously mentioned, several such 
cases at our department (Figure 29). 
In the literature however, it is, with few excep-
tions,137 difficult to find reports on this phenom-
enon. In addition, periprosthetic fracture is a 
well-known complication for all elderly patients 
with a long-lasting THA, whether it be cemented 
or uncemented.
Our results after risedronate treatment should 
indicate that there may be an indication for 
bisphosphonate treatment in patients with a low 
pre-operative BMD or these with manifest osteo-
porosis. The recently published study by Thille-
mann et al.288 points in this direction. 
However, no results from a sufficiently sized 
randomized controlled trail (RCT) with bisphos-
phonate treatment after THA yet been published. 
To our knowledge no such study is presently be-
ing conducted. Such a trial would require clini-
cally relevant end points, such as, reduction of 
fracture or revision risk. 
In the original work on risedronate for preven-
tion of hip fractures203 a 4.8% and 3.4% increase 
in BMD in the greater trochanter and femoral 
neck, roughly equivalent to Gruen zones 1 and 7, 
corresponded to a 70% reduction in hip fracture 
risk during a 3 year period (absolute risk reduc-
tion 1.1%). Assuming the effect was the same as 
in the original study with risedronate,203 a study 
done on a high-risk patient group for peripros-
thetic fracture178 would still require a sample size 
of at least 2.000 patients. Though in selected pa-
tients group, such as hip revision surgery, where 
the risk of periprosthetic fracture is significantly 
elevated, fewer patients would be needed. 
figure 62. The mystery of individual variation in 
periprosthetic bone remodelling 
Two female patients, 65 and 67 years of age, both with a 
normal preoperative BMD and who got the same stem size 
implanted. Both are from the placebo group of Study III. After 
2 years, the BMD decrease is significant in patient A, while 
patient B has an increased BMD. Also note that there are very 
few radiological signs of this change in BMD: calcar atrophy in 
A and a minimal distal cortical hypertrophy in B. 
-37%-37%
A
-1%
-1%
-3%
+6%
-8%
+11%+4%
B
+5%
+7%
+21%
+10%
+8%
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In Study IV, we have implemented the recom-
mended stepwise introduction of new implants 
(chapter 3.3).189-190 We used two methods vali-
dated for fixation of implants and bone remodel-
ling, that is, RSA and DXA. To our knowledge, 
no other study using such a combination of 
high-precision methods to evaluate a new hip 
prosthesis in osteoporotic patients with a FNF is 
being carried out. 
It must be noted, however, that the results of this 
study should be interpreted with caution as there 
is no control group. The study was designed as a 
pilot study and therefore cannot give any answer 
to questions regarding differences in fracture or 
mortality risk for uncemented versus cemented 
femoral stems in this patient group. 
Parvizi et al. reviewed the records of 23 pa-
tients (out of 38.488 procedures performed) 
who had died intra-operatively during hip ar-
throplasty at the Mayo Clinic 1969-1997.232  All 
deaths occurred in patients receiving cemented 
implants and the majority (n=14) of patients 
were being treated for a FNF. The autopsies of 
13 of these patients revealed bone marrow mi-
croemboli (n=11) and PMMA particles (n=3) 
in the lungs. By using methods to avoid femoral 
pressurization, such as thorough lavage and a 
low pressure cementing technique, the intra-
operative morality rate was reduced significantly. 
Vacuum mixing of bone cement, as opposed 
to using hand-mixing in a bowl, can also help to 
reduce mortality.172 
In another analysis of the same large cohort of 
patients, Parvizi and co-workers later found in-
creased thirty-day mortality following cemented 
rather than uncemented arthroplasty in patients 
with a FNF. The risk was 8 times greater in the 
cemented group after adjustments for other co-
morbidity factors.231 
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figure 63. Cumulative percent patient survival after hemiarthroplasty for FNFs in Australia 
ETS (Exeter trauma Stem) and Thompson stems are fixated with bone cement, whereas Austin-Moore is uncemented. Reprinted with permis-
sion from the Australian Orthopaedic Association National Joint Replacement Registry. Annual Report 2010.
Uncemented stems for patients with a femoral neck fracture
Are there any benefits in using a modern uncemented stem to treat FNFs in the elderly? 
Is the increased risk of fracture offset by a lower mortality for uncemented stems?
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However, no recent studies with sufficiently large 
sample size have been done on this patient group 
looking specifically at mortality, and taking into 
account the recent advancements in anesthesia 
and cementing technique.
Studies on this topic have, up until now, had an 
impact on the choice of uncemented versus ce-
mented technique in patients with FNFs. This is 
the probable explanation for the paradox in the 
Australian Hip Arthroplasty Register (Figure 63). 
Here, patients operated with the uncemented 
Austin-Moore stem have a small, but statistically 
significant, elevated mortality rate after surgery, 
first apparent after one year. The most likely 
explanation for this is selection bias by the sur-
geons who tend to select the patients with most 
co-morbidities for uncemented fixation. 
In the same register, the revision rate for unce-
mented hemiarthroplasties, compared to ce-
mented, is significantly elevated with a  3-5 fold 
increased revision risk during the first years after 
surgery (Figure 64).117
The fear of increased mortality with cemented 
implants can thus lead to an increased revision 
burden due to poor fixation and periprosthetic 
fractures in elderly patients with uncemented 
implants.
Despite the fact that a HA-coated femoral 
stem, as in Study IV, can work quite well in os-
teoporotic patients with a FNF, there is still little 
evidence to recommend it. The high rate of calcar 
split/periprosthetic fractures reported in this pa-
tient group is a risk that is perhaps unacceptable 
when we consider the low risk of adverse events 
occurring during cementation of the stem. 
Additional research should, in the context of 
multicentre randomized trials or population-
based register studies, focus on whether unce-
mented HA-coated femoral stems are inferior, 
equivalent or superior to cemented stems in the 
treatment of FNFs in the elderly. ◉
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figure 64. Cumulative percent revision of uncemented and cemented hemiarthroplasty for FNFs in Australia. 
Reprinted with permission from the Australian Orthopaedic Association National Joint Replacement Registry. Annual Report 2010.
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12 CONCLUSIONS
I Periprosthetic proximal bone loss after THA using an uncemented tapered 
proximally porous- and hydroxyapatite coated femoral stem is related to 
the stem size used. 
II In patients with moderate pre-revision bone defects, femoral revision 
surgery with an uncemented tapered proximally porous- and HA- coated 
femoral stem is a reliable procedure in the mid-term perspective.
III Risedronate given once weekly for 6 months after THA is effective in 
preventing periprosthetic proximal bone loss after THA around an unce-
mented femoral stem up to 12 months, with a trend towards an effect up to 
24 months post-operatively. 
IV The short time results from this study indicate that the new femoral stem 
can be used for elderly patients with osteoporotic fractures of the femoral 
neck. ◉
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13 IMPLICATIONS FOR FUTURE RESEARCH
• Large population based studies and RCTs 
studying bisphosphonate treatment in conjunc-
tion with THA and TKA.  
• High-sensitivity C-reactive protein is a sig-
nificant and independent risk predictor of non-
traumatic fracture, strengthening the hypothesis 
of a tight interplay between low-grade inflamma-
tion and bone turnover.50,261 It has never been 
studied in conjunction with periprosthetic bone 
loss.
• Further adequately-powered RCTs comparing 
modern uncemented stems with cemented for 
elderly patients with a FNF. The studies should 
be large enough to ascertain whether there are 
differences in clinical outcome, hip function and 
quality of life between the two methods of fixa-
tion.
• Further DXA studies on bone remodelling 
after THA for OA and FNFs, studying differences 
between modes of fixation and stem geometry.
• Future studies of bisphosphonate treatment 
after THA should focus on patients who have 
both osteoarthritis and a low BMD of the hip.
 
• Denosumab is a fully human monoclonal 
antibody to RANKL that blocks it’s binding to 
RANK, inhibiting the development and activity 
of osteoclasts. It is administered subcutaneously 
every 6 months and reduces the risk of vertebral, 
non-vertebral, and hip fractures in women with 
osteoporosis.63 Its mechanism of action makes it 
highly interesting for treatment of both peripros-
thetic bone loss and wear-induced osteolysis. ◉
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Background   Periprosthetic bone loss occurs around 
uncemented femoral stems and may be inﬂuenced by 
the stem size.
Patients and methods   We studied 138 consecu-
tive patients, 3 (2–7) years on average after a total 
hip arthroplasty operation (THA) for unilateral osteo-
arthritis with the Bi-Metric uncemented femoral stem. 
We analyzed Harris hip score and bone mineral den-
sity.
Results   The mean Harris hip score was 97 at follow-
up. Bone mineral density decreased proximally by 19% 
in both Gruen zones 1 and 7. Bone loss in zones 1, 2, 6, 
and 7 was signiﬁcantly associated with stem size. Dis-
tally, a small gain in bone mass was found in zones 3 and 
5 for medium femoral sizes.
Interpretation   We found a marked proximal BMD 
loss, especially for the larger stems, which may be spe-
ciﬁc for this particular implant. Long-term studies 
should reveal whether this proximal bone loss will affect 
the longevity of the THA.
■
In recent years, the most common designs with 
porous-coated femoral components or those with 
ceramic coating such as hydroxyapatite have 
shown promising mid-term results (McLaughlin 
and Lee 1997, McNally et al. 2000). However, a 
remodeling of the periprosthetic bone of the prox-
imal femur has been noted and gives cause for 
concern (Dorr et al. 1997, Khalily and Whiteside 
1998). A well-ﬁxed stem distally seems to cause 
stress-shielding, with proximal bone resorption 
(Engh et al. 1992, Kilgus et al. 1993). Prosthetic 
designs with only proximal coating (Khalily and 
Whiteside 1998), iso-elastic materials (Jacobsson 
et al. 1993, Ang et al. 1997) and short femoral 
components (Morrey et al. 2000) have all been 
designed to reduce this remodeling.
One long-standing concern is that asymptomatic 
bone loss may lead to implant subsidence, asep-
tic loosening or periprosthetic fractures around 
the stem. One factor known to inﬂuence the 
periprosthetic BMD is stem size of the femoral 
implant (Huiskes et al. 1992, Nishii et al. 1997), 
especially after insertion of a stem with a large 
diameter (Maloney et al. 1996). To achieve “ﬁt and 
ﬁll”, uncemented stems are typically larger than 
cemented stems. From a mechanical standpoint, 
increased stem size results in increased stiffness 
and subsequently to greater stress-shielding. We 
have previously found remodeling and proximal 
bone loss after uncemented THA with the Bi-
Metric femoral stem (Bodén and Adolphson 2004). 
Changes in periprosthetic BMD after THA can be 
assessed with high precision by DXA (Cohen and 
Rushton 1995, Venesmaa et al. 2001). This study 
was undertaken to investigate the extent of peri-
prosthetic bone loss and its relationship to femoral 
stem size after implantation of the uncemented Bi-
Metric femoral stem.
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Patients and methods
179 primary unilateral THAs were performed 
with the uncemented Bi-Metric femoral implant 
at Danderyd Hospital from 1997 through 2001. 31 
patients were excluded from this study (because of 
rheumatoid arthritis in 15 patients, peroperative or 
postoperative fractures of the femur in 7, cortico-
steroid treatment as a result of systemic illness in 6, 
congenital hip dysplasia with abnormal anatomy of 
the proximal femur in 2, and peroperative damage 
to the sciatic nerve in 1). 10 other patients were 
lost to follow-up (4 died, 2 refused to participate 
and 4 could not be reached). Thus, 138 patients 
(66 men) with the following characteristics were 
included in the study: mean age 58 (37–91) years, 
mean weight 81 (47–120) kg, and mean height 
171 (146–198) cm. The patients were operated on 
because of primary arthrosis (89%), congenital hip 
dysplasia (4%), posttraumatic arthritis (2%), and 
other diseases (5%). The distribution of stem sizes 
in the patients is shown in Figure 1.
All patients were operated on through a standard 
posterior approach. A 28-mm cobalt-chrome head 
was used for all patients. On the acetabular side, the 
patients received either an uncemented hydroxy-
apatite-coated cup with a cylindrical polyethylene 
liner (74 patients) or a cemented polyethylene cup 
(64 patients). After surgery, the patients were mobi-
lized on the day after the operation. Postoperative 
weight bearing was individualized according to the 
surgeon’s wishes. No protocol regarding weight 
bearing or use of crutches was used.
Within 6 weeks of surgery, 16 non-fatal com-
plications (7 superﬁcial wound infections that 
required antibiotics, 4 deep venous thromboses, 3 
pulmonary emboli, and 2 myocardial infarctions) 
were diagnosed. All patients were studied after a 
mean of 41 (24–80) months after surgery, which 
included clinical examination, radiographical 
assessment and DXA measurement.
We recorded Harris hip score. Standard anterio-
posterior and lateral radiographs were taken imme-
diately after surgery and at the time of survey. All 
radiographs were examined for prosthetic migra-
tion and remodeling changes (Engh et al. 1990).
The BMD of the periprosthetic femur was mea-
sured in the coronal plane by DXA (DPX-L, Lunar 
Co., Madison, WI). Avoiding interference from the 
femoral implant, the software detected the inter-
face between the bony part and the prosthesis stem 
on the basis of density changes and simulated the 
stem in the form of a prosthesis mask, which was 
superimposed on the healthy side. The healthy hip 
was scanned at the corresponding level and BMD 
in 7 regions of interest, based on Gruen zones, was 
analyzed. The values were expressed as areal BMD 
in g/cm2. The differences in BMD were compared 
with stem size and correlated to sex, age, weight, 
height, body mass index, implant time, initial 
BMD—expressed as BMD on the healthy femur—
and Harris hip score. 
To estimate the precision error of the DXA 
method, we had previously made double measure-
ments in 10 patients with complete repositioning 
of the patients and the scanner. The precision error 
was found to be 2.3% in Gruen zone 1, 1.0% in 
zone 2, 2.0% in zone 3, 3.5% in zone 4, 4.2% in 
zone 5, 1.3% in zone 6, and 3.7% in zone 7 (Bodén 
and Adolphson 2004). This precision is of the same 
order as reported by Kilgus et al. (1993) and Nishii 
et al. (1997). 
The investigation was approved by the ethics 
committee of Karolinska Hospital (D.nr approval 
no. 04-011/3). The patients also gave their informed 
consent before inclusion into the study.
Statistics
The mean values (SD) were calculated for absolute 
Figure 1. The distribution of femoral stem diameters.
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Patients and methods
179 primary unilateral THAs were performed 
with the uncemented Bi-Metric femoral implant 
at Danderyd Hospital from 1997 through 2001. 31 
patients were excluded from this study (because of 
rheumatoid arthritis in 15 patients, peroperative or 
postoperative fractures of the femur in 7, cortico-
steroid treatment as a result of systemic illness in 6, 
congenital hip dysplasia with abnormal anatomy of 
the proximal femur in 2, and peroperative damage 
to the sciatic nerve in 1). 10 other patients were 
lost to follow-up (4 died, 2 refused to participate 
and 4 could not be reached). Thus, 138 patients 
(66 men) with the following characteristics were 
included in the study: mean age 58 (37–91) years, 
mean weight 81 (47–120) kg, and mean height 
171 (146–198) cm. The patients were operated on 
because of primary arthrosis (89%), congenital hip 
dysplasia (4%), posttraumatic arthritis (2%), and 
other diseases (5%). The distribution of stem sizes 
in the patients is shown in Figure 1.
All patients were operated on through a standard 
posterior approach. A 28-mm cobalt-chrome head 
was used for all patients. On the acetabular side, the 
patients received either an uncemented hydroxy-
apatite-coated cup with a cylindrical polyethylene 
liner (74 patients) or a cemented polyethylene cup 
(64 patients). After surgery, the patients were mobi-
lized on the day after the operation. Postoperative 
weight bearing was individualized according to the 
surgeon’s wishes. No protocol regarding weight 
bearing or use of crutches was used.
Within 6 weeks of surgery, 16 non-fatal com-
plications (7 superﬁcial wound infections that 
required antibiotics, 4 deep venous thromboses, 3 
pulmonary emboli, and 2 myocardial infarctions) 
were diagnosed. All patients were studied after a 
mean of 41 (24–80) months after surgery, which 
included clinical examination, radiographical 
assessment and DXA measurement.
We recorded Harris hip score. Standard anterio-
posterior and lateral radiographs were taken imme-
diately after surgery and at the time of survey. All 
radiographs were examined for prosthetic migra-
tion and remodeling changes (Engh et al. 1990).
The BMD of the periprosthetic femur was mea-
sured in the coronal plane by DXA (DPX-L, Lunar 
Co., Madison, WI). Avoiding interference from the 
femoral implant, the software detected the inter-
face between the bony part and the prosthesis stem 
on the basis of density changes and simulated the 
stem in the form of a prosthesis mask, which was 
superimposed on the healthy side. The healthy hip 
was scanned at the corresponding level and BMD 
in 7 regions of interest, based on Gruen zones, was 
analyzed. The values were expressed as areal BMD 
in g/cm2. The differences in BMD were compared 
with stem size and correlated to sex, age, weight, 
height, body mass index, implant time, initial 
BMD—expressed as BMD on the healthy femur—
and Harris hip score. 
To estimate the precision error of the DXA 
method, we had previously made double measure-
ments in 10 patients with complete repositioning 
of the patients and the scanner. The precision error 
was found to be 2.3% in Gruen zone 1, 1.0% in 
zone 2, 2.0% in zone 3, 3.5% in zone 4, 4.2% in 
zone 5, 1.3% in zone 6, and 3.7% in zone 7 (Bodén 
and Adolphson 2004). This precision is of the same 
order as reported by Kilgus et al. (1993) and Nishii 
et al. (1997). 
The investigation was approved by the ethics 
committee of Karolinska Hospital (D.nr approval 
no. 04-011/3). The patients also gave their informed 
consent before inclusion into the study.
Statistics
The mean values (SD) were calculated for absolute 
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change and percentage change in BMD. Student’s 
t-test was used to analyze the difference between 
the legs (paired observations) and also the differ-
ences between stem sizes in the different Gruen 
zones (unpaired observations). To investigate fac-
tors that may inﬂuence bone remodeling, we used 
the Pearson’s product moment correlation coef-
ﬁcient to analyze the relationship between BMD 
and sex, age, weight, height, body mass index, 
implant time, initial BMD—expressed as BMD on 
the healthy femur—and Harris hip score. The sta-
tistical analyses were performed with the statistical 
package JMP (SAS Institute Inc., Cary, NC). Dif-
ferences were considered signiﬁcant at p-values of 
less than 0.05.
Results
At follow-up, the mean Harris hip score was 97 
(63–100) points with only 6 patients having slight 
thigh pain. There were no signs of stem loosening.
The mean BMD values and the percentage 
change for all implants in the different Gruen zones 
are summarized in the table. BMD loss most pro-
nounced in zones 1 and 7 (Figure 2). All stem sizes 
caused signiﬁcant bone loss in zone 1 (Figure 3). 
There was a decrease of 2% in zone 2. The 15-mm 
and 16-mm stems lost 8% and 9%, respectively, 
and these were the only stems that gave statistically 
signiﬁcant losses (r2 = 0.091, p < 0.001). The BMD 
in zone 3 showed a gain of 5%. Stem sizes of 10 
mm (7%), 12 mm (7%), 13 mm (5%), 14 mm (5%) 
and 15 mm (5%) were signiﬁcantly increased. No 
correlation between stem size and BMD gain was 
found. In zone 4, a BMD loss of 2% was found. 
Stem size 11 mm decreased by 5% and was the 
only size that showed signiﬁcant change. We found 
BMD in the 7 Gruen zones for all stem sizes. Mean 
values (SD) 
Gruen  Operated side Unoperated side Change
zone (g/cm2) (g/cm2) (%)
1 0.85 (0.16) 1.05 (0.17) –19 (11)
2 1.81 (0.28) 1.85 (0.26)   –2 (10)
3 2.00 (0.25) 1.92 (0.25)   +5 (8)
4 1.91 (0.29) 1.95 (0.26)   –2 (9)
5 2.09 (0.23) 1.99 (0.23)   +5 (7)
6 1.78 (0.28) 1.87 (0.23)   –5 (10)
7 1.09 (0.29) 1.35 (0.24) –19 (15)
Figure 2. Bar graph illustrating the 
mean percentage BMD changes in 
the periprosthetic femur in Gruen 
zones 1–7 as a function of the 12 
different femoral stem sizes. An 
asterisk indicates a signiﬁcant side-
related difference for a particular 
size in a particular zone.
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no correlation between stem size and bone loss in 
this zone. A gain of 5% was found in zone 5. Sizes 
9 mm, 11–16 mm, and 19 mm were all signiﬁ-
cantly increased with a gain of 4–15%. However, 
we found no correlation between stem size and 
change in BMD. In zone 6, there was a BMD loss 
of 5%. Stem sizes 12 mm (–5%), 13 mm (–7%), 
15 mm (–7%), 16 mm (–14%), and 19 mm (–29%) 
were signiﬁcantly reduced. The correlation analy-
sis indicated a strong relationship between stem 
size and bone loss (r2 = 0.16, p < 0.001). Finally, in 
zone 7, the mean BMD loss was 19%. The correla-
tion analysis yielded r2 = 0.14, p < 0.001 (Figure 
4).
Multiple regression analysis with stem size as 
the control variable showed no correlation between 
bone loss of the operated femur in any zone and 
sex, age, weight, height, body mass index, implant 
time, initial BMD—expressed as BMD on the 
healthy femur—or Harris hip score. In addition, 
we did not ﬁnd any difference in BMD loss in any 
zone between the patients who received an unce-
mented hydroxyapatite-coated cup and those who 
received a cemented polyethylene cup.
Discussion
The clinical outcomes in our study are similar to 
those of other studies with the Bi-Metric stem and 
other uncemented porous-coated THAs from a mid-
term standpoint (Robertsen et al. 1996, Meding et 
al. 2004). Most patients had an excellent clinical 
outcome, with only 6 patients (4%) complaining 
of slight thigh pain, and there was no loosening 
of any stem. We did, however, ﬁnd pronounced 
bone resorption of the proximal femur. There is 
concern that bone loss may lead to osteolysis, with 
loosening of the stem or a periprosthetic fracture. 
Although there is no evidence that bone resorption 
causes clinical symptoms or complications, a large 
amount of—or continuous—femoral bone resorp-
tion may reduce the stability of the stem. 
Retrospective studies using contralateral com-
parisons have shown a 40% decrease in proximal 
femoral BMD after 7–14 years (McCarthy et al. 
1991). Kilgus et al. (1993) noted largest BMD loss 
(35%) in the most proximal 1 cm of the medial 
femoral cortex. Longitudinal studies have also 
been performed (Trevisan et al. 1997, Venesmaa et 
al. 2001), conﬁrming the results of cross-sectional 
studies.
There was a signiﬁcant correlation between stem 
size and periprosthetic change in BMD in zones 
Figure 4. Correlation between stem size and BMD ratio 
(percentage of the contralateral value) in Gruen zone 7. 
Regression line and 95% conﬁdence intervals are given.
Figure 3. Correlation between stem size and BMD ratio 
(percentage of the contralateral value) in Gruen zone 1. 
Regression line and 95% conﬁdence intervals are given.
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no correlation between stem size and bone loss in 
this zone. A gain of 5% was found in zone 5. Sizes 
9 mm, 11–16 mm, and 19 mm were all signiﬁ-
cantly increased with a gain of 4–15%. However, 
we found no correlation between stem size and 
change in BMD. In zone 6, there was a BMD loss 
of 5%. Stem sizes 12 mm (–5%), 13 mm (–7%), 
15 mm (–7%), 16 mm (–14%), and 19 mm (–29%) 
were signiﬁcantly reduced. The correlation analy-
sis indicated a strong relationship between stem 
size and bone loss (r2 = 0.16, p < 0.001). Finally, in 
zone 7, the mean BMD loss was 19%. The correla-
tion analysis yielded r2 = 0.14, p < 0.001 (Figure 
4).
Multiple regression analysis with stem size as 
the control variable showed no correlation between 
bone loss of the operated femur in any zone and 
sex, age, weight, height, body mass index, implant 
time, initial BMD—expressed as BMD on the 
healthy femur—or Harris hip score. In addition, 
we did not ﬁnd any difference in BMD loss in any 
zone between the patients who received an unce-
mented hydroxyapatite-coated cup and those who 
received a cemented polyethylene cup.
Discussion
The clinical outcomes in our study are similar to 
those of other studies with the Bi-Metric stem and 
other uncemented porous-coated THAs from a mid-
term standpoint (Robertsen et al. 1996, Meding et 
al. 2004). Most patients had an excellent clinical 
outcome, with only 6 patients (4%) complaining 
of slight thigh pain, and there was no loosening 
of any stem. We did, however, ﬁnd pronounced 
bone resorption of the proximal femur. There is 
concern that bone loss may lead to osteolysis, with 
loosening of the stem or a periprosthetic fracture. 
Although there is no evidence that bone resorption 
causes clinical symptoms or complications, a large 
amount of—or continuous—femoral bone resorp-
tion may reduce the stability of the stem. 
Retrospective studies using contralateral com-
parisons have shown a 40% decrease in proximal 
femoral BMD after 7–14 years (McCarthy et al. 
1991). Kilgus et al. (1993) noted largest BMD loss 
(35%) in the most proximal 1 cm of the medial 
femoral cortex. Longitudinal studies have also 
been performed (Trevisan et al. 1997, Venesmaa et 
al. 2001), conﬁrming the results of cross-sectional 
studies.
There was a signiﬁcant correlation between stem 
size and periprosthetic change in BMD in zones 
Figure 4. Correlation between stem size and BMD ratio 
(percentage of the contralateral value) in Gruen zone 7. 
Regression line and 95% conﬁdence intervals are given.
Figure 3. Correlation between stem size and BMD ratio 
(percentage of the contralateral value) in Gruen zone 1. 
Regression line and 95% conﬁdence intervals are given.
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1, 2, 6 and 7. Stress-shielding and disuse atrophy 
are considered to be the main factors contributing 
to BMD loss after THA (Engh and Bobyn 1988, 
Bryan et al. 1996). Engh et al. (1987) noted that 
stems equal to or greater than 13.5 mm showed 5 
times the amount of resorption of those 12 mm or 
less. The concept of stems that mimic the elastic-
ity of the normal femur, i.e. isoelastic stems, was 
introduced to reduce stress-shielding and sub-
sequent bone loss (Morscher and Mathys 1974, 
Butel and Robb 1988). Earlier isoelastic stems 
have suffered from early loosening and a high revi-
sion rate (Nistor et al. 1991, Jacobsson et al. 1993, 
Niinimäki et al. 1994). However, Glassman et al. 
(2001) and Kärrholm et al. (2002) presented good 
results with the Epoch isoelastic stem.
DXA is an accurate and reproducible method for 
measurement of bone remodeling (Kalender 1992). 
It is possible to measure the quantity of bone near 
a metallic implant accurately (Kiratli et al. 1996, 
Kröger et al. 1996, 1997). The accuracy error of 
DXA in the femur is less than 3% (Barden and 
Mazess 1989). The precision error of the method 
is also low: 1.1–5.3% (Cohen and Rushton 1995, 
Kröger et al. 1996). We have previously found 
a precision error of the same order (Bodén and 
Adolphson 2004). 
A large degree of bone loss of the proximal 
femur has been identiﬁed in longitudinal studies as 
early as 3–6 months after implantation of an unce-
mented stem; thereafter, the BMD stabilizes during 
the ﬁrst postoperative year (Marchetti et al. 1996, 
Nishii et al. 1997, Wixson et al. 1997, Kröger et al. 
1998). None of our patients were measured until 
2 years after surgery. We could not ﬁnd any cor-
relation between implant time and bone loss in any 
zone, and we therefore conclude that one can use 
varying follow-up time beyond 2 years.
Factors that could inﬂuence periprosthetic bone 
remodeling after THA include sex, age, weight, 
density of bone, activity level, diagnosis, disease 
state, medications, duration of implantation, and 
stem stiffness. Different researchers have found 
conﬂicting results regarding the effect of anthro-
pometrical factors on bone remodeling. Thus, 
Brodner et al. (2004) found a correlation between 
gender and BMD in most Gruen zones, and 
between age and BMD in Gruen zones 1 and 7. 
However, Korovessis et al. (1997) did not ﬁnd any 
correlation between age and BMD changes; only 
body mass index correlated with BMD in zone 3 in 
their study. Kärrholm et al. (2002) evaluated pos-
sible confounding factors (sex, age, weight, diag-
nosis, BMD and stem size) immediately after the 
operation, and found that periprosthetic BMD was 
inﬂuenced only by stem design. Kiratli et al. (1996) 
reported that weight was the only variable that 
affected bone remodeling. Maloney et al. (1996) 
found that patients with low weight lost more bone 
distally. We could not ﬁnd any correlation between 
anthropometrical factors and BMD loss.
There is controversy as to whether preoperative 
BMD predicts the rate of bone loss after THA. 
Some authors have found that the lower the BMD is 
before the THA, the larger the BMD loss becomes 
after the THA (Nishii et al. 1997). However, 
Aldinger et al. (2003) did not ﬁnd any correlation 
between initial BMD and degree of periprosthetic 
bone loss. Using multiple regression analysis with 
stem size as control variable, we could not ﬁnd 
any correlation between BMD loss on the operated 
side and initial BMD (expressed as BMD on the 
unoperated side) in any zone.
Bone atrophy depends on stem elasticity (Ang et 
al. 1997): the stiffer the stem, the greater the atro-
phy (Bobyn et al. 1992). Also, femoral stem size 
and amount of hydroxyapatite coating may inﬂu-
ence BMD (Bobyn et al. 1992). Some authors have 
found a correlation between femoral stem size and 
proximal bone loss (Engh and Bobyn 1988, Nishii 
et al. 1997), while other investigators have found 
no such correlation (Petersen et al. 1995, Yamagu-
chi et al. 2000, Sychterz et al. 2001). Petersen et 
al. (1995) concluded that the Taperloc prosthesis 
design transferred the load in a way that made the 
stem size of minor importance. However, these 
authors used a prosthesis with sizes ranging from 
7.5 to 15 mm and studied only 22 patients, so the 
number of hips of any speciﬁc size was probably 
too low. Thus, it is doubtful whether their study 
had sufﬁcient power to indicate whether size is 
associated with bone loss with this prosthesis.
Our investigation has some limitations. It is a 
cross-sectional study in which periprosthetic BMD 
is compared to the value of the healthy side. This 
could be a cause of error because of a possible side-
related difference in bone mass preoperatively. 
Some authors have found a lower BMD on the 
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arthrosis side before operation (Kiratli et al. 1996, 
Martini et al. 1999). Thus, the BMD difference 
found in cross-sectional studies could be overes-
timated, and only a longitudinal study would give 
more accurate information about the remodeling 
process. In a cross-sectional study, it is impor-
tant to perform the investigation after the changes 
have stabilized. We found no correlation between 
duration of implantation and BMD changes in any 
zone; thus, we conclude that a longer implant time 
would not have affected the results. Also, Hughes 
et al. (1995) considered that approximately 3 
years—after which time most remodeling was 
complete—is an optimum time to assess atrophy 
of the proximal femur.
In conclusion, we found that this uncemented 
femoral prosthesis induced a large degree of bone 
loss in proximal periprosthetic zones. Intervention 
with antiresorptive drugs should be considered to 
inhibit this bone loss. Long-term studies will reveal 
whether this proximal bone loss is a negative factor 
for the longevity of this uncemented THA.
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Martini et al. 1999). Thus, the BMD difference 
found in cross-sectional studies could be overes-
timated, and only a longitudinal study would give 
more accurate information about the remodeling 
process. In a cross-sectional study, it is impor-
tant to perform the investigation after the changes 
have stabilized. We found no correlation between 
duration of implantation and BMD changes in any 
zone; thus, we conclude that a longer implant time 
would not have affected the results. Also, Hughes 
et al. (1995) considered that approximately 3 
years—after which time most remodeling was 
complete—is an optimum time to assess atrophy 
of the proximal femur.
In conclusion, we found that this uncemented 
femoral prosthesis induced a large degree of bone 
loss in proximal periprosthetic zones. Intervention 
with antiresorptive drugs should be considered to 
inhibit this bone loss. Long-term studies will reveal 
whether this proximal bone loss is a negative factor 
for the longevity of this uncemented THA.
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Background and purpose   Proximal bone loss due to 
stress-shielding is a matter of concern after uncemented 
femoral hip revision. We have used short, proximally 
hydroxyapatite-coated prostheses in revision since 1989, 
and we now report the results.
Methods   60 patients (62 hips) were revised because 
of aseptic loosening. Bone defects prior to revision were 
mostly of type II according to the Gustilo-Pasternak 
and Endo-Klinik classiﬁcations. Follow-up time was 73 
(24–161) months. 9 patients had died before follow-up; 
8 of these still had the stem in place. Clinical assessment 
was performed with the Harris hip score. Radiographs 
were evaluated for bone defects at revision, postopera-
tive stem ﬁxation, and periprosthetic bone remodeling.
Results   Mean Harris hip score was 75 (30–100) 
points. There was no stem loosening or progressive 
subsidence. 8 patients had mild to moderate thigh pain. 
Osteolysis, present at revision, had diminished, partially 
or completely, in four-ﬁfths of the hips at follow-up. 4 
hips had required re-revision due to fracture or disloca-
tion. The 6-year prosthesis survival rate was 95% (95% 
CI: 0.83–0.98).
Interpretation   Uncemented revision with a short, 
proximally hydroxyapatite-coated prosthesis is a reli-
able procedure with encouraging results in the medium 
term if bone defects at revision are moderate.
■
Cemented revision for prosthetic loosening after 
cemented total hip arthroplasty (THA) has shown 
an unacceptably high failure rate (Dohmae et al. 
1988, Eisler et al. 2000, Haydon et al. 2004). This 
method might be chosen in the elderly patient with 
low demands regarding activity. In active patients 
with a poor bone stock, hip revision with cement 
and impacted morselized allograft bone has shown 
good long-term results (Gie et al. 1993, Ornstein et 
al. 2002, Ullmark et al. 2002, Halliday et al. 2003). 
Uncemented hip revision after aseptic loosening 
has been promising in the short to medium term 
(Bohm and Bischel 2001, Moreland and Moreno 
2001, Trikha et al. 2005) and also in the long term 
(Wagner 1987, Paprosky et al. 1999, Raman et al. 
2005, Reikerås and Gunderson 2006). Most stems 
used in these studies are long-stemmed, exten-
sively coated, or distally anchored. A disadvan-
tage with these stems is the transfer of excessive 
load distally, leading to diminished proximal bone 
stock. Stress-shielding could lead to an increased 
risk of periprosthetic fractures and even stem loos-
ening (Engh et al. 1987, Huiskes 1990). Several 
studies of proximally coated uncemented stems in 
hip revision have shown a high incidence of failure 
due to aseptic loosening or fracture (Berry et al. 
1995, Malkani et al. 1996, Mulliken et al. 1996). 
The reason for this is insufﬁcient ﬁxation of the 
implant in the proximal metaphysis due to poor 
bone stock. However, Kelly et al. (2006) reported 
good results with a proximally coated stem in hip 
revision. We have used a similar stem and now 
report our results.
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Patients and methods
Patients
All patients who had been reoperated at the Ortho-
pedic Department of Danderyd Hospital with the 
proximally porous- and HA-coated tapered Bi-
Metric stem between 1989 and 2002 due to asep-
tic loosening were included in the study. We used 
this prosthesis for revision in younger patients and 
in elderly patients who had a good bone stock. 62 
hips in 60 patients were reoperated (Table 1). The 
index diagnoses were primary osteoarthritis (44 
hips), fractures and related complications (9 hips), 
inﬂammatory arthritis (5 hips), and developmen-
tal dysplasia (4 hips). The mean time between the 
ﬁrst hip arthroplasty and the revision was 7 (1–19) 
years. 41 of the hips had been operated only once 
in the same hip before revision. Mean follow-up 
time was 6 (2–13) years. At follow-up, 9 of the 60 
patients had died. 1 of these had been re-revised 3 
months after the uncemented stem revision due to 
a fracture adjacent to a peroperative fenestration. 
The other 8 patients still had their stem in place. 
No stem-related problems were found in these 
patients. 1 patient had only attended the radio-
graphic part of the study. 
Implant
The patients were reoperated with the Bi-Metric 
femoral stem (Biomet Inc., Warsaw, IN, USA). 
This is a collarless, tapered stem (3º) made of tita-
nium alloy, where the proximal 30% of the stem 
has a porous-coated (100–200 µm) surface with 
plasma-sprayed HA (thickness 40–70 µm, crys-
tallinity 50–70%, purity > 95%). The distal 70% 
has a textured surface. The femoral component is 
available in 13 proportional sizes and has a modu-
lar head of cobalt chrome. Only 1 offset option was 
available.
Surgery
All operations were performed using a poste-
rior approach. 53 of the 62 revised stems were 
cemented and 9 were uncemented; 1 of these was 
a hemiarthroplasty. Bone grafting around the neck 
of the stem was carried out simultaneously in 33 
of the cases. In 24 of the operations, only the stem 
was revised. At follow-up, 39 of the patients had 
a cemented polyethylene cup and 21 patients an 
uncemented cup. The patients were mobilized on 
the day after the revision under the supervision of a 
physiotherapist. Postoperative weight bearing was 
individualized according to the preferences of the 
surgeon.
Clinical evaluation
We evaluated the patients clinically with an inter-
view and physical examination performed by one 
of the authors (MS) who had not been involved in 
the operations. We categorized the patients accord-
ing to Charnley’s clinical classiﬁcation (Charnley 
1972). At follow-up, 26 patients were classiﬁed as 
belonging to class C, i.e. they had disabilities other 
than the hip that interfered with their functional 
capacity (Table 1).
 Clinical outcome was assessed with the Harris 
hip score (HHS) and with questions concerning 
mid-thigh pain. The mid-thigh pain was graded by 
the patient as mild, moderate, or severe.
Radiographic evaluation
Standardized anterioposterior and lateral radio-
graphs after the index operation were compared 
with radiographs taken before and immediately 
after the revision, and with radiographs taken at 
the time of survey. A coefﬁcient—the ratio of the 
actual diameter and the measured diameter of the 
femoral head—was calculated for each radiograph 
and was used to adjust all measurements for mag-
niﬁcation.
We analyzed the radiographs in order to address 3 
particular issues. Firstly, we classiﬁed bone defects 
prior to revision surgery. Secondly, we determined 
the degree of ﬁxation of the stem, and thirdly, the 
amount of the periprosthetic bone remodeling. We 
classiﬁed bone defects according to the classiﬁca-
tions of Gustilo and Pasternak (1988) and Endo-
Table 1. Demographic data for the patients
Age at follow-up, years a   65 (35–84)
Male / female   37 / 23
Weight, kg a   81 (51–128)
Height, cm a 174 (159–191)
BMI a   27 (18–39)
Harris hip score at follow-up a   75 (30–100)
Charnley clinical classiﬁcation (A / B / C)   17 / 11 / 26
a mean (range)
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Klinik (Engelbrecht and Siegel 1989). Stem ﬁxa-
tion was assessed using the criteria of Engh’s ﬁxa-
tion/stability score (FSS) for uncemented femoral 
implants (Engh et al. 1990): absence/appearance 
of endosteal bone bridges (spot welds), absence/
appearance of reactive lines in the coated region of 
the stem, absence/appearance of reactive lines in the 
uncoated region, pedestal formation, calcar model-
ing, and interface deterioration (widening radiolu-
cent lines). Migration of the femoral implant was 
deﬁned as a change in the vertical distance between 
the easily identiﬁed inferior border of the coating 
to the most medial point of the lesser trochanter or 
as any change in alignment or rotation. The sub-
sidence was considered deﬁnite if the change was 
more than 4 mm (Malchau et al. 1995).
 We also assessed presence of focal osteolysis 
(scalloping) with deﬁned borders and distal corti-
cal hypertrophy, deﬁned as new enlargement of the 
external femoral diameter around the distal part of 
the prosthesis, compared to the radiographs taken 
immediately postoperatively. We recorded the 
radiographic changes according to Gruen zones on 
the anterioposterior radiographs. Heterotopic ossi-
ﬁcation was recorded using the grading system of 
Brooker et al. (1973). 
According to the Ethics Board of Karolinska 
Institutet, no permission was required for this 
study (04-453/3). The investigation was approved 
by the committee for protection against radiation at 
Danderyd Hospital (2003-3).
Statistics
We used the Mann-Whitney U test for non-para-
metric variables (independent groups) to assess the 
association between HHS and Charnley’s clinical 
classiﬁcation. The statistical analyses were per-
formed with the statistical package JMP 6.0 (SAS 
Institute, Cary, NC). The results were considered 
signiﬁcant at p-values of < 0.05.
Results
Clinical results
Between the femoral revision operation and the 
follow-up, 5 patients had undergone a cup revi-
sion. At follow-up, the mean HHS score was 75 
(30–100) points. 23 of the patients had a good or 
excellent result with an HHS of > 79 points, 18 
patients had a poor outcome (HHS of < 70 points). 
We noted a lower HHS for patients in Charnley’s 
class C compared to patients in class A (p < 0.001) 
and B (p < 0.005) (Figure 1). We found no differ-
ence in HHS between patients with different types 
of bone defects at revision. 4 patients complained 
of mild thigh pain and 4 other patients of moder-
ate pain. None of the patients suffered from severe 
thigh pain. 28 patients used no support for walking 
and 28 patients had no limp at all.
Radiographic results
Bone defects were mostly of type II in both clas-
siﬁcations, and no type IV defect was observed 
(Table 2). We saw no stem loosening. All stems 
showed several signs of rigid ﬁxation. In 30 hips, 
endosteal bone bridges (spot welds) were noted 
and there was a total absence of reactive lines in 
28
CBA
Charnley functional class
100
80
60
40
20
0
Harris hip score 
A vs B
n.s.
B vs C
p=0.005
A vs C
p=0.001
69
81
94
(n=11)(n=17) (n=25)
Figure 1. Box plot of Harris hip score (53 hips) in the differ-
ent Charnley classes. (HHS; median, quartile and extreme 
values).
Table 2. Femoral bone defects at revision (53 hips)
Type Gustilo and Pasternak Endo-Klinik
I 17 4
II 35 38
III 1 11
IV 0 0
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Patients and methods
Patients
All patients who had been reoperated at the Ortho-
pedic Department of Danderyd Hospital with the 
proximally porous- and HA-coated tapered Bi-
Metric stem between 1989 and 2002 due to asep-
tic loosening were included in the study. We used 
this prosthesis for revision in younger patients and 
in elderly patients who had a good bone stock. 62 
hips in 60 patients were reoperated (Table 1). The 
index diagnoses were primary osteoarthritis (44 
hips), fractures and related complications (9 hips), 
inﬂammatory arthritis (5 hips), and developmen-
tal dysplasia (4 hips). The mean time between the 
ﬁrst hip arthroplasty and the revision was 7 (1–19) 
years. 41 of the hips had been operated only once 
in the same hip before revision. Mean follow-up 
time was 6 (2–13) years. At follow-up, 9 of the 60 
patients had died. 1 of these had been re-revised 3 
months after the uncemented stem revision due to 
a fracture adjacent to a peroperative fenestration. 
The other 8 patients still had their stem in place. 
No stem-related problems were found in these 
patients. 1 patient had only attended the radio-
graphic part of the study. 
Implant
The patients were reoperated with the Bi-Metric 
femoral stem (Biomet Inc., Warsaw, IN, USA). 
This is a collarless, tapered stem (3º) made of tita-
nium alloy, where the proximal 30% of the stem 
has a porous-coated (100–200 µm) surface with 
plasma-sprayed HA (thickness 40–70 µm, crys-
tallinity 50–70%, purity > 95%). The distal 70% 
has a textured surface. The femoral component is 
available in 13 proportional sizes and has a modu-
lar head of cobalt chrome. Only 1 offset option was 
available.
Surgery
All operations were performed using a poste-
rior approach. 53 of the 62 revised stems were 
cemented and 9 were uncemented; 1 of these was 
a hemiarthroplasty. Bone grafting around the neck 
of the stem was carried out simultaneously in 33 
of the cases. In 24 of the operations, only the stem 
was revised. At follow-up, 39 of the patients had 
a cemented polyethylene cup and 21 patients an 
uncemented cup. The patients were mobilized on 
the day after the revision under the supervision of a 
physiotherapist. Postoperative weight bearing was 
individualized according to the preferences of the 
surgeon.
Clinical evaluation
We evaluated the patients clinically with an inter-
view and physical examination performed by one 
of the authors (MS) who had not been involved in 
the operations. We categorized the patients accord-
ing to Charnley’s clinical classiﬁcation (Charnley 
1972). At follow-up, 26 patients were classiﬁed as 
belonging to class C, i.e. they had disabilities other 
than the hip that interfered with their functional 
capacity (Table 1).
 Clinical outcome was assessed with the Harris 
hip score (HHS) and with questions concerning 
mid-thigh pain. The mid-thigh pain was graded by 
the patient as mild, moderate, or severe.
Radiographic evaluation
Standardized anterioposterior and lateral radio-
graphs after the index operation were compared 
with radiographs taken before and immediately 
after the revision, and with radiographs taken at 
the time of survey. A coefﬁcient—the ratio of the 
actual diameter and the measured diameter of the 
femoral head—was calculated for each radiograph 
and was used to adjust all measurements for mag-
niﬁcation.
We analyzed the radiographs in order to address 3 
particular issues. Firstly, we classiﬁed bone defects 
prior to revision surgery. Secondly, we determined 
the degree of ﬁxation of the stem, and thirdly, the 
amount of the periprosthetic bone remodeling. We 
classiﬁed bone defects according to the classiﬁca-
tions of Gustilo and Pasternak (1988) and Endo-
Table 1. Demographic data for the patients
Age at follow-up, years a   65 (35–84)
Male / female   37 / 23
Weight, kg a   81 (51–128)
Height, cm a 174 (159–191)
BMI a   27 (18–39)
Harris hip score at follow-up a   75 (30–100)
Charnley clinical classiﬁcation (A / B / C)   17 / 11 / 26
a mean (range)
Do
wn
lo
ad
ed
 B
y:
 [
Ka
ro
li
ns
ka
 I
ns
ti
tu
te
 L
ib
ra
ry
] 
At
: 
12
:3
5 
14
 O
ct
ob
er
 2
00
9
186 Acta Orthopaedica 2008; 79 (2): 184–193
Klinik (Engelbrecht and Siegel 1989). Stem ﬁxa-
tion was assessed using the criteria of Engh’s ﬁxa-
tion/stability score (FSS) for uncemented femoral 
implants (Engh et al. 1990): absence/appearance 
of endosteal bone bridges (spot welds), absence/
appearance of reactive lines in the coated region of 
the stem, absence/appearance of reactive lines in the 
uncoated region, pedestal formation, calcar model-
ing, and interface deterioration (widening radiolu-
cent lines). Migration of the femoral implant was 
deﬁned as a change in the vertical distance between 
the easily identiﬁed inferior border of the coating 
to the most medial point of the lesser trochanter or 
as any change in alignment or rotation. The sub-
sidence was considered deﬁnite if the change was 
more than 4 mm (Malchau et al. 1995).
 We also assessed presence of focal osteolysis 
(scalloping) with deﬁned borders and distal corti-
cal hypertrophy, deﬁned as new enlargement of the 
external femoral diameter around the distal part of 
the prosthesis, compared to the radiographs taken 
immediately postoperatively. We recorded the 
radiographic changes according to Gruen zones on 
the anterioposterior radiographs. Heterotopic ossi-
ﬁcation was recorded using the grading system of 
Brooker et al. (1973). 
According to the Ethics Board of Karolinska 
Institutet, no permission was required for this 
study (04-453/3). The investigation was approved 
by the committee for protection against radiation at 
Danderyd Hospital (2003-3).
Statistics
We used the Mann-Whitney U test for non-para-
metric variables (independent groups) to assess the 
association between HHS and Charnley’s clinical 
classiﬁcation. The statistical analyses were per-
formed with the statistical package JMP 6.0 (SAS 
Institute, Cary, NC). The results were considered 
signiﬁcant at p-values of < 0.05.
Results
Clinical results
Between the femoral revision operation and the 
follow-up, 5 patients had undergone a cup revi-
sion. At follow-up, the mean HHS score was 75 
(30–100) points. 23 of the patients had a good or 
excellent result with an HHS of > 79 points, 18 
patients had a poor outcome (HHS of < 70 points). 
We noted a lower HHS for patients in Charnley’s 
class C compared to patients in class A (p < 0.001) 
and B (p < 0.005) (Figure 1). We found no differ-
ence in HHS between patients with different types 
of bone defects at revision. 4 patients complained 
of mild thigh pain and 4 other patients of moder-
ate pain. None of the patients suffered from severe 
thigh pain. 28 patients used no support for walking 
and 28 patients had no limp at all.
Radiographic results
Bone defects were mostly of type II in both clas-
siﬁcations, and no type IV defect was observed 
(Table 2). We saw no stem loosening. All stems 
showed several signs of rigid ﬁxation. In 30 hips, 
endosteal bone bridges (spot welds) were noted 
and there was a total absence of reactive lines in 
28
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100
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n.s.
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p=0.005
A vs C
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94
(n=11)(n=17) (n=25)
Figure 1. Box plot of Harris hip score (53 hips) in the differ-
ent Charnley classes. (HHS; median, quartile and extreme 
values).
Table 2. Femoral bone defects at revision (53 hips)
Type Gustilo and Pasternak Endo-Klinik
I 17 4
II 35 38
III 1 11
IV 0 0
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37 hips (Table 3). In 44 hips, initial lucencies had 
been obliterated—either partially or completely—
with new bone formation at follow-up (Figure 2). 5 
stems had subsided by more than 4 mm at follow-
up; all showed other signs of stability. The maxi-
mum subsidence was 8 mm. None of the stems 
migrated into varus, valgus, or rotated. In 2 hips, 
new formation of focal osteolysis was detected in 
Gruen zone 1. Several additional signs of remodel-
ing were observed; these are listed in Table 3. 
Complications
9/62 hips had dislocations; 7 of these had only 1 
dislocation and 2 had recurrent dislocations. Of 
the 2 latter patients, 1 was successfully treated 
with exchange of liner and a larger size of head. 
The other has cerebral paresis and has not been 
reoperated. We had 4 peroperative ﬁssures during 
stem insertion. 3 were noted at operation and were 
treated with partial weight bearing, and 2 of them 
also with cerclage wires. The fourth patient, who 
got a ﬁssure in the lesser trochanter peroperatively, 
suffered from pain and subluxations. The stem 
subsided and he was re-revised using impacted 
morselized bone allograft and a cemented stem. 
4 fractures were seen postoperatively. 2 of these 
were ﬁssures without loosening of the stem. They 
were treated nonoperatively. 1 patient sustained a 
fracture, just after being operated, through a fen-
estration done at the revision operation. He was 
re-revised using a longer stem. The fourth patient 
fell on his hip 2 years after the revision and then 
complained of pain and subluxation phenomenon.
During the revision that followed, we noted that 
the stem had subsided and rotated in retroversion—
and had subsequently been osseointegrated again. 
In all, 4 hips have been re-revised on the femoral 
side. The 6-year prosthesis survival rate was 95% 
(95% CI: 0.83–0.98). 
2 patients had a postoperative wound infec-
tion and 1 patient got a deep infection in the hip. 
1 patient developed a clinically apparent deep vein 
thrombosis. 1 patient suffered from a sciatic nerve 
injury with partial loss of skin sensibility but no loss 
of motor function. No case of pulmonary embolus 
or vascular complication was seen.
Figure 2. Remodeling changes around the stem. Arrows indicate heterotopic ossiﬁcation (A), calcar round-off (B), and 
regression of osteolysis (C).
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Discussion
The frequency of loosening after revision with 
second-generation cementing technique is 15–
20% at 10 years of follow-up, and third-genera-
tion cementing technique has not improved these 
results (Eisler et al. 2000). One cause of the high 
incidence of mechanical failure after cemented 
revision may be the lack of endosteal cancellous 
bone in the femur. This leads to a decrease in shear 
strength between the cement and the bone, due to 
inferior cement-bone micro-interlock (Dohmae et 
al. 1988, Berry 1998). If bone stock is poor, or if 
endosteal cancellous bone is lacking, other surgical 
methods are said to give better results. Impaction 
bone grafting with morselized allograft bone and 
cementation of the stem have been used in femo-
ral revision arthroplasty. This technique has obvi-
ous advantages in bone stock restitution. Several 
authors have reported good or excellent results 
(Ullmark et al. 2002, Halliday et al. 2003, Mahoney 
et al. 2005). However, impaction bone grafting sur-
gery is technically demanding and time consum-
Figure 3. Remodeling changes around the stem. Arrows indicate spot welds (A), pedestal formation (B), and distal cortical 
hypertrophy (C).
Table 3. Bone remodeling at follow-up (53 hips)
  No.
Stem stability parameters
 Fixated stems 53
 Subsidence (maximum 8 mm) 19
 Change in varus-valgus alignment 0
 Spot welds 30
Stress-shielding parameters
 Calcar resorption 16
 Calcar “round-off” 7
 Distal cortical hypertrophy (1–4 mm) 14
Bone remodeling parameters
 Osteolysis at revision 48
 Regression of osteolysis 
    total 7
    partial 37
 Newly formed osteolysis 2
Unspeciﬁc parameters
 Pedestal formation 36
 Reactive lines 16
 Heterotopic ossiﬁcation
    grade 1 13
    grade 2 6
    grade 3 5
    grade 4 0
A
BC
A
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37 hips (Table 3). In 44 hips, initial lucencies had 
been obliterated—either partially or completely—
with new bone formation at follow-up (Figure 2). 5 
stems had subsided by more than 4 mm at follow-
up; all showed other signs of stability. The maxi-
mum subsidence was 8 mm. None of the stems 
migrated into varus, valgus, or rotated. In 2 hips, 
new formation of focal osteolysis was detected in 
Gruen zone 1. Several additional signs of remodel-
ing were observed; these are listed in Table 3. 
Complications
9/62 hips had dislocations; 7 of these had only 1 
dislocation and 2 had recurrent dislocations. Of 
the 2 latter patients, 1 was successfully treated 
with exchange of liner and a larger size of head. 
The other has cerebral paresis and has not been 
reoperated. We had 4 peroperative ﬁssures during 
stem insertion. 3 were noted at operation and were 
treated with partial weight bearing, and 2 of them 
also with cerclage wires. The fourth patient, who 
got a ﬁssure in the lesser trochanter peroperatively, 
suffered from pain and subluxations. The stem 
subsided and he was re-revised using impacted 
morselized bone allograft and a cemented stem. 
4 fractures were seen postoperatively. 2 of these 
were ﬁssures without loosening of the stem. They 
were treated nonoperatively. 1 patient sustained a 
fracture, just after being operated, through a fen-
estration done at the revision operation. He was 
re-revised using a longer stem. The fourth patient 
fell on his hip 2 years after the revision and then 
complained of pain and subluxation phenomenon.
During the revision that followed, we noted that 
the stem had subsided and rotated in retroversion—
and had subsequently been osseointegrated again. 
In all, 4 hips have been re-revised on the femoral 
side. The 6-year prosthesis survival rate was 95% 
(95% CI: 0.83–0.98). 
2 patients had a postoperative wound infec-
tion and 1 patient got a deep infection in the hip. 
1 patient developed a clinically apparent deep vein 
thrombosis. 1 patient suffered from a sciatic nerve 
injury with partial loss of skin sensibility but no loss 
of motor function. No case of pulmonary embolus 
or vascular complication was seen.
Figure 2. Remodeling changes around the stem. Arrows indicate heterotopic ossiﬁcation (A), calcar round-off (B), and 
regression of osteolysis (C).
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Discussion
The frequency of loosening after revision with 
second-generation cementing technique is 15–
20% at 10 years of follow-up, and third-genera-
tion cementing technique has not improved these 
results (Eisler et al. 2000). One cause of the high 
incidence of mechanical failure after cemented 
revision may be the lack of endosteal cancellous 
bone in the femur. This leads to a decrease in shear 
strength between the cement and the bone, due to 
inferior cement-bone micro-interlock (Dohmae et 
al. 1988, Berry 1998). If bone stock is poor, or if 
endosteal cancellous bone is lacking, other surgical 
methods are said to give better results. Impaction 
bone grafting with morselized allograft bone and 
cementation of the stem have been used in femo-
ral revision arthroplasty. This technique has obvi-
ous advantages in bone stock restitution. Several 
authors have reported good or excellent results 
(Ullmark et al. 2002, Halliday et al. 2003, Mahoney 
et al. 2005). However, impaction bone grafting sur-
gery is technically demanding and time consum-
Figure 3. Remodeling changes around the stem. Arrows indicate spot welds (A), pedestal formation (B), and distal cortical 
hypertrophy (C).
Table 3. Bone remodeling at follow-up (53 hips)
  No.
Stem stability parameters
 Fixated stems 53
 Subsidence (maximum 8 mm) 19
 Change in varus-valgus alignment 0
 Spot welds 30
Stress-shielding parameters
 Calcar resorption 16
 Calcar “round-off” 7
 Distal cortical hypertrophy (1–4 mm) 14
Bone remodeling parameters
 Osteolysis at revision 48
 Regression of osteolysis 
    total 7
    partial 37
 Newly formed osteolysis 2
Unspeciﬁc parameters
 Pedestal formation 36
 Reactive lines 16
 Heterotopic ossiﬁcation
    grade 1 13
    grade 2 6
    grade 3 5
    grade 4 0
A
BC
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ing. There are well-known complications associ-
ated with this technique, such as major subsidence 
and per- and postoperative fractures (Eldridge et 
al. 1997, Pekkarinen et al. 2000, van Biezen et al. 
2000, Ornstein et al. 2002).
Another alternative in femoral revision is the use 
of uncemented implants. The aim of using these 
components is to achieve biological ﬁxation, i.e. 
ingrowth of endosteal bone by new bone formation 
within the porous surface structure of the implant 
(Turner et al. 1986, Engh et al. 1987, Engh and 
Bobyn 1988, Rosenberg 1989). In a revision situa-
tion, proximal bone stock in the femur is often com-
promised. To achieve early postoperative stability, 
most uncemented stems are designed to bypass the 
proximally damaged zone and to achieve initial 
stability from press-ﬁt distally. Distally anchored 
stems have shown good clinical results in the 
short- to medium-term (Wagner 1987, Kolstad et 
al. 1996, Isacson et al. 2000, Bohm and Bischel 
2001). These long stems have the disadvantage 
of inducing severe stress-shielding, thus causing 
further bone loss proximally. Removal of such a 
stem would be more technically demanding and 
the outcome is likely to be worse thereafter. In an 
attempt to achieve sufﬁcient initial stability with 
shorter stems, extensively porous-coated or HA-
coated, canal-ﬁlling cobalt-chrome or titanium 
alloy stems have been used with good or excellent 
results (Lawrence et al. 1994, Paprosky et al. 1999, 
Moreland and Moreno 2001, Crawford et al. 2004, 
Raman et al. 2005, Trikha et al. 2005, Reikerås and 
Gunderson 2006). At least initially, the biological 
ﬁxation is probably most pronounced in the distal 
part of the stem because the contact between the 
stem surface and the host bone is more intimate 
in this region, and the surrounding bone stock is 
of better quality distally than in the compromised 
proximal bone. Extensively coated stems get ﬁx-
ated both proximally and distally. 
Stress-shielding is still of some concern to vary-
ing degrees. Reikerås and Gunderson (2006) con-
cluded that they had no stress transfer in the distal 
direction because they had a low amount of proxi-
mal bone loss and a low incidence of distal corti-
cal hypertrophy. In other studies with extensively 
coated stems, there were signs of stress-shielding 
(Paprosky et al. 1999, Moreland and Moreno 2001). 
These divergent results may have been caused by 
different stem designs. The stem used in the study 
by Reikerås and Gunderson (2006) is of tapered 
titanium alloy with a narrow tip. Cylindrical stems 
probably cause more load transfer distally than 
tapered stems do, and titanium alloy stems are 
less stiff than cobalt-chrome stems—which might 
contribute to the degree of stress-shielding. Theo-
retically, stress-shielding could increase the risk of 
periprosthetic fractures, avulsions of muscle inser-
tions in the trochanteric region, and even the risk of 
stem loosening. These theoretical problems have 
not been seen clinically yet, but the follow-up time 
may not be long enough. 
In an attempt to reduce stress-shielding, stems 
with only proximal coating have been used. 
Depending on the length, shape, and surface of the 
stem, they are more or less likely to get ﬁxated dis-
tally also. According to this, it would be difﬁcult 
to strictly categorize these implants into a uniform 
group. The aim, though, of using any of these com-
ponents is to enhance the proximal ﬁxation in order 
to prevent further bone loss proximally and to min-
imize the load transfer distally. Earlier studies with 
stems aimed at proximal ﬁxation have not shown 
entirely promising results (Table 4).
Our report deals with the results of using a prox-
imally porous- and hydroxyapatite-coated unce-
mented tapered stem in femoral revisions because 
of aseptic loosening. We have used this stem 
in cases when it was judged that the bone stock 
at revision could give initial rigid stability to the 
implant. This seems to be a key factor in achiev-
ing good results in hip revisions using uncemented 
stems.
We chose to use 2 classiﬁcation systems to 
determine bone defects prior to revision. The sys-
tems differ in their sensitivity in classiﬁcation of 
bone defects. The classiﬁcation from Endo-Klinik 
(Engelbrecht and Siegel 1989) is more sensitive to 
small bone defects. If the initial stem has subsided, 
it is referred to as a type II defect. That is not the 
case in the Gustilo and Pasternak (1988) classiﬁca-
tion, where there is also a large step between a type 
II and a type III defect. To be considered as a type 
II defect, there must be a large defect involving the 
lesser trochanter and the posterior-medial wall of 
the proximal femur. We had very few such exten-
sive bone defects in our series which contributed 
to the excellent radiographic outcome. As a conse-
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quence of the small bone defects, we were able to 
achieve initial stability of almost all implants—and 
100% well-ﬁxated stems at follow-up. We could 
not see any difference in clinical result associated 
with the bone defects. This is probably due to the 
fact that there was rigid ﬁxation of all stems in our 
study and—as compared to other materials—the 
great proportion of patients were in Charnley’s 
functional class C, thus contributing to a lower 
HHS than would have been the case if it were only 
the operated hip that interfered with their func-
tional capacity.
The clinical result, with a mean HHS of 75 
points, is of the same order as in other studies of 
uncemented femoral revision using stems aimed at 
proximal ﬁxation (Malkani et al. 1996, Mulliken et 
al. 1996). These studies concluded that the over-
all results, clinically and radiographically, were 
suboptimal. During the follow-up in our study, we 
found that the patients were satisﬁed with their 
reoperated hip but almost half of them had other 
disabilities impairing their functional capacity, for 
example inﬂammatory arthritis, knee osteoarthritis, 
or spinal stenosis (Figure 1). We believe that this 
is the reason for us not ﬁnding a higher HHS. 8 
of 62 hips had mild-to-moderate thigh pain and 
no patients suffered from severe thigh pain. This 
compares favorably with other studies (Moreland 
and Moreno 2001, Raman et al. 2005, Trikha et al. 
2005). Radiographically, several patients showed 
signs of load transfer distally, which suggests a 
possible reason for their mid-thigh pain. The fact 
that few of the patients suffered from pain was 
probably due to the rigid ﬁxation of the stem. 
Although the pain parameter is referred to in many 
studies concerning uncemented stems, we consider 
that this parameter is difﬁcult to evaluate because 
of its low speciﬁcity.
Compared to other studies, we had a larger pro-
portion of stem subsidence (19/53 hips). Although 
some of the stems had subsided when we compared 
the radiographs taken immediately after revision 
with the radiographs taken at follow-up, they all 
had several radiographic signs of stable ﬁxation. It 
is possible that a proximally-coated, tapered stem 
is more likely to subside initially in the smooth 
femoral canal with lack of cancellous bone than a 
cylindrical, extensively coated implant. We saw no 
continuous subsidence or progressive radiolucent 
lines in the coated region of the stems. The radiolu-
cent lines adjacent to the stems on the radiographs 
taken immediately after revision had been ﬁlled out 
Table 4. Studies on uncemented femoral revisions with proximally coated stems
First author Follow-up No. of   Type of stem Survival rate Comments 
 (years) hips
Berry (1995)    8 375 6 different types 58% aseptic Insufﬁcient ﬁxation
    survival rate proximally due to
     inadequate bone stock
Peters et al.  (1995)    5 (4–7) 49 Long, curved Endpoints Unacceptably high
    -revision 96% incidence of 
    -rev. or subsidence 37% progressive subsidence
Malkani (1996)    3 (2–5) 69 Metaphyseal 82% for entire group Intraoperative
    ﬁlling, long, curved 58% in fracture group fractures in 46%
Mulliken (1996)    5 (4–6) 52 Metaphyseal 76% overall mechanical Intraoperative
   ﬁlling, long, curved survival rate fractures in 40%
     Insufﬁcient ﬁxation if
     moderate or severe
     bone defects
Suominen and    5  39 Long, curved Endpoints Unacceptably high
Santavirta (1996)    -revision 83% incidence of revision
    -rev. or stem loosening 72% or radiographical
     loosening
Emerson et al. (2003)  12 (9–15)  66 Metaphyseal 94% overall and Used strut allografts if
   ﬁlling, long, curved 97% aseptic survival rate insufﬁcient bone stock
      proximally
Kelly (2006)    5 (4–7)  33 Straight, tapered 100% Good results if  
     sufﬁcient bone stock 
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quence of the small bone defects, we were able to 
achieve initial stability of almost all implants—and 
100% well-ﬁxated stems at follow-up. We could 
not see any difference in clinical result associated 
with the bone defects. This is probably due to the 
fact that there was rigid ﬁxation of all stems in our 
study and—as compared to other materials—the 
great proportion of patients were in Charnley’s 
functional class C, thus contributing to a lower 
HHS than would have been the case if it were only 
the operated hip that interfered with their func-
tional capacity.
The clinical result, with a mean HHS of 75 
points, is of the same order as in other studies of 
uncemented femoral revision using stems aimed at 
proximal ﬁxation (Malkani et al. 1996, Mulliken et 
al. 1996). These studies concluded that the over-
all results, clinically and radiographically, were 
suboptimal. During the follow-up in our study, we 
found that the patients were satisﬁed with their 
reoperated hip but almost half of them had other 
disabilities impairing their functional capacity, for 
example inﬂammatory arthritis, knee osteoarthritis, 
or spinal stenosis (Figure 1). We believe that this 
is the reason for us not ﬁnding a higher HHS. 8 
of 62 hips had mild-to-moderate thigh pain and 
no patients suffered from severe thigh pain. This 
compares favorably with other studies (Moreland 
and Moreno 2001, Raman et al. 2005, Trikha et al. 
2005). Radiographically, several patients showed 
signs of load transfer distally, which suggests a 
possible reason for their mid-thigh pain. The fact 
that few of the patients suffered from pain was 
probably due to the rigid ﬁxation of the stem. 
Although the pain parameter is referred to in many 
studies concerning uncemented stems, we consider 
that this parameter is difﬁcult to evaluate because 
of its low speciﬁcity.
Compared to other studies, we had a larger pro-
portion of stem subsidence (19/53 hips). Although 
some of the stems had subsided when we compared 
the radiographs taken immediately after revision 
with the radiographs taken at follow-up, they all 
had several radiographic signs of stable ﬁxation. It 
is possible that a proximally-coated, tapered stem 
is more likely to subside initially in the smooth 
femoral canal with lack of cancellous bone than a 
cylindrical, extensively coated implant. We saw no 
continuous subsidence or progressive radiolucent 
lines in the coated region of the stems. The radiolu-
cent lines adjacent to the stems on the radiographs 
taken immediately after revision had been ﬁlled out 
Table 4. Studies on uncemented femoral revisions with proximally coated stems
First author Follow-up No. of   Type of stem Survival rate Comments 
 (years) hips
Berry (1995)    8 375 6 different types 58% aseptic Insufﬁcient ﬁxation
    survival rate proximally due to
     inadequate bone stock
Peters et al.  (1995)    5 (4–7) 49 Long, curved Endpoints Unacceptably high
    -revision 96% incidence of 
    -rev. or subsidence 37% progressive subsidence
Malkani (1996)    3 (2–5) 69 Metaphyseal 82% for entire group Intraoperative
    ﬁlling, long, curved 58% in fracture group fractures in 46%
Mulliken (1996)    5 (4–6) 52 Metaphyseal 76% overall mechanical Intraoperative
   ﬁlling, long, curved survival rate fractures in 40%
     Insufﬁcient ﬁxation if
     moderate or severe
     bone defects
Suominen and    5  39 Long, curved Endpoints Unacceptably high
Santavirta (1996)    -revision 83% incidence of revision
    -rev. or stem loosening 72% or radiographical
     loosening
Emerson et al. (2003)  12 (9–15)  66 Metaphyseal 94% overall and Used strut allografts if
   ﬁlling, long, curved 97% aseptic survival rate insufﬁcient bone stock
      proximally
Kelly (2006)    5 (4–7)  33 Straight, tapered 100% Good results if  
     sufﬁcient bone stock 
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with new bone in four-ﬁfths of the hips at follow-
up (Figure 2). Spot welds were seen in half of the 
hips, and they were usually distributed in Gruen’s 
zones 1 and 7, i.e. in the coated region of the stem 
(Figure 3). In primary arthroplasty, using the same 
prosthesis, the incidence of spot welds is higher 
(Bodén et al. 2006). The reason for this may be that 
the endocortex in the proximal femur is smooth 
with less trabecular bone in a revision situation. 
In addition to this, as a result of earlier surgery, 
the femoral bone is altered—leading to unspeciﬁc 
skeletal ﬁndings on the radiographs. These signs, 
in combination with proximal osteopenia (Figure 
4), sometimes made the evaluation regarding oste-
olysis and spot welds difﬁcult.
This stem is designed to be osseointegrated 
in the proximal part of the femur, thus aiming at 
load transfer proximally and preventing from fur-
ther bone loss in this region. However, our radio-
graphic data revealed that this is not the case. The 
stem becomes osseointegrated both proximally 
and distally. We saw several signs of stress-shield-
ing— such as calcar resorption, proximal cortical 
thinning, proximal osteopenia, and distal cortical 
hypertrophy—of varying degrees (Figures 2–4). 
The larger stems used in femoral revision are 
stiffer than the stems used in primary arthroplasty, 
and patients in need of femoral revision have 
lower femoral bone density than patients in need 
of a primary hip arthroplasty. Both of these fac-
tors will contribute to a more pronounced stress-
shielding after femoral revision than after a pri-
mary arthroplasty. It is important to mention that 
both the sensitivity and the speciﬁcity of evaluating 
bone loss radiographically are low. On plain radio-
graphs, bone loss is not detected until about one-
third of the bone is lost and the loss is not repro-
ducibly recognized until two-thirds of the bone is 
resorbed (Engh et al. 2000); thus, it is sometimes 
difﬁcult to differentiate whether bone remodeling 
seen in the femur is due to osteopenia or to oste-
olysis.
We had 2 cases with proximal focal osteolysis. 
Several hips showed signs of proximal osteope-
nia. Even though the stem is designed to prevent 
unloading of the proximal part of the femur, we 
found no other explanation for the proximal osteo-
penia than that the stems also get a distal ﬁxation 
A
C
B
Figure 4. Remodeling changes around the stem. Arrows indicate proximal osteopenia (A), distal cortical hypertrophy (B), 
and pedestal formation (C).
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in the diaphysis, contributing to partial unloading 
of the proximal part of the femur.
During the revision operation, after insertion 
of the uncemented stem, we often noted a non-
circumferential space between the proximal body 
of the stem and the surrounding bone. We did not 
always ﬁll this space with impacted bone chips. 
Despite the presence of this gap, we found no 
distal osteolysis at follow-up. A possible explana-
tion for this is that the HA coating has sealed off 
the interface between the bone and the implant, 
thus preventing migration of debris into the peri-
implant space (Rahbek et al. 2005). HA was intro-
duced to enhance the osteoconductive properties 
of uncemented hip implants (Geesink et al. 1987). 
It has been found that supplementary HA also has 
osteogenetic capacity (Furlong and Osborn 1991). 
Within the gap between host bone and implant, 
bone formation is induced not only from the side 
of the host bone but also from the side of the HA-
coated implant, enabling bone to bridge over wider 
gaps and to do so more rapidly than without the 
use of HA. 
Dislocation was the most common complication 
in our series (9 of 62 hips). This is higher than in 
other studies. We believe that this was caused by 
our use of 22- to 29-mm head size (except in 3 
cases in which the head diameter was 32 mm), and 
that we only had 1 offset option available at that 
time. We had 4 peroperative fractures during stem 
insertion and also noted 4 postoperative fractures. 
These ﬁgures are lower than what other groups 
have reported (Malkani et al. 1996, Mulliken et al. 
1996).
One strength of our study is that we were able 
to re-examine all patients. The weaknesses are the 
retrospective design and the fact that we did not 
have recordings of HHS prior to revision.
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in the diaphysis, contributing to partial unloading 
of the proximal part of the femur.
During the revision operation, after insertion 
of the uncemented stem, we often noted a non-
circumferential space between the proximal body 
of the stem and the surrounding bone. We did not 
always ﬁll this space with impacted bone chips. 
Despite the presence of this gap, we found no 
distal osteolysis at follow-up. A possible explana-
tion for this is that the HA coating has sealed off 
the interface between the bone and the implant, 
thus preventing migration of debris into the peri-
implant space (Rahbek et al. 2005). HA was intro-
duced to enhance the osteoconductive properties 
of uncemented hip implants (Geesink et al. 1987). 
It has been found that supplementary HA also has 
osteogenetic capacity (Furlong and Osborn 1991). 
Within the gap between host bone and implant, 
bone formation is induced not only from the side 
of the host bone but also from the side of the HA-
coated implant, enabling bone to bridge over wider 
gaps and to do so more rapidly than without the 
use of HA. 
Dislocation was the most common complication 
in our series (9 of 62 hips). This is higher than in 
other studies. We believe that this was caused by 
our use of 22- to 29-mm head size (except in 3 
cases in which the head diameter was 32 mm), and 
that we only had 1 offset option available at that 
time. We had 4 peroperative fractures during stem 
insertion and also noted 4 postoperative fractures. 
These ﬁgures are lower than what other groups 
have reported (Malkani et al. 1996, Mulliken et al. 
1996).
One strength of our study is that we were able 
to re-examine all patients. The weaknesses are the 
retrospective design and the fact that we did not 
have recordings of HHS prior to revision.
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BAcKground
Bone resorption around uncemented femoral stems is a well-known phenom-
enon which could increase the risk of periprosthetic fractures or loosening of 
the implant. The aim of this trial was to investigate the effect of risedronate on 
femoral periprosthetic bone resorption after total hip arthroplasty in patients 
with osteoarthritis of the hip.
methods
We enrolled 73 patients between 40 and 70 years of age scheduled for total hip 
arthroplasty in a single-center, randomized, double-blind, placebo-controlled 
trial. Subjects were randomly assigned to receive either 35 mg of risedronate 
(n=36) or placebo (n=37) orally once weekly for 6 months. The primary end 
point was change in bone mineral density in femoral Gruen zones 1 and 7. 
Bone mineral density scans were taken pre- and postoperatively and at 3, 6, 
12 and 24 months. Secondary end points included migration of the stem and 
clinical outcome. 
results
Of the 73 patients included, 70 were analyzed for the primary end point. In the 
placebo group (n=37) we found a continuous bone loss in zones 1 and 7 which 
amounted to 18% at 24 months. Postoperative bone loss was less with risedro-
nate (n=33) during the treatment period and this effect was still significant up 
to 12, but not 24 months. Patients with a low preoperative bone mineral density 
of the hip lost significantly more bone during the study. The migration of the 
stem, the clinical outcome and the frequency of adverse events did not differ 
between the groups but in the risedronate group 4 participants discontinued 
the study drug due to adverse events.
conclusions 
Risedronate given once weekly for 6 months after total hip arthroplasty is ef-
fective in preventing periprosthetic bone resorption around an uncemented 
femoral stem up to 12 months postoperatively but has no effect on implant 
migration. Future studies of bisphosphonate treatment after THA should focus 
on patients who have both osteoarthritis and a low BMD of the hip (Clinical-
Trials.gov number, NCT00772395). ◉
ABSTrACT
Risedronate given once weekly prevents periprosthetic 
bone resorption after total hip arthroplasty
A randomized, double-blind, placebo-controlled trial
Olof G Sköldenberg, Mats O Salemyr, Henrik S Bodén, Torbjörn E Ahl, Per Y Adolphson
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This locally induced osteoporosis progress more 
rapidly than the natural ageing of the femur,13 
thereby possibly explaining the increase in the 
annual incidence of late presenting peripros-
thetic fractures.33 
There is also a concern that this bone resorp-
tion, in the long-time perspective, can lead to 
aseptic loosening of the stem, as well as increas-
ing the difficulty involved in revision surgery.
Several clinical trials have been performed 
involving bisphosphonates and THA.7,48-50,52-
53 The clinical insight gained from these trials 
have been hampered by the small study sizes, 
often with a short follow-up period and varying 
methods of analyzing the effect. Nevertheless, 
earlier studies have indicated that bisphospho-
nates can significantly influence periprosthetic 
bone resorption after THA. Bisphosphonates 
have also been shown to reduce the migration of 
uncemented acetabular components in THA and 
cemented tibial components in total knee arthro-
plasty (TKA).22,28 These are important findings 
since the continuous migration of implants is 
associated with an increased risk for future revi-
sion.30,32 
Risedronate is a bisphosphonate with potent 
antiresorptive activity that is used in the treat-
ment of Paget’s disease of bone and multiple 
myeloma. It can reduce the risk of vertebral frac-
tures and hip fractures in osteoporotic patients.25
In the current study, we tested the hypothesis 
that 35 mg of risedronate, given postoperatively 
once weekly for 6 months, would reduce the 
periprosthetic bone resorption around the stem 
for up to 2 years. We also studied if risedronate 
had an impact on the migration of the stem and 
the general bone mineral density (BMD) of the 
patients or if it affected the clinical outcome. ◉
This randomized, double-blind, placebo-
controlled study followed the guidelines of the 
CONSORT statement.3 The study was carried 
out between August 2006 and May 2010 at the 
Orthopaedic Department of Danderyd Hospital, 
Stockholm, Sweden and was performed in ac-
cordance with Good Clinical Practice (GCP) and 
the ethical principles of the Helsinki declaration. 
The Ethics Committee of the Karolinska In-
stitut (Dnr 04-745/4), the Committee for protec-
tion against radiation at Danderyd Hospital (Dnr 
005-4) and the Swedish Medical Products agency 
(Dnr 151:2005/8091) approved the study. 
The trial was initiated, designed and performed 
as an academic investigation. The pharmaceutical 
company Sanofi-Aventis/Warner Chilcott Phar-
maceuticals Inc. funded in part the risedronate 
and placebo used. Beyond this, the company had 
no futher input or participation in the trial.
study suBjects
All patients planned for primary THA were 
screened for participation in the study. Patients 
who met the inclusion criteria were given written 
information about the trial and were contacted by 
a research nurse. Those who agreed to participate 
gave their written informed consent at a screen-
ing visit 2 weeks preoperatively. Patients aged 40-
70 years, with primary osteoarthritis of the hip, 
and a type A or B femur according to Dorr et al.18 
were eligible for inclusion in the study. 
Patients were excluded if they had a condition 
that could affect bone mineral density (BMD) 
or its measurement, for example, an abnormal 
anatomy of the proximal femur. Patients were 
also excluded if they had had previous surgery of 
the hip or received drugs known to affect bone 
metabolism, for example, ongoing oestrogen or 
oestrogen related drugs within 1 month prior to 
INTrODuCTION
PATIENTS AND METHODS
Adaptive bone resorption around a femoral stem after total hip arthroplasty (THA) is a well-
known phenomenon.10,20 Since a well-fixated stem, which is stiffer than the surrounding femur, 
bears the majority of the load, the bone is stress-shielded and a disuse atrophy results.11
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the screening visit; bisphosphonates, cortisol or 
chemotherapy drugs within 6 months of screen-
ing. Patients with a hypersensitivity to risedro-
nate, who had hypocalcaemia, or who, for any 
reason, were unsuitable to take part of a random-
ized controlled trial were also excluded. 
Since fracture healing is impossible to dif-
ferentiate from adaptive bone remodeling with 
measurements of bone mineral density (BMD), 
we also excluded patients who sustained a peri-
prosthetic fracture during stem insertion.  
surgery
THA was performed with an uncemented, ta-
pered, proximally porous- and hydroxyapatite 
(HA)-coated femoral stem manufactured of a 
titanium alloy (Ti-6AI-4V), (Bi-Metric HA™, 
Biomet, Warsaw, Indiana, U.S.A.) and a 28 mm 
chrome-cobalt head. 
The acetabular component was a cemented 
(ZCA™, Zimmer, Warsaw, Indiana, U.S.A) or an 
uncemented titanium-backed and HA-coated 
press-fit cup (Trilogy™, Zimmer, Warsaw, Indi-
ana, U.S.A). Regardless of the type of fixation, a 
highly cross-linked polyethylene liner (Longev-
ity™, Zimmer, Warsaw, Indiana, U.S.A.) was used. 
The procedures were performed by 9 experi-
enced surgeons using a standard posterior ap-
proach with repair of the posterior capsule and 
external rotator muscles. Intravenous tranexamic 
acid (Cyclokapron®, Pfizer, Sweden) was ad-
ministered before the start of surgery to reduce 
bleeding. Prophylactic antibiotics (Cloxacillin®, 
Meda, Sweden) were given in the first 24 hours 
postoperatively and daltaparin (Fragmin®, Astra-
Zeneca, Sweden) was given 10 days postopera-
tively to prevent thromboses. 
The patients were mobilized using a standard 
physiotherapy program. They were encouraged 
to weight bear fully using crutches for support.  
rAndomizAtion, intervention And Blinding
The patients were randomized on the second post-
operative day to take either a tablet of 35 mg rise-
dronate or the placebo once weekly for 6 months. 
Patients were instructed to take the tablet on an 
empty stomach 30 minutes before breakfast and 
to remain in an upright position for 1 hour after 
ingestion of the tablet. All patients received oral 
supplements of calcium carbonate (1000 mg) and 
vitamin-D (400 IU) daily for 6 months. 
The computerized randomization and blind-
ing procedure was carried out by the central 
pharmacy (Apoteket AB, Stockholm, Sweden), 
which produced the study drug and the placebo 
tablets in physically indistinguishable and coded 
containers. Patients were block-randomized in 
groups of 10 using sealed envelopes and random-
ization was stratified to ensure that the gender 
distribution would be the same in both groups. 
All patients, staff and investigators were 
blinded as to the treatment assignment during 
the study. Two patients in the risedronate group 
were unblinded due to adverse events. Compli-
ance (≥80% of study drug taken) was controlled 
at the 6 week, 3 and 6 monthly follow-up visit.
tABle 1. Baseline characteristics of the patients
risedronate 
(n=36)
placebo  
(n=37)
Age, yrsa 61±7 60±7
Sexb
Female 22 (61) 21 (57)
Male 14 (39) 16 (43)
Weight, kga 79±14 86±17
Height, cma 171±8 174±9
BMIa 27±4 28±6
ASA classificationb
1-2 35 (97) 34 (92)
3-4 1 (3) 3 (8)
Charnley classb
A 20 (56) 16 (43)
B 13 (36) 16 (43)
C 3 (8) 5 (14)
Total hip (WHO)b
Normal bone density 27 (75) 32 (87)
Osteopenia 9 (25) 3 (8)
Osteoporosis 0 (0) 2 (5)
BMD (g/cm²)a 1.02±0.16 1.05±0.19
Vertebrae L1-L4 (WHO)b
Normal bone density 27 (75) 29 (78)
Osteopenia 8 (22) 6 (16)
Osteoporosis 1 (3) 2 (6)
BMD (g/cm²)a 1.24±0.20 1.29±0.27
Surgery
Cup cemented/uncemented (n) 27/9 26/11
Stem size 8-10/11-13/14-15 
mm (n)    
15/16/5 7/24/6
Surgery time (min)a 88±21 92±19
a = mean ±SD, b = n (%)
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end points
The primary end point was a change in the BMD 
in the Gruen23 zones 1 and 7 around the femoral 
stem in subjects receiving risedronate compared 
to those receiving placebo during a 2 year period 
with measurement points 2 days postoperatively 
and at 3, 6, 12 and 24 months. 
Secondary end points included change in 
BMD in the entire periprosthetic region (zones 
1-7) and in the individual zones 2, 3, 4, 5 and 
6. Vertical migration of the stem, radiological 
results, clinical outcome and the occurrence of 
adverse events were also examined. The study 
protocol is shown in Figure 1. 
Bone minerAl density meAsurements
BMD was measured using dual-energy x-ray 
absorptiometry (DXA), (DPX-L™, Lunar Co., 
Madison, Wisconsin, U.S.A.). During scanning, 
the patients were placed in a supine position 
with a foot support to ensure that the femur was 
positioned in a neutral rotation. Two days post-
operatively and at each follow-up visit, the BMD 
was measured around the femoral stem in the 7 
Gruen23 zones in the frontal plane. Using double 
scans, we had previously established the preci-
sion error of the method.12 
The longitudinal change in periprosthetic BMD 
in individual zones, as well as the entire peripros-
thetic region (zone 1-7), was calculated by divid-
ing the BMD value at each follow-up visit with the 
first postoperative BMD value and calculating a 
percentage value. Preoperatively, we measured 
BMD of the proximal femur of the diseased hip 
(WHO total hip) and vertebrae L1-L4 (WHO 
lumbar spine) to assess the patient’s general bone 
mass. The BMD of the L1-L4 vertebrae were also 
measured at 24 months postoperatively (Figure 1).
rAdiologicAl AnAlysis
Digital anterioposterior and lateral radiographs 
(Bucky Diagnostics™, Philips, Eindhoven, 
Netherlands) were taken and uploaded to a 
workstation. Migration of the femoral stem was 
measured with Einzel-Bild-Roentgen-Analyse 
Femoral Component Analysis (EBRA-FCA), 
(University of Innsbruck, Austria). This is an ac-
curate method used to analyze clinically relevant 
migration of a femoral stem after THA.9,30 The 
method has an accuracy of 1.5 mm and it can 
detect a migration larger than 1.0 mm with a 
specificity of 100% and a sensitivity of 78%.9 
Stem fixation and stability were assessed ac-
cording to the criteria of Engh et al.21 Radiolucent 
lines between bone and cement (for cemented 
cups) or bone and porous coating (for uncement-
ed cups) in DeLee and Charnley17 zones around 
the cup were recorded. Heterotopic ossification 
was evaluated according to Brooker et al.14 
clinicAl outcome
Hip function was evaluated with Harris hip score 
(HHS).26 Health-related Quality of Life was as-
sessed using EQ-5D.15-16,38 EQ-5D describes 
health status in 5 dimensions: mobility, self-care, 
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figure 1. Study protocol
DXF=DXA scan of proximal femur (WHO total hip), DXV=DXA scan of 
vertebrae L1-L4 (WHO lumbar spine), DXG=DXA scan of Gruen zones, 
Rad=Anterioposterior and lateral radiographs, Clin=Clinical outcome 
including Harris hip score, EQ-5D and Pain Numeric Rating Scale
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usual activity, pain/discomfort and anxiety/
depression. Each dimension is divided into 3 
levels: 1 – no problem, 2 – some problems and 
3 – extreme problems. This generates 243 differ-
ent “health states” and the EQ-5D index score as-
signs each “health state” to a value, ranging from 
-0.59, indicating the worst possible health state, 
to a value of 1, indicating full health. 
Pain in the operated hip was recorded using 
Pain Numeric Rating Scale (PNRS).19 PNRS is 
an 11-point (0-10) numerical rating scale, were 
patients were asked to evaluate the level of pain 
they experienced in the operated hip during the 
previous week. A score of 0 denotes no pain and 
10 indicates the most pain imaginable. 
sAmple size And stAtisticAl AnAlysis 
A power analysis (two-sided, p=0.05) based 
upon one of our studies with the Bi-Metric 
stem44 was performed in advance on the primary 
end point. A total of 30 patients in each group 
indicated a power of 90% to detect a clinically 
relevant difference of 10% (SD 11%) in BMD in 
the periprosthetic zones 1 and 7 between the 2 
treatment arms. We estimated that we could have 
a loss of data of up to 20% and therefore planned 
to recruit 37 patients in each group. 
Analyses of efficacy were based on the in-
tention-to-treat principle and all patients, who 
received at least 1 dose of either risedronate or 
placebo, were included in the final analysis. 
Subjects with missing BMD data at any of the 
follow-ups (5 individual follow-up visits in the 
risedronate group and 4 in the placebo group) 
were analyzed with the last observation carried 
forward. The analyses were repeated with the use 
of only the available data, and the same results 
were produced (data not shown).
We used a one-way repeated measures analy-
sis of variance (ANOVA) to detect an overall 
effect of treatment throughout the study period. 
Factors known to influence periprosthetic bone 
loss (sex,2 age, BMI, stem size44 and preoperative 
BMD of the hip39) were included as covariates in 
the analyses. Stem size was categorized into sizes 
8-10/11-13/14-15 (size 8-10 as reference). Medi-
an preoperative hip BMD (1.014 g/cm2) was used 
to dichotomize the subjects into 2 groups; pa-
tients with high or low BMD (mean 1.173±0.130 
g/cm2 and 0.896±0.096 g/cm2, respectively). Our 
reference category was made up of patients with 
a high BMD. The effect of general bone mass 
(WHO total hip and WHO lumbar spine) on 
periprosthetic bone loss was also analyzed using 
the Pearson’s correlation coefficient at 24 months. 
For BMD and migration data, we used the 
Kolmogorov-Smirnov and Levene’s tests to test 
for normality and homogeneity of variance of 
data. Thereafter the unpaired Student’s t-test was 
used for between-group comparisons at follow-
ups and the paired Student’s t-test for longitudi-
nal changes. Between-group comparisons of not 
normally distributed clinical outcome scores at 
follow-up visits were analyzed with the Mann-
Whitney U-test and within-group comparisons 
between baseline and follow-up values were 
analyzed with the Wilcoxon signed-rank test. P-
values ≤0.05 were considered significant. ◉
figure 2. CONSORT diagram. Flow of patients in accordance with CON-
SORT (Consolidated Standards of Reporting Trials).
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chArActeristics of suBjects
We enrolled 73 patients, 36 in the risedronate 
group and 37 in the placebo group (Figure 2). All 
patients received at least 1 dose of study medica-
tion and completed 24 months of follow-up. The 
compliance was 93% in the risedronate and 97% 
in the placebo group. Baseline characteristics 
were similar between the groups (Table 1).
efficAcy for primAry end point
In the placebo group, a continuous bone loss was 
seen with a BMD decrease of 18% in zone 1 and 
7 after 24 months. 
In the risedronate group, bone resorption was 
effectively reduced during the first 6 months with 
an efficacy (difference between the 2 groups) 
of 9.2% and 8.0% at 6 months in zone 1 and 7 
respectively (p<0.001 and p=0.003). In zone 1, 
the difference between the groups was still sta-
tistically significant at 12 months (risedronate vs. 
placebo; -7.4% versus -14.5%, p=0.006) with a 
trend towards a difference at 24 months (risedro-
nate vs. placebo; -13.6% versus -17.7%, p=0.066). 
In zone 7, there was no statistically significant 
difference between the risedronate and placebo 
groups at 12 and 24 months (Table 2). 
The protective effect of risedronate on bone 
resorption during the entire study period was 
statistically significant when controlling for sex, 
age, BMI, stem size and preoperative BMD of 
the operated hip (zone 1, p=0.005 and zone 7, 
p=0.006, ANOVA), (Figure 3). In addition, the 
larger stem sizes (size 11-13 and 14-15) were 
associated with increased bone loss in zone 1 
(p=0.045). 
Low preoperative BMD of the hip correlated 
with an increased bone resorption post surgery 
in zone 1 and 7 (p=0.05 and p<0.001, respec-
tively), (Figure 4 and 5). Sex, age or BMI did not 
affect the primary end point at any time (data not 
shown).
efficAcy for secondAry end points 
In the combined periprosthetic regions (zones 
1-7), the patients in the risedronate group had a 
significantly lower bone resorption at all follow-
ups compared to patients in the placebo group 
(Table 2). Bone resorption was also reduced in 
the risedronate group in zones 2, 3 and 6 with 
the same tendency as for zone 1 and 7; reduced 
resorption during the first 6 and 12 months and 
then increased resorption up till 24 months (Fig-
ure 3). In zone 3, the difference between the rise-
dronate and placebo group was still statistically 
significant at 24 months. 
The vertical migration of the stem did not dif-
fer between the groups and was mean -1.7 mm in 
both groups at 24 months (Table 2). The patients’ 
Harris hip score, EQ-5D and PNRS all improved 
compared to the preoperative value and did not 
differ between the groups at any time (Table 2, 
Figure 6). At 24 months, we found no difference 
between the groups in vertebral BMD or the rate 
of heterotopic ossification. 
All stems were stable according to the fixation/
stability score,21 but the score was higher in the 
placebo group (risedronate vs. placebo; 15.5 ver-
sus 18.0, p=0.004, Mann-Whitney U-test). This 
was due to a higher number of spot welds in the 
placebo group (risedronate vs. placebo; 9 of 33 
versus 21 of 37, p=0.013). There was no differ-
ence between the groups with regards to other 
fixation/stability parameters (data not shown). 
On the acetabular side, we found radiolucent 
lines between bone and cement in DeLee and 
Charnley17 zone 1 in 2 hips in the risedronate 
group and 1 in the placebo group. There was no 
radiolucent line around the uncemented cups.  
Adverse events
The frequency of adverse events was similar in 
both groups (risedronate vs. placebo; 20 versus 
24, p=0.416, Table 3). 
In the risedronate group, compared to the 
placebo group, a significantly larger number of 
patients discontinued the study drug because of 
adverse events [2 due to urticaria and 2 due to 
nausea (p=0.037 versus placebo)]. 
Two patients in the placebo group suffered 
from a non-traumatic dislocation of the hip; 1 
patient had to undergo a stem revision 6 days 
postoperatively and 1 patient was treated with 
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tABle 2. The effect of risedronate on primary and secondary end points
outcome risedronate placebo difference (95% ci) p value
primAry end point
Change in BMD zone 1 (%)a
3 months 1.2±7.6 -5.9±9.0 7.2 (3.2 – 11.1) <0.001
6 months -0.5±10.8 -9.7±9.9 9.2 (4.2 – 14.1) <0.001
12 months -7.4±14.7 -14.5±11.2 7.2 (1.0 – 13.3) 0.006
24 months -13.6±12.3 -17.7±13.1 4.1 (-2.0 – 10.2) 0.066
Change in BMD zone 7 (%)a
3 months -3.6±10.2 -10.3±10.9 6.7 (1.6 – 11.7) 0.007
6 months -5.1±10.6 -13.1±11.7 8.0 (2.7 – 13.4) 0.003
12 months -11.9±12.3 -16.1±12.0 4.3 (-1.5 – 10.1) 0.318
24 months -17.2±13.2 -18.1±14.9 0.9 (-5.9 – 7.7) 0.699
secondAry end points
Change in BMD zone 1-7 (%)a
3 months -0.9±3.6 -3.4±4.1 2.5 (0.7 – 4.4) 0.005
6 months -0.3±3.7 -4.0±5.0 3.8 (1.6 – 5.9) <0.001
12 months -0.9±4.8 -4.5±4.9 3.6 (1.3 – 5.9) 0.001
24 months -2.9±4.9 -5.1±4.9 2.2 (0.2 – 4.6) 0.032
Vertical migration of the stem (mm)a
6 months -1.2±1.2 -1.0±0.8 -0.2 (-0.7 – 0.3) 0.520
12 months -1.5±1.5 -1.4±1.0 -0.1 (-0.7 – 0.5) 0.809
24 months -1.7±1.5 -1.7±1.2 0.1 (-0.6 – 0.8) 0.807
Harris hip scoreb
Preoperatively 45 (13-69) 48 (13-69) 0.688
24 months 100 (81-100) 98 (46-100) 0.084
EuroQoLb
Preoperatively 0.42 (-0.14-0.85) 0.30 (-0.18-0.73) 0.081
24 months 1.0 (0.52-1.0) 0.80 (-0.07-1.0) 0.134
PNRSb
Preoperatively 7 (4-10) 7 (3-10) 0.761
24 months 0 (0-3) 0 (0-8) 0.183
other end points
BMD L1-L4 24 months (g/cm²)a 1.27±0.24 1.30±0.27 -0.03 (-0.16 – 0.10) 0.631
Fixation/Stability scoreb 15.5 (7.5 – 23.5) 18.0 (9.5 – 23.5) 0.004
Heterotopic ossificationc
None 25 (69) 28 (76)
Class I-II 11 (31) 8 (22) 0.551
Class III-IV 0 (0) 1 (2)
a mean ±SD, p-value Student’s t-test,  b median (range), p-value Mann-Whitney U test,  c n (%), p-value chi-square test
closed reduction 8 weeks postoperatively. Both 
hips have been stable thereafter. 
One patient suffered a pulmonary embolism and 
another a deep vein thrombosis, both in the pla-
cebo group. 
pAtients who declined pArticipAtion
The 44 patients who declined to participate in the 
study did not differ from the study subjects with 
regards to sex (participants vs. non-participants; 
male/female: 30/43 versus 14/30, p=0.316) or age 
(participants vs. non-participants; mean ±SD 
61±7 versus 62±6 years, p=0.361) but there was 
a tendency for higher ASA class in those patients 
who declined to participate (participants vs. 
non-participants; ASA 1-2/3-4: 69/4 versus 37/7, 
p=0.061). The clinical outcome for non-partici-
pants, as registered in the hospital records, did 
not differ from the patients included in the study 
(data not shown). ◉
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figure 3. Periprosthetic bone remodelling 
The mean (95% CI) percentage change in BMD around the stem in patients receiving risedronate (solid line) or placebo (dashed line). 
*p≤0.05 
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The potentially adverse effect of bone resorp-
tion around hip implants has been widely dis-
cussed.4,13,20,29 
Besides an increased risk for periprosthetic 
fractures,33 a long-term negative effect on im-
plant stability and loosening has also been feared. 
The length of time that prosthesis has to serve in 
a younger patient, puts focus on the continuous 
accommodation and ageing of the host bone in 
the proximal femur. 
There is no study with a long enough follow-
up period to rule out the potential danger of 
this effect on stem stability after several decades. 
Also, if, for any reason, a reoperation is required, 
the prerequisite of an acceptable bone quality is 
crucial for a satisfactory surgical result. 
The most pronounced stress-shielding effect is 
known to occur within 6 months postoperative-
ly.7,41 Several attempts to reduce this influence on 
BMD have been made. Design variations such 
as ultra-short stems,1 only proximally porous 
coated stems,13 custom made stems,34 iso-elastic 
stems31 etc. have all shown a moderate effect 
on bone resorption. A more aggressive postop-
erative weight bearing regime also seems to be of 
limited importance.12,46
The possibility to reduce bone resorption with 
bisphosphonates has also been addressed by 
several researchers and positive effects have been 
noted in the short and mid-term perspective 
(Table 4).6-7,27,35,48-50,52-54 
In animal models, bisphosphonates can cause 
augmentation of bony ingrowth around and 
onto orthopaedic implants,37,45 increase pull-out 
strength of screws43 and reduce wear-induced 
osteolysis.42 Indirect evidence for positive effects 
also in humans includes decreased migration of 
prosthetic implants.28 
This is important since early migration of im-
plants is a risk factor for later revision.32,40 Hild-
ing et al. used radiostereometry (RSA) to show 
that intravenous administration of clodronate in 
humans reduced the migration of the cemented 
tibial component in TKA.28 The same research 
group later demonstrated a similar effect of a lo-
cal elution of ibandronate applied to the freshly 
cut bone surfaces, but failed to show any effect on 
migration in uncemented components with the 
use of oral alendronate.24 
The method used to assess the migration of 
our implants, EBRA, has a lower resolution than 
RSA, and, even though 1 study, using EBRA, has 
shown less migration of uncemented acetabular 
DISCuSSION
In patients with osteoarthritis, 6 months of oral risedronate treatment taken weekly is effective 
in reducing proximal femoral periprosthetic bone resorption up to 12 months after THA with a 
trend towards an effect up to 24 months. 
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figure 4. Bone loss in relation to preoperative Bmd
The mean (95% CI) percentage change in BMD in patients with high 
(bold lines) or low (thin lines) preoperative BMD of the hip in the 
risedronate (solid lines) and placebo (dashed lines) groups.
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components after bisphosphonate treatment,22 
another study, has failed to do so.49 For TKA, the 
mean effect of bisphosphonate treatment is in the 
magnitude of 0.1 mm24,28 which is far too small 
to be detected by EBRA. To date, there is no pub-
lished study showing effect of bisphosphonates 
on femoral or acetabular implant migration after 
THA using RSA. 
Our primary outcome variable, prevention of 
bone resorption, is, like migration of implants, a 
proxy variable for clinical success. When the trial 
was designed, our hypothesis was an efficacy up 
to 2 years with 6 months of treatment, a result we 
almost managed to show. 
Trying to decrease the effect of stress-shield-
ing using bisphosphonates, 6 months of treat-
ment has been advocated since the bone loss is 
largest during the first postoperative period.7,51 
Arabmotlagh et al.7 studied the duration of anti-
resorptive treatment and suggested that the min-
imum time needed for treatment is 6 months, at 
least when using alendronate. They compared 4 
and 6 months of treatment with alendronate and 
found that the protective effect of alendronate on 
bone resorption in the 4-month group decreased 
so that the 4-month group did not differ after 1 
year compared to placebo. They concluded that 6 
months of treatment should protect against bone 
loss up to 1 year. On the other hand, the same 
research team recently published a 6-year follow-
up of a smaller material where they have shown 
and effect after only 5 weeks and 10 weeks treat-
ment with alendronate.6 Though this study had 
the drawback of too few subjects being included 
and 2 different implants being used.
In a recently published study by Yamasaki et 
al.54 on patients with osteoarthritis secondary to 
dysplasia of the hip, they found a marked reduc-
tion of bone resorption in zones 1, 2, 3, 6 and 7 
after 6 months with risedronate given once daily. 
This is well in accordance with our results even if 
their dosage was lower (2.5 mg orally once daily 
whereas we gave 35 mg each week). The same 
researchers also found a positive effect in zone 
7 after 30 months if early treatment with cyclic 
therapy with etidronate for 12 months was ap-
plied.53 However, as in our study, a significant 
decrease in BMD was noticed in the proximal 
zones after withdrawal of therapy.
Thus, the proxy variables periprosthetic bone 
atrophy and migration of implants after bisphos-
phonate treatment have been extensively studied, 
as opposed to the outcome variables that truly are 
of interest; clinical outcome and risk for revision. 
In a recent nationwide population-based 
study, results concerning postoperative use of 
tABle 3. Adverse events 
risedronate 
(n=36)
placebo 
(n=37) 
p-
value
Any adverse event 20 24 0.416
Drug-related adverse eventa 5 3 0.429
Urticaria 3 1
Nausea 2 0
Dyspepsia 0 2
Surgery-related adverse 
eventa
8 10 0.634
Leg swelling or leg pain 
operated side
3 5
Postoperative anaemia 
requiring transfusion
2 1
Superficial wound infec-
tion
2 1
Deep venous thrombosis 0 1
Pulmonary embolism 0 1
Dislocation 1 1
Other adverse eventb 7 11 0.308
Contusion lower extremity 4 0
Upper respiratory tract 
infection
0 4
Other minor infections 0 2
Hypothyroidism 0 1
Fracture upper extremity 1 0
Vertigo 0 3
Conjunctivitis 1 0
Hypoglycemia 1 0
Urinary tract infection 0 1
serious adverse eventc 1 2
discontinuation of study 
drug due to adverse event 4 0 0.037
Number of events are given.
a Adverse events classified as having a certain or probable 
relationship to study drug or surgery.
b Adverse events classified as having no relationship to study 
drug or surgery. 
c 3 subjects were hospitalized during the study period, 2 due to 
dislocation and 1 due to pulmonary embolism.
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bisphosphonates and risk for revision after pri-
mary THA in osteoporotic patients were pre-
sented.47 A total of 632 patients who were revised 
after primary THA were compared to 1.262 non-
revised controls. No overall difference in risk for 
revision due to aseptic loosening was detected 
between users and non-users of bisphospho-
nates. However, a subgroup analysis of patients 
with bisphosphonate treatment for more than 
240 days, showed a tendency towards a decreased 
risk for revision. 
In our study, we found that patients with a 
lower preoperatively BMD lose significantly 
more bone after THA (Figure 4 and 5). Before 
surgery, we measured BMD of the proximal fe-
mur and vertebrae L1-L4 and found that patients 
in the placebo group with low preoperative bone 
mass had lost 23% and 27% in zone 1 and 7 of 
the operated hip after 2 years whereas patients 
with high systemic BMD lost only 14% and 11%, 
figure 5. Effect of general bone mass on primary end point after 24 months.
Scatter plot of periprosthetic bone loss in zone 1 and 7 at 24 months against preoperative BMD in the hip (A, B) and lumbar spine (C, D) 
with regression lines for risedronate (solid line) and placebo (dashed line).
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respectively. This is consistent with results from 
other studies showing a correlation between low 
preoperative bone mass and increased bone loss 
around uncemented stems.5,39 
Together with the results from Thillemann 
et al.47 above, this may indicate that prolonged 
treatment with bisphosphonate after THA in 
osteoporotic patients is warranted. Bone loss 
around THA is suspected to be continuous and 
to be faster than normal ageing, at least in zone 
7.13 The length of treatment must be long enough 
to reach the normal steady state in bone metabo-
lism, maybe life-long.
We found a statistically significant higher num-
ber of endosteal bone bridges (spot welds) in the 
placebo group. Despite this, all stems were firmly 
fixed and the migration did not differ between 
the groups. There are two possible explanations 
who alone, or together, could explain this. 
First, the higher regional bone resorption 
identified in the placebo group lowers the at-
tenuation and makes the bone bridges easier to 
observe on plain X-ray film. Typically spot-welds 
are found in the proximal regions where the 
stress-shielding effect is most obvious and the 
bone bridges contrast distinctly with the sur-
rounding bone. In the treatment group where the 
stems apparently are just as well fixed according 
to other parameters, the spot welds are blurred by 
the high attenuation. 
Second, normally, foci of traumatized and de-
vitalized cancellous bone trabeculae are remod-
eled post-operatively by osteoclasts followed by 
an osteoblast phase. Since risedronate effectively 
aborts the osteoclast response at the interface, we 
hypothesize that bone repair is slower and prob-
ably more homogenous which would explain 
absence of spot-welds seen on the radiographs in 
the treatment group. 
This finding requires further investigation, 
since this study was not power calculated for this 
end point.
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figure 6. Clinical outcome
Mean (95% CI) values in patients receiving either risedronate (solid line) or placebo (dashed line) for Harris Hip Score (HHS), Health-
related Quality of Life (EuroQoL) and Pain Numeric Rating Scale (PNRS).
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strengths And weAKnesses
The strengths of our study include a high follow-
up rate and a large sample size. To our knowl-
edge this is the largest randomized clinical trial 
studying the effect of bisphosphonates after an 
arthroplasty. The study was also double-blinded 
and analysis of efficacy was done according to 
intention-to-treat, an approach that is lacking, or 
not reported, in most previously published stud-
ies.48,50,52-54 
One aim of this trial was to replicate the 
clinical setting; patients will stop taking the study 
medication if there are side-effects, something 
that occurred in 4 of our subjects in the treat-
ment group. This is important, because if you 
exclude patients not taking their medication this 
will boost the effect of the studied drug.
A weakness of this study is the 2 different con-
cepts of fixation of the acetabular component. 
However, the polyethylene was the same for both 
types of fixation and different types of articula-
tion have not been shown to affect adaptive bone 
remodelling after THA.36
conclusion
In accordance with other studies, we demonstrate 
the antiresorptive effect of a bisphosphonate after 
THA but also that this effect is time-dependent 
and the bone sparing effect diminishes in the 
year following cessation of therapy. Whether 
the initial benefit of a time-limited bisphospho-
nate treatment in adjunction with THA can be 
justified is unclear.8 A prolonged treatment (life-
long?) may show other results. 
In conclusion, risedronate given once weekly 
for 6 months after THA is effective in prevent-
ing periprosthetic bone resorption around an 
uncemented femoral stem up to 12 months, with 
a trend towards an effect up to 24 months post-
operatively. 
Future studies of bisphosphonate treatment 
after THA should focus on patients who have 
both osteoarthritis and a low BMD of the hip. ◉
tABle 4. Studies on bisphosphonates and THA in humans, the current study in the bottom for comparison. 
A B C D E F G H I J K
Venesmaa et al.32 2001 oral alendronate 10 mg q.d. 6 m I:8, C:5 OA UPP BMD DXA 6 m no n.r.
Wilkinson et al.34 2001 i.v. pamidronate 90 mg bol. I:23, C:24 M CT BMD DXA 6 m yes no
Hennigs et al.30 2002
I1: oral alendronate 10 mg 
q.d. 10 w
I2: oral alendronate 20 mg 
q.d. 5 w
I1:21, I2:21, C:24 M UPP/GB BMD DXA 12 m no n.r.
Nehme et al.31 2003
oral alendronate 10 mg q.d. 
24 m
I:18, C:20 N/A CT BMD DXA 24 m yes n.r.
Yamaguchi et al.36 2003 oral cyclic ethidronate q.d. 12 m I:23,C:30 CDH UFP/UPP BMD DXA 12 m no no
Yamaguchi et al.35 2004
I1: oral cyclic ethidronate q.d. 
12 m, start postop
I2:  oral cyclic ethidronate q.d. 
12 m start after 18 m
I1:16, I2:15, C:24 CDH UFP/UPP BMD DXA 30 m no no
Wilkinson et al.33 2005 trial extension55 I:23, C:24 M CT
BMD/ 
migration
DXA/EBRA 24 m yes no
Arabmotlagh et al.29 2006
oral alendronate 20 mg q.d. 2 m,
then 10 mg q.d. 2 (I1) or 4 (I2) m
I1:13, I2:14, C:24 OA UPP/GB BMD DXA 12 m yes n.r.
Yamasaki et al.37 2007 oral risedronate 2.5 mg q.d. 6 m I:19, C:21 CDH UFP/UPP BMD DXA 6 m no no
Arabmotlagh et al.28 2009 trial extension7 I1:14, I2:15, C:20 M UPP/GB BMD DXA 72 m no n.r.
Friedl et al.39 2009 i.v. zoledronic acid 4 mg bol. I:25, C:24 ON GB migration EBRA 36 m yes n.r.
Sköldenberg et al. 2010 oral risedronate 35 mg q.w. 6 m I:36, C:37 OA UPPH BMD DXA/EBRA 24 m yes yes
A Author
B Year published
C Bisphosphonate regimen: q.d.=once daily, bol.= 
single bolus dose, q.w.=once weekly
D Sample size: I=intervention group, C=control 
group
E Diagnosis: OA=osteoarthritis, M=mixed 
diagnoses, CDH=congenital dysplasia of the hip, 
ON=osteonecrosis of the femoral head
F Design of stem: GB=uncemented grit-blasted, 
CT=cemented tapered, UFP=uncemented full 
porous-coated, UPP= uncemented proximally 
porous-coated, UPPH=uncemented proximally 
porous-coated with hydroxyapatite
G Primary outcome variable
H Method used for determining efficacy
I Length of follow-up 
J Blinding
K Study analyzed according to intention-to-treat. 
n.r. = not reported
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BAcKground
The aim of this study was to evaluate the fixation of, bone remodelling around, and 
clinical outcome after surgery of a new, uncemented, fully hydroxyapatite-coated, 
collared and tapered femoral stem, designed specifically for elderly patients with 
a femoral neck fracture. 
methods
We enrolled 50 patients, of at least 70 years of age, with an acute displaced femoral 
neck fracture in this prospective single cohort study. The patients received a total 
hip arthroplasty using the new stem and were followed up at regular intervals for 
a period of 2 years.
 
results
The fixation was evaluated with radiostereometric analysis and dual-energy x-
ray absorptiometry was used to investigate bone remodelling. Hip function and 
health-related quality of life were assessed using the Harris hip score and EQ-5D.
Up to 6 weeks post surgery, we noted a mean subsidence of 0.2 mm and a retrover-
sion of a mean of 1.2°. No stem migrated after the 3 month follow-up. The patients 
had a continuous loss of periprosthetic bone that amounted to 16% at 2 years. At 
the 2-year follow-up the mean Harris hip score was 82. 
conclusions
A total hip arthroplasty with this new uncemented stem can be used for osteopo-
rotic fractures of the femoral neck. ◉
ABSTRACT
A new uncemented hydroxyapatite-coated femoral 
stem for treatment of femoral neck fractures
A two-year radiostereometric and bone densitometric  
evaluation in 50 hips
Olof G Sköldenberg1, Mats O Salemyr1, Henrik S Bodén1, Torbjörn E Ahl1,  
Arne Lundberg2, Per Y Adolphson1
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Cemented femoral stems are used both in total 
hip arthroplasty (THA) and hemiarthroplasty 
and earlier studies have supported the use of 
cemented stems in hip fracture patients, mainly 
due to decreased post-operative pain during re-
habilitation.5-7 
However, the concept of inserting an un-
cemented stem, even in elderly patients, is at-
tractive to many surgeons8 as bone cement has 
several major, albeit uncommon, negative side-
effects. These are mainly cardiac arrhythmias and 
cardio-respiratory collapse which can occur dur-
ing the cementing process.9 
The mechanisms involved are not yet fully 
understood but are most likely caused by pulmo-
nary embolization of bone marrow and methyl-
methacrylate particles.10-11 The mortality rate in 
this frail patient group may therefore be higher 
after cemented rather than uncemented arthro-
plasty.12-13 
The potential advantages of an uncemented 
femoral stem are also related to the shorter du-
ration of surgery (thereby possibly minimizing 
intraoperative bleeding and decreasing the risk 
of infection).5 The disadvantages include an 
increased risk for periprosthetic fractures, thigh 
pain and stress-shielding of the proximal femur. 
A new uncemented femoral stem, based on a 
successful earlier design,14-15 with full hydroxy-
apatite (HA) coating to enable fast ingrowth in 
osteoporotic bone,16 and a collar to avoid exces-
sive subsidence, has been developed specifically 
for femoral neck fractures [Biomet Fracture Stem 
(BFX®)]. 
The purpose of this investigation was to study 
the fixation of and bone remodelling around the 
new stem in a representative sample of elderly 
patients with a displaced femoral neck fracture. 
We used radiostereometric analysis (RSA)17 
to evaluate the fixation of the stem and although 
RSA has been used to study the healing of femo-
ral neck fractures after IF,18 no study using RSA 
has been carried out after hip arthroplasty in this 
patient group. 
Similarly, bone remodelling around femoral 
stems after THA in patients with degenerative 
joint disease has been extensively studied using 
dual-energy x-ray absorptiometry (DXA) but, to 
our knowledge, it has never been used before in 
this patient group.19-21 ◉
INTRODUCTION
This prospective single cohort study was carried 
out between October 2005 and April 2010 (inclu-
sion period October 2005 to April 2008) at the 
Orthopaedic Department, Danderyd Hospital, 
Stockholm, Sweden. The study was performed in 
accordance with Good Clinical Practice (GCP) and 
the ethical principles of the Helsinki declaration. 
Both the Ethics Committee of the Karolinska Insti-
tute (Dnr 04-086/4) and the Committee for Protec-
tion Against Radiation at Danderyd Hospital (Dnr 
005-5) approved the study. 
The trial was initiated, designed and per-
formed as an academic investigation. Biomet 
(Biomet Orthopaedics AB, Sjöbo, Sweden) 
marked the femoral implants but took no other 
part of the study.
pAtients
All 229 patients who were admitted to our emer-
gency department with an acute (<24h before 
admission) femoral neck fracture during the in-
clusion period between October 2005 and April 
2008 were screened for participation in the study. 
The inclusion criteria were a displaced frac-
ture (Garden III or IV),22 an age of at least 70 
years, intact cognitive function [at least 8 correct 
answers on a 10-item (SPMSQ) mental test],23 
the ability to walk independently with or with-
PATIENTS AND METHODS
There is solid evidence to support recommending a primary hip arthroplasty instead of 
internal fixation (IF) for a displaced femoral neck fracture in elderly patients who are inde-
pendent walkers and have no severe cognitive impairment.1-4 
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out the help of walking aids and a willingness to 
participate in the study. Patients with a previous 
fracture in the same hip, a pathological fracture, 
those deemed not suitable for THA by the anaes-
thesiologist or those who for any other reason 
were unsuitable to participate in the study, were 
excluded (Figure 1). 
A research nurse gave the patients oral and 
written information about the study, and those 
who agreed to take part of the study gave their 
written informed consent (Table 1). 
stem design
The new implant, Biomet Fracture Stem, BFX® 
(Biomet UK Ltd, Bridgend, U.K.), (Figure 2) is a 
tapered, collared, stem intended for uncemented 
fixation in the femur. It is made of a titanium 
alloy (Ti-6Al-4V) with a grit-blasted surface 
roughness of 7.5-10 µm. It has a straight 3° prox-
imal-to-distal taper in 2 planes and a taper from 
the lateral shoulder to the medial calcar area. 
The geometry of the stem, except for the collar, 
is identical to the Bi-Metric® stem.14-15 The stem 
has plasma-sprayed HA on the entire surface 
(thickness 65-95 µm, crystallinity 50-70%, purity 
>95%) to enable fast ingrowth in osteoporotic 
bone.24 
The stem is available in 6 sizes (7-17 mm, 
uneven sizes only), all with a neck/shaft angle of 
140°.
figure 1. Study protocol 
RadRSA=Calibrated stereo radiographs for RSA, DXG=DXA scan of Gruen zones, DXF=DXA scan of the contralateral proximal femur 
(WHO), DXV=DXA scan of vertebrae L1-L4, Rad
AP= anterioposterior and lateral radiographs, Clin=clinical outcome scores (HHS, EQ-5D 
and PNRS). Patients lost to follow-up have been contacted by phone, they have no hip related pain and their hips have not dislocated or 
been revised. Their RSA, DXA and clinical data have been included in the analyses until the last follow-up. 
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surgery
Preoperative planning was performed with a 
digital templating software (mDesk®, RSA Bio-
medical, Umeå, Sweden). The patients under-
went surgery with a THA using the new stem 
articulating on a 32 mm cobalt-chrome head 
against a cemented cup (ZCA®, Zimmer, Warsaw, 
Indiana, U.S.A.). 
The operations were all done within the first 
48 hours after admission by 1 of 4 surgeons (OS, 
MS, HB or TA). A posterior approach, with re-
pair of the posterior capsule and external rotator 
muscles, was used in all patients. 
The resection of the femoral neck was done 
using a template and the femur was reamed until 
cortical bone contact was obtained. Thereafter, 
the proximal femur was prepared with broaches 
of increasing size until rotational stability was 
achieved. With the final broach in place, the 
calcar femoris was planed flush using a planing 
tool. Thus, the prosthetic collar rests on the calcar 
femoris when the prosthesis is fully seated and 
rotationally stable (collar-calcar contact). 
For some hips, the fracture line was more 
distal than the ideal collar resection line; in these 
hips, the collar of the stem did not rest on bone 
when the stem was rotationally stable (no pros-
thetic collar-calcar contact). 
Before the final implant was inserted, 5 to 9 
tantalum marker beads (1.0 mm in diameter) 
were inserted in the cancellous bone of the proxi-
mal femur. 
Intravenous tranexamic acid (Cyclokapron®, 
Pfizer, Sweden) was administered before the start 
of surgery to reduce bleeding. Prophylactic anti-
biotics (Cloxacillin®, Meda, Sweden) were given 
in the first 24 hours post-operatively and daltapa-
rin (Fragmin®, AstraZeneca, Sweden) was given 
10 days post-operatively to prevent thromboses. 
The patients were mobilized using a standard 
physiotherapy program. They were encouraged 
to weight bear fully using crutches for support.
outcome meAsures
The primary end point of the study was migra-
tion of the stem. Secondary end points included 
change in bone mineral density (BMD) in 7 Gru-
en zones25 around the stem and clinical outcome. 
The study protocol is shown in Figure 1.
Radiostereometric analysis
RSA is a high-precision method to measure three 
dimensional (3-D) micro-motions from calibrated 
stereo radiographs17 and is a standard for evaluat-
ing new implants since early migration can pre-
dict implant loosening.26 The RSA method in this 
study follows the published guidelines for RSA.27 
We took digital calibrated radiographs (Bucky 
Diagnostic®, Philips, Eindhoven, Netherlands) 
using 1 fix and 1 mobile Roentgen source (120 
kV, 4-6 mAs), and a uniplanar calibration cage 
(Uniplanar digital 43, RSA Biomedical AB, 
Umeå, Sweden). All data were analysed using the 
UmRSA® computer software (RSA Biomedical 
AB, Umeå, Sweden). 
The markers in the proximal femoral bone 
form one segment. The centre of the prosthetic 
head, in combination with the tantalum marker 
beads in the femoral stem, forms another seg-
ment. The 3-D translations and rotations of the 
calculated centre of gravity of the femoral stem 
segment in relation to the femoral bone segment 
figure 2. Biomet Fracture Stem 
(BFX®)
The implant has been modified for 
RSA with tantalum marker beads 
at the shoulder, collar and tip of 
the prosthesis.
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were calculated at each follow-up visit with the 
immediate post-operative examination as base-
line. We also measured the maximum total point 
motion (MTPM). This is the 3-D translation 
vector of the femoral stem marker that has the 
largest movement and is seen as an indicator of 
the overall magnitude of migration. 
At 12 months, we performed double examina-
tions 15 minutes apart on 25 patients with com-
plete repositioning of the roentgen tubes and the 
calibration cage. We calculated the precision as 
the 99% confidence limits (SD 2.7) of the differ-
ence between these examinations. For translation 
along the x (transverse), y (vertical) and z (ante-
rioposterior) axes, it was 0.27, 0.19 and 0.52 mm, 
respectively. For rotation about the x-axis (flex-
ion/extension), y-axis (ante-/retroversion) and 
z-axis (varus/valgus) it was 0.52, 0.76 and 0.27°, 
respectively and for MTPM it was 0.74 mm. The 
precision for our RSA-setting is similar to previ-
ously reported trials.16,28  
The mean error of rigid body fitting29 is used 
to evaluate the stability of marker position over 
time. We excluded examinations where this value 
was >0.3 mm, indicating migration of markers. 
Condition number29 is used to evaluate marker 
distribution and a high value precludes accurate 
measurements of z-translation as well as segment 
rotation and MTPM. Therefore, in examinations 
where the condition number exceeds 100, only 
transverse (x) and vertical (y) translations were 
calculated. 
Bone mineral density and radiological evaluation
BMD of the periprosthetic femur was measured 
in the 7 Gruen zones25 in the frontal plane using 
DXA (DPX-L™, Lunar Co., Madison, Wisconsin, 
U.S.A.). During scanning, the patient was placed 
in the supine position with standard knee and 
foot supports and the femur was positioned in 
neutral rotation. The change in periprosthetic 
BMD ratio in all individual zones, as well as 
the entire periprosthetic region (zone 1-7), was 
calculated by dividing the BMD value at each 
follow-up visit by the post-operative BMD and 
converting it to percentage change. 
We have previously made double measure-
ments in 10 patients with complete repositioning 
of the patients and the scanner.30 Postoperatively, 
we measured BMD of the proximal femur of 
the healthy hip (WHO total hip) for patients in 
Charnley class A, and vertebrae L1-L4 (WHO lum-
bar spine) of all patients to assess the patient’s gen-
eral bone mass. The BMD of the L1-L4 vertebrae 
were also measured at 24 months postoperatively.
Varus/valgus angle and fill31 of the stem in 
the femoral canal were measured on radio-
graphs with the digital templating software. The 
proximal fill was measured at the upper border 
of the lesser trochanter and the distal fill 3 cm 
proximally from the tip of the prosthesis. Fill was 
defined as good when there was an 80% fill on the 
anterioposterior radiograph and 70% fill on the 
lateral radiograph.31 At 24 months, the presence 
of heterotopic ossification was evaluated accord-
ing to Brooker et al.32
 
tABle 1. Baseline data for the 50 patients.  
Age – years, mean (range) 81 (70-92)
Female/male (n) 36/14
Height – cm, mean ±SD 168±9
Weight – kg, mean ±SD 66±14
BMI, mean ±SD 23±4
Charnley classification (A/B/C) (n) 31/5/14
Total hip (WHO)a
Normal bone density (n) 9
Osteopenia (n) 14
Osteoporosis (n) 16
BMD – g/cm², mean ±SD 0.775±0.136
Lumbar spine (WHO)b
Normal bone density (n) 16
Osteopenia (n) 13
Osteoporosis (n) 16
BMD – g/cm², mean ±SD 1.050±0.254
Injured hip (right/left) (n) 22/28
Concurrent medical disease (1-5) (n) 3/16/20/8/3
ASA classification (1-4) (n) 2/27/19/2
Stem size (9/11/13/15/17) (n) 3/10/22/10/5
a  Measured in 39 patients with a healthy contralateral hip at 
inclusion
b  Measured in 45 patients where lumbar spine BMD could be 
evaluated at inclusion
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Clinical outcome
Hip function was evaluated with Harris hip score 
(HHS).33 This score has been validated for pa-
tients with femoral neck fractures.34
Health-related quality of life was assessed 
with the EQ-5D (EuroQoL).35 It describes health 
status in terms of 5 dimensions: mobility, self-
care, usual activity, pain/discomfort and anxiety/
depression. Each dimension is divided into 3 
levels: 1 – no problems, 2 – some problems and 
3 – extreme problems. This generates 243 differ-
ent “health states” and the EQ-5D index score 
assigns each “health state” to a value, ranging 
from -0.59, indicating the worst possible health 
state, to 1, indicating full health. In this score, it 
is possible to have negative values, i.e. a perceived 
health state worse than death. 
Pain from the operated hip was recorded us-
ing Pain Numeric Rating Scale (PNRS).36 PNRS 
is an 11-point (0-10) numerical rating scale, the 
patients were asked to record their average pain in 
the operated hip during the last week. 0 denotes 
no pain and 10 indicates unbearable pain.
stAtisticAl AnAlysis
With 20 patients, the study had a power (two-
sided, p=0.01) of more than 99% and 93% to 
detect a continuous migration in MTPM and 
y-translation, respectively. These estimates were 
based upon a previous RSA study with the HA-
coated version of the Bi-Metric stem16 where 
MTPM was mean (SD) 1.9 (1.3) mm and y-
translation was 0.2 (0.2) mm. We recruited 50 
patients to allow for loss to follow-up and to al-
low for sub-group analysis in subjects with high 
and low BMD.
We used analysis of covariance (ANCOVA) to 
study covariates affecting implant migration and 
bone loss. Firstly; to evaluate the effect of peri-
prosthetic BMD on implant migration and bone 
loss, we used MTPM and BMD change in zone 
1-7 as dependent variables and sex, age, BMI, 
stem size and immediate post-operative BMD in 
zone 1-7 as covariates. Median BMD was used to 
dichotomize the subjects into 2 groups, patients 
with either high or low BMD (high vs. low: mean 
BMD 1.77 ± 0.33 g/cm2 and 1.35 ±0.11 g/cm2, 
respectively). 
In the second analysis, we evaluated the effect 
of preoperative BMD on bone loss in a subgroup 
of 36 patients. These patients had a healthy con-
tralateral femur at inclusion and we had complete 
follow-up data at the 24-month visit. These pa-
tients were all in Charnley class A or C, but did 
not differ from the rest of the patients with re-
gards to anthropometrical data (data not shown). 
Post-operative DXA scans of the healthy hip 
and vertebrae L1-L4 (WHO total hip and lum-
bar spine) were used as a proxy for preoperative 
BMD and categorized as normal (T-score >-1 
SD), osteopenia (-1 SD≥ T-score >-2.5 SD) and 
osteoporosis (T-score ≤-2.5 SD). In the analysis, 
BMD change in zone 1-7 was then used as the 
dependent variable and sex, age, BMI, stem size 
and T-score category of the hip or lumbar spine 
as covariates. 
Between-group comparisons of continuous 
variables at follow-up were analyzed with the 
Mann-Whitney U test and within-group com-
parisons between baseline and follow-up values 
were analyzed with the Wilcoxon signed-rank 
test. We used chi-square test for nominal vari-
ables. P-values ≤0.05 were considered significant. 
We used the statistical software PASW Statistics 
18.0 for Windows (IBM Corporation, Armonk, 
New York, U.S.A.). ◉
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complicAtions
One stem was revised during the study, it was 
removed and another uncemented stem was im-
planted 3 weeks after the initial surgery due to 
a deep wound infection; the infection has since 
healed uneventfully. 
We noted 1 intraoperative fracture of the 
greater trochanter. The trochanter was reattached 
during surgery. Post-operatively, in the same 
patient, an undisplaced femoral fracture at the 
distal tip of the prosthesis was discovered. The 
patient was treated with protected weight bear-
ing for 6 weeks. 
At 18 months post-operatively this patient 
presented with a deep infection in the operated 
hip and was treated with an open synovectomy 
and antibiotics. The infection healed but the hip 
dislocated repeatedly after the reoperation. The 
cup was later replaced with a double-mobility 
press-fit cup and there has been no further dis-
location since then. 
The stem was not replaced and RSA results 
show that there has been no migration of the 
stem and the patients’ hip function is excellent. 
In all, 7 hips (14%) dislocated, 3 of these hips 
had recurrent dislocations, only the cup which 
was converted to a double-mobility cup has been 
replaced. Two patients were treated with antibi-
otics due to a superficial wound infections.
surgicAl And rAdiologicAl results
Median operation time was 85 (range, 59-140) 
minutes and the intraoperative bleeding was 400 
(range, 100-1400) ml. Thirteen patients required 
1-2 and 3 patients required 3-4 blood transfu-
sions during the hospital stay. Patients stayed in 
the hospital for a median of 7 (range, 5-11) days 
before continued rehabilitation at home (17 pa-
tients) or at a rehabilitation centre (33 patients).
Two stems were placed in 3˚ of varus; all other 
stems had neutral alignment. 
The fill of the implant in the femoral canal 
was classified as good in 17 hips (34%) and we 
succeeded in achieving a collar-calcar contact 
in 33 hips (66%). The fill or collar-calcar contact 
did not affect migration or bone loss (data not 
shown). 
At 24 months, 25 hips had no evidence of het-
erotopic ossification, 13 had class I-II and 7 class 
III-IV ossification.32 
RESULTS
tABle 2. Migration of the stem 
RSA data are missing for the hip that was revised as the result of a deep wound infection. In one dislocating hip, the stem retroverted 15 degrees and 
had a MTPM of 13 mm at 6 weeks. The stem has been stable on all subsequent examinations but due to the large initial migration, the stem is treated 
as an outlier and is not included in the RSA analysis. Mean ±SD values are shown.
Follow-up p-value
6 weeks
(n=44)
3 months
(n=43)
6 months
(n=44)
12 months
(n=43)
24 months
(n=43) p
a pb pc pd pe
Translation (mm) transverse (x) -0.03±0.27 -0.03±0.22 -0.04±0.23 -0.04±0.25 -0.02±0.25 0.37 0.80 0.81 0.97 0.57
vertical (y) -0.16±0.48 -0.18±0.48 -0.17±0.49 -0.16±0.52 -0.16±0.50 0.03 0.57 0.25 0.89 0.66
anterioposterior (z) -0.31±0.60 -0.33±0.56 -0.34±0.52 -0.19±0.60 -0.18±0.58 0.002 0.69 0.78 0.01 0.88
Rotation (°) flexion/extension (x) -0.16±0.53 -0.30±0.55 -0.27±0.62 -0.40±0.64 -0.56±0.76 0.02 0.05 0.86 0.001 0.01
ante-/retroversion (y) -1.16±1.88 -1.33±1.79 -1.29±1.91 -1.17±1.90 -1.16±1.99 <0.001 0.11 0.25 0.11 0.48
varus/valgus (z) 0.01±0.62 0.03±0.52 0.02±0.53 0.01±055 -0.03±0.60 0.23 0.92 0.99 0.92 0.80
Total migration MTPM 1.83±1.34 1.81±1.32 1.85±1.27 2.00±1.44 2.17±1.30 <0.001 0.22 0.51 0.32 0.47
n  is the number of examinations analyzed after loss to follow-up, technical error,  
high values for mean error of rigid body fitting or a condition number over 100
a  calculated between postop and 6 weeks
b  calculated between 6 weeks and 3 months
c  calculated between 3 months and 6 months
d  calculated between 6 months and 12 months
e  calculated between 12 months and 24 months  
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migrAtion of the stem
Thirty-four stems migrated above the detection 
limit up to 6 weeks post-operatively and 4 stems 
had further migrated at the 3 month follow-up. 
After 3 months, all stems had stabilized. 
The mean (SD) initial translation in the x, y 
and z-axes was -0.03 ±0.27, -0.16 ±0.48 and -0.26 
±0.56 mm with the corresponding rotation -0.16 
±0.53, -1.16 ±1.88 and 0.01 ±0.62 degrees at 6 
weeks. MTPM was 1.83 ±1.30 mm at 6 weeks. 
After this, the mean migration stopped except 
for rotation in flexion/extension (x), which in-
dicated a small, but statistically significant, con-
tinuous migration between 12 and 24 months 
(Table 2, Figure 3). 
Migration of the stem was significantly more 
pronounced in patients with a low periprosthetic 
BMD (Figure 4). 
Bone remodelling
We found a continuous decrease of peripros-
thetic BMD, with the highest rate of bone loss 
occuring during the first 12 months, in all zones 
but zone 4, with a reduction of the total peripros-
thetic BMD of mean 16% at 24 months (Table 3 
and Figure 5). 
The bone loss was greatest in zone 1 and 7, 
with a decrease of 30% and 26%, respectively, at 
24 months. Bone loss was significantly related to 
both the initial BMD surrounding the implant 
and the patients’ general bone mass (Figure 4 
and 6). 
The 24-month BMD of vertebrae L1-L4 did 
not differ from that immediately postoperatively. 
clinicAl outcome
There was a slight deterioration in function and 
an increased pain in the operated hip during the 
study period (HHS and PNRS pre-fracture vs. 24 
months; mean 87 ±11 and 0.4 ±1.3 versus 82 ±13 
and 1.0 ±1.9, p=0.006 and 0.033, respectively). 
The outcome was worse for patients in Charn-
ley class C where degenerative disease in other 
joints and/or associated medical comorbidities 
affected outcome. The median (range) HHS was 
88 (100-52), 90 (91-80) and 76 (88-51) in class A, 
B and C, respectively.
Health-related quality of life also declined 
during the study but did not reach statistical 
significance (EQ-5D pre-fracture vs. 24 months; 
mean 0.71 ±0.23 versus 0.63 ±0.37, p=0.112), 
(Table 4). 
We found no correlation between clinical 
outcome and migration or bone loss (data not 
shown). ◉
figure 3. Migration of the stem
The mean (95% CI) migration of the stem in 
translation (A) and rotation (B). The mean 
(95%CI ) (solid line) and individual MTPM 
(dashed line) with arrow showing the detec-
tion limit of true (at 99% level) migration (C). 
*indicates a significant (p≤0.05) mean migra-
tion compared to the previous examination.
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figure 4. The effect of 
periprosthetic BMD on implant 
migration and bone loss
The mean (95%CI) MTPM and 
percentage change in BMD in 
zone 1-7 for patients with a high 
(solid line) or low (dashed line) 
post-operative periprosthetic BMD 
in zone 1-7. 
MTPM was at all follow-ups and 
bone loss was at 24 months signifi-
cantly larger in patients with low 
BMD after controlling for sex, age, 
BMI and stem size (ANCOVA). 
The bone loss, but not the migra-
tion, was continuous between 12 
and 24 months for patients with 
low BMD (p=0.001). 
The difference in migration 
between the groups was similar for 
y- and z-translation as well as y-
rotation during the study (data not 
shown).*p≤0.05 for between-group 
comparison.
DISCUSSION
The stem was designed to be easy to use by trau-
matologists or general orthopaedic surgeons and 
is marketed with a unipolar or bipolar hemi-
articulation. In clinical practice, operation with 
a hemiarthroplasty is still the most common 
procedure for a displaced femoral neck fracture 
in elderly patients despite recent evidence that a 
THA provides better hip function than a hemi-
arthroplasty.38 
In this study, we wanted to exclude the possibil-
ity of acetabular erosion and the pain associated 
with this, and therefore used THA in all patients.
A stepwise clinical introduction of new im-
plants and methods has been advocated.39-40 This 
involves pre-clinical testing, small prospective 
trials using high precision methods like RSA17 to 
assess implant fixation, larger multicenter trials 
and finally population-based register studies. In 
this study, we have used 2 methods validated for 
fixation of implants and bone remodelling, RSA 
and DXA. To our knowledge, there is no other 
study using this combination of high-precision 
methods to evaluate a new hip prosthesis in os-
teoporotic patients with a femoral neck fracture. 
Our results should be interpreted with cau-
tion since we have no control group. The study 
was designed as a pilot study and the next step in 
evaluating this implant will be to conduct a large 
randomized controlled trial in which this implant 
is compared to a cemented stem. 
In a cognitively intact cohort of elderly patients operated with a new HA-coated stem due to 
a displaced FNF, all stems were stable after 3 months. The mean subsidence, retroversion and 
total migration were of the same, or smaller, magnitude than those reported from other RSA 
studies of clinically successful uncemented stems.16,37 We also found a continuous decrease in 
BMD around the stems up to 2 years after surgery.
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To be able to access the influence of the injury 
on clinical outcome scores (HHS, EQ-5D and 
PNRS), the patients were asked to report their 
prefracture status when they were included in 
the study. It is obvious that the patients’ ability to 
correctly record this when waiting for acute sur-
gery may be questioned. It is however impossible 
to collect this data in a prospective manner and 
the method is regularly used in trauma studies on 
hip fracture patients.1-2,4
Our dislocation rate was high even though 
we used posterior repair and 32 mm heads in all 
cases. A high dislocation rate for the posterolat-
eral approach after THA in patients with a femo-
ral neck fracture has previously been reported,41 
and after the completion of the current trial we 
have subsequently reduced the dislocation rate 
after arthroplasty for femoral neck fractures by 
adopting the anterolateral approach.42 
why use uncemented femorAl stems in treAt-
ment of femorAl necK frActures?
Uncemented stems in THA are popular implants. 
In younger patients with osteoarthritis, some 
perform as well, or better, than cemented stems 
in the 10-year perspective.43 
The rationale for using these devices for dis-
placed femoral neck fractures in osteoporotic 
elderly patients, often with a stove-pipe femur, 
is mainly theoretical. During pressurization, ce-
ment and fat embolism are known to occur10-11 
and can have an impact on mortality.12-13 
In the literature, there is evidence for an 
improved functional outcome in hip fracture 
patients when using a cemented implant, mainly 
when comparing uncemented Austin-Moore 
and cemented Thompson stems.44 However, a 
new study showed equivalence between a mod-
ern HA-coated stem and a modern cemented 
stem.45 Nevertheless, we acknowledge that there 
are several potential problems when using an 
uncemented stem in this patient group. The most 
obvious is the increased risk for periprosthetic 
fractures. In a coming report from the Swedish 
Hip Arthroplasty Register, modern HA-coated 
uncemented stems used for hemiarthroplasty in 
this elderly population are, compared to modern 
cemented stems, associated with an increased 
risk for revision due to femoral fractures (odds 
ratio 3.8, 95%CI 2.0-7.1).46 Similar results can 
be seen in the Australian National Arthroplasty 
register where uncemented stems in fracture pa-
tients have a significantly higher risk of revision 
compared to cemented stems.47 
In our study, we only had 1 fracture; a femoral 
crack distal to the tip of the prosthesis. We have 
not had any femoral split fracture or calcar frac-
tures. However, all the surgeons who performed 
the operations in this trial are experienced hip 
surgeons, and therefore we cannot be sure that 
our results can be translated to a standard clinical 
setting. 
The risk for femoral split fractures is perhaps 
also implant-specific; the most commonly used 
uncemented stem for femoral neck fractures 
in Sweden is a press-fit type of stem (Corail®), 
where the technique is to use increasing sizes of 
broaches and to impact as much cancellous bone 
as possible. 
So, despite the fact that a HA-coated femoral 
stem can work quite well in osteoporotic patients, 
there is still little evidence to recommend it. In 
fact, the rate of calcar split/periprosthetic frac-
tures in this patient group in published papers 
range between 0-17% and is typically around 
4% (Table 5), a risk that perhaps is unacceptable 
when compared to the low risk of adverse events 
during cementation of the stem.  
tABle 3. Percentage change in BMD for the whole peripros-
thetic region and in zone 1 and 7
mean SD 95% CI n
zONe 1-7
3 months -6.0 6.9 -8.2 – -3.9 46
6 months -8.2 9.6 -11.1 – -5.3 46
12 months -11.4 10.9 -14.8 – -8.1 45
24 months -15.9 13.0 -20.0 – -11.7 44
zONe 1
3 months -9.6 11.8 -13.1 – -6.0 46
6 months -14.2 15.6 -19.0 – -9.5 46
12 months -23.3 14.2 -27.6 – 19.0 45
24 months -30.0 13.1 -34.2 – -25.8 44
zONe 7
3 months -12.5 13.8 -16.7 – -8.3 46
6 months -17.5 15.3 -22.1 – -12.8 46
12 months -20.9 16.6 -26.0 – -15.8 45
24 months -25.7 20.1 -32.1 – -19.3 44
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figure 5.periprosthetic bone remodelling
The mean (95% CI) percentage change in BMD around the stem. * indicates a significant (p≤0.05) change in BMD compared to the 
preceding value. 
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Aspects of implAnt design
The BFX stem is modified compared to the origi-
nal Bi-Metric design. It is marketed in uneven 
sizes only, has a single offset option and has a 
collar. The first 2 factors are unnecessary limita-
tions of the stem; particularly in respect to males, 
as more than one offset option is lacking and the 
high dislocation rate seen in this study can, in 
part, be attributed to this fact. 
We cannot prove that the collar is either an 
advantage or disadvantage concerning migra-
tion.  Still, we believe that it makes insertion of 
the implant safer with regards to the risk of ac-
cidentally causing calcar split fractures at final 
impaction of the stem. 
The full HA-coating is probably also advanta-
geous in this patient group since it has strong 
osteoconductive properties. Despite the fact that 
we only attained a tight fill in the femoral canal in 
about one third of the hips, all stems were fixated 
after 3 months. 
migrAtion And Bone remodelling
In RSA studies, the amount of migration that 
increases the risk of revision, varies between 
implants and the method of fixation. For the 
cemented Lubinus SP I stem, a subsidence ex-
ceeding 1.2 mm during the first post-operative 
year indicates a 50% risk for revision within 5-7 
years.26 In uncemented stems, there is evidence 
that subsidence should be lower than 1-1.5 mm 
and retroversion less than 3° during the first year 
to avoid revision surgery.48 
HA coating has been advocated for unce-
mented femoral stems since the HA coating 
decreases migration. In 1 study on patients with 
osteoarthritis, the MTPM of the Bi-Metric stem 
was 1.7 (HA coating) and 3.9 mm (no HA coat-
ing) after 12 months.16 The subsidence (0.2 mm 
at 12 months) did not differ between the groups 
but the retroversion was smaller in the HA group. 
However, the Bi-Metric stem, with and with-
out HA coating, has excellent long-term results, 
so the relevance of this small difference in migra-
tion can be of negligible clinical relevance.49
Migration of stems in elderly patients with a 
femoral neck fracture has only been investigated 
once before. Klestil et al.50 evaluated the migra-
tion of the uncemented Zweimüller stem in 
23 patients with a femoral neck fracture using 
Einzel-Bild-Roentgen-Analyse Femoral Com-
ponent Analysis51 and found that active patients 
had a significant migration, 30% of all stems sub-
sided more than 2 mm. Whether this migration 
was continuous was not evident from the study. 
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figure 6. The relation between BMD and bone loss
 Change in BMD in zone 1-7 shown for 36 patients who were included in a substudy of what effect the BMD of total hip (the non-oper-
ated contralateral hip) and lumbar spine had on bone loss after 24 months. Low BMD was significantly related to periprosthetic bone loss 
after controlling for sex, age, BMI and stem size (total hip p=0.015, p<0.001 and lumbar spine p=0.021, p=0.027, ANCOVA).
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Even though there was no stem revision or calcar 
split fracture, they did not recommend the stem 
for this patient group because of high migration 
and thereby fear of early loosening. 
In the present study, we observed that some 
patients had a large initial migration, at most 13 
mm in MTPM (Table 2). Despite this, all stems 
stabilized. However, there was a tendency for a 
continuous migration (z-rotation and MTPM) at 
24 months. This could be attributed to the bone 
resorption that occurred around the stem. 
Stress related bone loss around femoral stems 
has been extensively studied,19-21 but so far, only 
with few reports of clinical consequences.52 This 
bone loss is also related to stem size and, as in our 
investigation, the initial BMD of the patients.53-55 
Investigation of bone remodelling in this patient 
group has, to our knowledge, only been done 
once before involving a new acetabular compo-
nent.56 The bone remodelling around the stem in 
this study can therefore serve as a reference for 
other implants in this patient group. 
Our patients lost significant amount of bone 
but, up to 2 years, this had no certain effect on the 
stability of the implant. However, we cannot rule 
out a negative effect of this bone loss in a longer 
perspective. 
Recently, electrochemically deposited HA, 
compared to plasma sprayed HA as in our study, 
has been found to yield a higher BMD in zone 
1 in osteoarthritic patients operated with an 
uncemented press-fit stem.57 A randomized trial 
would be required to investigate if this bone spar-
ing effect also occurs in patients with a femoral 
neck fracture. 
We found a difference in stem migration between 
patients with high or low periprosthetic BMD 
(Figure 4). BMD around the stem was the stron-
gest predictor for migration. Since the subjects 
who were osteopenic or osteoporotic before the 
fracture, as estimated by the BMD of the contra-
lateral femur, also had lost more bone around the 
stem at 2 years, this is a potentially problematic 
situation as this bone loss could lead to loosening 
of the stem or predispose to a fracture. 
compArison to other clinicAl triAls
The majority of data on modern uncemented 
stems (i.e. not Thompson or Austin-Moore types) 
in patients with a femoral neck fracture is from 
single cohort studies50,58-62 and there are only 2 
trials where HA-coated stems were compared to 
other stem types (Table 5).45,63 
Livesley et al.63 compared a HA-coated Fur-
long hemiarthroplasty (JRI) and the convention-
al uncemented Austin-Moore stem and found 
better functional results in the JRI group. 
However, the trial was not randomized; pa-
tients were allocated to treatment by week of 
admission. They also compared the HA-coated 
implant against an implant that we now know is 
inferior; the revision rate for the Austin-Moore 
prosthesis is high in the Swedish Hip Arthro-
plasty Register and its use is no longer recom-
mended.64 
Figved et al. has performed the only ran-
domized study comparing a modern cemented 
implant (Spectron) and a HA-coated press-fit 
implant (Corail).45 
tABle 4. Clinical outcome scores with pre-fracture status as 
baseline for comparison
Outcome score mean SD 95% CI n p-value
HHS
Pre-fracture 87 11 84 – 90 50
6 weeks 73 15 69 – 77 49 <0.001
6 months 83 12 80 – 87 47 0.021
12 months 83 13 79 – 87 46 0.013
24 months 82 13 79 – 86 45 0.006
eQ-5D INDex
Pre-fracture 0.71 0.23 0.65 – 0.78 50
6 weeks 0.58 0.24 0.51 – 0.65 49 0.005
6 months 0.72 0.22 0.65 – 0.78 47 0.988
12 months 0.70 0.29 0.61 – 0.79 46 0.516
24 months 0.63 0.37 0.52 – 0.74 45 0.112
PNRS
Pre-fracture 0.4 1.3 0 – 0.8 50
6 weeks 1.6 2.2 1.0 – 2.2 49 0.001
6 months 1.0 1.7 0.5 – 1.4 47 0.048
12 months 1.1 2.2 0.5 – 1.7 46 0.032
24 months 1.0 1.9 0.5 – 1.6 45 0.033
P-values derived from Wilcoxon signed-rank test
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tABle 5. Studies on modern uncemented stems (not Thompson or Moore type) in femoral neck fractures with the current 
study for comparison 
A B C D e F G H I J K L M N O P
Livesley63 JRI/Austin-Moore 1993 HA BHA RCT 1 hip function 48 81 n.r. 17/0 2/1 n.r. n.r. 4
Bezwada62 Taperloc 2004 PP BHA PSC 3.5 hip function 168 77 69 0 2 82 n.r. n.r.
Klestil50 zweimüller 2006 GB UHA PSC 2 migration 46 76 65 0 0 n.r. AL 0
Klein59 Taperloc, Accolade 2006 PP THA RSC 3.8 complications 85 78 74 4 0 82 AL 4
Chandran58 Furlong 2006 HA BHA RSC 4 revision 112 78 96 2 5 n.r. AL n.r.
Öztürkmen61 F40, Helios 2008 FP BHA RSC 4.2 n.r. 48 88 76 n.r. 1 84 PL 2
Barnett60 Corail 2009 HA THA PSC 1 dislocation 46 72 72 7 0 n.r. AL 0
Figved45 Corail/Spectron 2009 HA BHA RCT 1 hip function 200 83 76 6/3 2/1 79/80 PL 5
Sköldenberg BFx 2010 HA THA PSC 2 migration 50 81 72 2 1 82 PL 14
A Author
B Implants used
C Year published
D Design of stem: 
HA=hydroxyapatite-coated, FP=fully 
porous-coated, PP=proximally 
porous-coated, GB=grit-blasted
e Type of articulation: THA=total 
hip arthroplasty, UHA=unipolar 
hemiarthroplasty, BHA=bipolar 
hemiarthroplasty
F Type of study: PSC=prospective 
single cohort, RSC=retrospective 
single cohort, RCT=randomized 
controlled trial
G Follow-up (years)
H Primary outcome variable
I Hips (n)
J Mean age (years) 
K Females (%)
L Intra- and post-operative peripros-
thetic fractures (%)
M Stem revisions (n)
N Harris hip score (mean)
O Surgical approach: 
AL=anterolateral, PL=posterolateral
P Dislocation rate (%)
n.r.= not reported
Their study showed equivalence between the 
groups in Harris hip score after 1 year. The pa-
tient selection was similar to our study, with a 
mean age of 83 years, and predominantly female 
patients. Hip function and health-related quality 
of life were similar to our results. 
They had more intra- and post-operative peri-
prosthetic fractures in the uncemented group, 
compared to the cemented group; 6% versus 2% 
after 1 year. They also excluded 4 patients during 
surgery because they could not achieve primary 
stability with uncemented fixation of the stem. 
Despite this, they concluded that both femoral 
implants in the study could be used with good 
results in displaced femoral neck fractures. 
conclusion
In conclusion, the short-time results from this 
trial indicate that the new femoral stem can be 
used for elderly patients with osteoporotic frac-
tures of the femoral neck. 
Additional research should, in the context of 
multicentre randomized trials or population-
based register studies, focus on whether unce-
mented HA-coated femoral stems are superior, 
equivalent or inferior to cemented stems in the 
treatment of femoral neck fractures. ◉
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